Search Results

Written by Clare Koning, RN, PhD June 2026 5 min read Key Highlights ✅ Diabetic kidney disease affects approximately 1 in 4 people with T2D ✅ It is largely silent until significant damage has occurred ✅ SGLT2 inhibitors have revolutionized kidney disease treatment ✅ Guidelines recommend earlier initiation of kidney-protective medications ✅ A simple urine test and blood creatinine check can detect early kidney involvement Of all the complications of type 2 diabetes, diabetic kidney disease is perhaps the quietest. It produces no pain, no visible signs, and often no symptoms at all until kidney function has declined substantially. Yet it is the single leading cause of kidney failure requiring dialysis in Canada, and it affects approximately one in four people with T2D. The clinical landscape around diabetic kidney disease has changed dramatically in the past five years, with new medications, updated guidelines, and a fundamental shift in how providers approach kidney protection in T2D. Here is what you need to know. How Diabetes Damages the Kidneys The kidneys contain millions of tiny filtering units called glomeruli, each fed by a network of capillaries. Chronic high blood sugar damages these capillaries in two ways: first, by causing direct glycation damage to the capillary walls; second, by increasing pressure within the glomeruli (hyperfiltration), which forces the filters to work harder and accelerates their deterioration. The first detectable sign of this damage is usually microalbuminuria, the appearance of small amounts of the protein albumin in the urine, indicating that the kidney filter is becoming leaky. As damage progresses, protein loss increases, blood pressure typically rises, and the estimated glomerular filtration rate (eGFR), which measures how efficiently the kidneys are filtering blood, begins to fall. The 2026 ADA Standards of Care recommend annual screening for all people with T2D, beginning at diagnosis, using both a urine albumin-to-creatinine ratio (uACR) and an eGFR blood test. The combination of these two simple tests provides an early warning system that most people with T2D are entitled to but not all routinely receive. The SGLT2 Revolution The most significant development in diabetic kidney disease management in recent years has been the emergence of SGLT2 inhibitors, including dapagliflozin (Forxiga) and empagliflozin (Jardiance), originally approved as glucose-lowering medications, as kidney-protective agents in their own right. Landmark randomized trials including DAPA-CKD and EMPA-Kidney demonstrated that SGLT2 inhibitors significantly reduce the risk of kidney disease progression and kidney failure in people with chronic kidney disease, with benefits seen whether or not participants had diabetes. In trials specifically focused on diabetic kidney disease, SGLT2 inhibitors reduced the risk of a sustained decline in kidney function by approximately 50% compared with placebo, a magnitude that has prompted a fundamental reassignment of these drugs from glucose-lowering agents to cardiorenal-protective agents. The mechanism goes beyond glucose control. SGLT2 inhibitors reduce intraglomerular pressure, the harmful elevated filtration pressure that drives chronic kidney disease (CKD) progression in diabetes, through a hemodynamic effect on the glomerular afferent arteriole. They also reduce inflammation, reduce body weight, lower blood pressure, and appear to protect kidney tubular cells directly from metabolic stress. Let's pause on that... SGLT2 inhibitors reduce kidney disease progression by approximately 50% in people with diabetic CKD. That is a remarkable clinical result for a class of drugs that was originally approved purely for blood sugar. This Harvard Medical School Continuing Education video examines these key questions: How do SGLT2 inhibitors provide kidney protection? What key findings in CREDENCE and DAPA-CKD, two landmark kidney outcomes trials, have led to new SGLT2i guidelines for patients with CKD? Updated 2026 Guidelines The 2026 ADA Standards of Care include new guidance on glucose-lowering therapies in people with chronic kidney disease, including use by those on dialysis, reflecting a continued expansion of the kidney-protective treatment framework. Importantly, the guidelines now support initiating SGLT2 inhibitors at earlier stages of CKD than previously recommended, extending kidney protection to more people with T2D. The 2026 guidelines also highlight finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, as an additional kidney and heart-protective agent in T2D-associated CKD, based on the FIDELIO and FIGARO trials showing reduced risk of kidney failure and cardiovascular events. What People with T2D Should Ask Their Provider If you have T2D and have not recently had your kidneys checked, ask for both a urine albumin test and a blood creatinine/eGFR at your next appointment. These are standard of care and should be done annually. If you are already on an SGLT2 inhibitor for blood sugar control, your kidneys are likely already benefiting. If you are not, and have any degree of kidney involvement, ask your provider whether you are a candidate. Early detection and treatment is the difference between slowing this condition and arresting it before serious harm occurs. For more on managing diabetes complications, visit the T2D Network's Monitoring & Medication and Learn More pages.

Written by Clare Koning, RN, PhD June 2026 5 min read Key Highlights ✅ A 2025 meta-analysis of 8 RCTs found time-restricted eating (TRE) significantly improved fasting glucose, HbA1c, and time in range in people with T2D ✅ A head-to-head trial at ENDO 2025 found intermittent fasting (two days per week) outperformed continuous calorie restriction on insulin sensitivity and adherence ✅ A January 2026 study found TRE without calorie reduction produced no metabolic benefit, complicating the picture ✅ When does matter: early TRE aligned with morning eating windows shows stronger effects than late-night eating windows ✅ Medication timing and hypoglycaemia risk require careful planning before starting any fasting protocol Intermittent fasting is one of the most searched dietary topics in health right now, and for people with type 2 diabetes, the question of whether it helps, hinders, or simply does not matter is both practically urgent and genuinely unsettled. The evidence in 2026 is richer than it was two years ago, but also more nuanced, and that nuance is worth communicating clearly. What Time-Restricted (fasting) Eating Shows Time-restricted eating (TRE) limits daily food intake to a defined window, typically six to ten hours, leaving a fasting period of fourteen to eighteen hours, usually overnight. A systematic review and meta-analysis published in the International Journal of Molecular Sciences in July 2025 analysed eight randomized controlled trials involving 312 participants with T2D or impaired fasting glucose. The pooled results were meaningfully positive: TRE significantly reduced fasting glucose (mean difference: -0.74 mmol/L), reduced HbA1c, and increased time in range by an average of 10.51%. A separate trial presented at ENDO 2025, the Endocrine Society's annual meeting, directly compared three dietary approaches in people with T2D and obesity: intermittent energy restriction (IER, fasting two days per week), time-restricted eating, and continuous energy restriction. All three improved HbA1c. But the IER group showed the greatest advantages in reducing fasting blood glucose, improving insulin sensitivity, reducing triglycerides, and crucially, maintaining adherence over time. Across trials, intermittent fasting approaches consistently improved blood sugar metrics in people with T2D. The two-day fasting model also produced better adherence than continuous dieting, which is a clinically meaningful distinction. A study published in Science Translational Medicine in October 2025 added a significant caveat. Researchers in Germany tested TRE under strictly isocaloric conditions, meaning participants ate the same total number of calories whether fasting or not. The result: no clinically meaningful improvement in insulin sensitivity, blood sugar, blood fats, or inflammatory markers. The conclusion: when TRE produces metabolic benefits, it appears to be largely through reduced caloric intake, not through fasting itself as a metabolic trigger. The circadian timing shift was confirmed, but metabolic improvement was not. This does not invalidate TRE as a strategy. It clarifies the mechanism. TRE works in practice partly because restricting the eating window tends to reduce overall calorie consumption naturally and sustainably for many people, particularly those who previously ate from morning until late at night. The fasting itself may not be the active ingredient. A Case Study Fasting is one of the oldest dietary practices known to humanity. Physician, researcher, and author Jason Fung explains the physiological changes that occur during fasting and describes its role in helping a 69-year-old patient reverse type 2 diabetes. Intermittent fasting works by shifting the body's primary fuel source from glucose to stored fat. Its potential benefits include simplicity, convenience, flexibility, low cost, and compatibility with a wide range of dietary approaches. Timing Matters: Earlier Is Better One consistently emerging finding across TRE studies is that early eating windows, finishing the final meal by early evening, produce stronger metabolic effects than late or unrestricted windows. This aligns with circadian biology: insulin sensitivity is highest in the morning and declines through the day. Eating in alignment with this rhythm, front-loading calories earlier and fasting from late afternoon onward, amplifies the benefit. Research supports the idea that circadian misalignment caused by late-night eating is itself a contributor to metabolic risk. Shifting the eating window earlier, even without reducing total calories, may carry circadian benefits beyond simple caloric arithmetic. What This Means If You Have T2D Fasting protocols are not without risk for people with T2D, particularly those on insulin or sulfonylurea medications that can cause hypoglycaemia during fasting periods. Before starting any fasting protocol, it is essential to discuss medication adjustment with your care team. With appropriate medical oversight, the evidence now supports TRE and intermittent energy restriction as viable, evidence-based dietary strategies for people with T2D seeking non-pharmacological approaches to improving blood sugar, weight, and metabolic health. They are not magic, they work primarily through caloric reduction and circadian alignment, but they may be more sustainable for many people than conventional continuous dieting. For guidance on eating strategies and T2D, visit the T2D Network's Healthy Eating page or sign up for our weekly insights.

Written by Clare Koning, RN, PhD June 2026 5 min read Key Highlights ✅ People with T2D have a 3-fold higher risk of muscle loss compared to those without diabetes ✅ Muscle is the body's primary glucose disposal organ, so losing it directly worsens insulin resistance ✅ T2D causes a distinct type of muscle loss that differs from normal aging ✅ Resistance training slows muscle loss, and may be more important than cardio for people with T2D ✅ GLP-1 medications, while effective for weight loss, may accelerate muscle loss without adequate protein and resistance training When people think about the complications of type 2 diabetes (T2D), they typically think about the eyes, the kidneys, the heart, and the feet. Muscle rarely makes the list. But skeletal muscle is the largest glucose disposal organ in the human body, responsible for absorbing up to 70-80% of insulin-stimulated glucose uptake during a meal. When you lose muscle, that capacity shrinks, and blood sugar control gets harder. This relationship between T2D and muscle loss, increasingly referred to as diabetic sarcopenia, is one of the most underrecognized and clinically important aspects of living with the condition. What Diabetic Muscle Loss (Sarcopenia) Actually Is Sarcopenia is defined as the progressive loss of skeletal muscle mass, strength, and function. It is classically associated with aging. But research published in Frontiers in Endocrinology has demonstrated that T2D-related muscle loss is a distinct entity, with a different pathological pattern than age-related sarcopenia. Where normal sarcopenia primarily affects fast-twitch Type II muscle fibres, T2D targets the slow-twitch, oxidative Type I fibres that are most important for sustained, endurance-type activity and metabolic regulation. A 2025 review published in Diseases identified key risk factors for diabetic sarcopenia: poor glycemic control (HbA1c above 8%), longer diabetes duration over five years, low BMI, and reduced levels of vitamin D and insulin-like growth factor-1 (IGF-1). Importantly, the review found that people with T2D have a 3-fold higher risk of sarcopenia compared to those without, and that 8.2% of people with newly diagnosed T2D already have sarcopenia at the time of diagnosis. The mechanisms are multiple and reinforcing. Chronic elevated blood sugar promotes the accumulation of advanced glycation end-products (AGEs) in muscle tissue, impairing contractile function. Insulin resistance itself impairs the anabolic signalling pathways, particularly the mTOR pathway, that drive muscle protein synthesis. And elevated cortisol, common in people with poorly managed T2D, directly accelerates muscle protein breakdown. More muscle mass, and not just less body fat, is critical to lowering your risk for type 2 diabetes, a study by UCLA's Dr Preethi Srikanthan and colleagues suggests. T2D causes muscle loss through at least four distinct biological mechanisms: glycation of muscle proteins, impaired anabolic signalling, inflammation, and elevated cortisol. This is not just aging. It is disease-driven. The GLP-1 Weight Loss Warning One timely dimension of this issue relates to the extraordinary popularity of GLP-1 receptor agonists for weight loss. These medications are effective, and their benefits for glycemic control, cardiovascular health, and kidney protection are well-documented. But rapid weight loss from any cause, including GLP-1 therapy, carries a risk of significant muscle loss alongside fat loss. A 2025 review in Nutrients specifically examining creatine supplementation, exercise, and T2D noted that for people with pre-existing insulin resistance and sarcopenic risk, losing weight rapidly without concurrent resistance training and adequate protein intake may worsen the muscle-mass deficit even as metabolic markers improve. This is not an argument against GLP-1 therapy. It is an argument for pairing it with structured resistance exercise and protein-focused nutrition, a combination that evidence strongly supports for preserving muscle during weight loss. What the Exercise Evidence Shows A 2025 systematic review and meta-analysis published in Diabetes Research and Clinical Practice, examining 19 randomized controlled trials in older adults with T2D, found that resistance exercise training significantly improved HbA1c (mean difference: -0.51%, p < 0.0001) and fasting blood glucose, alongside meaningful improvements in muscle mass, strength, and body composition. A 2025 review in Metabolites comparing aerobic, resistance, HIIT, and combined training protocols concluded that combined aerobic and resistance training produced the best overall metabolic outcomes, with resistance training showing particular advantages for muscle preservation and insulin sensitivity in people with T2D. The key finding from the meta-regression work is that training effect matters: the greater the strength gain, the greater the HbA1c reduction. This points toward progressive overload, gradually increasing weight or resistance, as the mechanism behind blood sugar benefits, not simply moving the body. Practical Targets For people with T2D, the current evidence supports at least two resistance training sessions per week targeting major muscle groups, combined with adequate dietary protein (generally 1.2 to 1.6g per kg body weight daily, adjusted for kidney function). Both are underutilized in standard T2D care. Talk to your diabetes education team about incorporating resistance training, even if it is bodyweight exercise at home, into your management plan. This is not supplementary to your diabetes care. For many people, it may be one of the most impactful interventions available. For more on exercise and T2D, visit the T2D Network's Healthy Lifestyle page or join our network for weekly insights.

Written by Clare Koning, RN, PhD 6 min read Key Highlights: ✅ Diabetes was independently associated with increased odds of death during BC's 2021 heat dome. ✅ People with T2D have impaired thermoregulation, they cannot cool themselves as effectively as people without diabetes. ✅ Wildfire smoke PM2.5 drives systemic inflammation and insulin resistance, worsening glycemic control. ✅ Insulin degrades above 30°C, often without any visible change in appearance. ✅ BC has a Heat Alert and Response System (BC HARS), providers should know how it works and what it triggers. British Columbia's summers have changed. What was once a season of reliable mild weather is now defined by heat events that break records, wildfire seasons that extend from June through October, and smoke advisories that keep patients indoors for weeks at a time. For people living with type 2 diabetes, these are not inconveniences, they are clinical risks. The 2021 western heat dome killed 619 British Columbians in six days, the deadliest weather event in Canadian history. A peer-reviewed analysis published in GeoHealth found that diabetes was independently associated with increased odds of death during that event, alongside depression and chronic kidney disease. More than 80% of those who died were on three or more chronic disease registries. This is not a distant public health statistic. It is a clinical reality that providers across BC will face again, likely this summer. Why People with T2D Are at Higher Risk in the Heat Most people understand that extreme heat is dangerous. What is less widely appreciated is that diabetes specifically impairs the body's ability to respond to heat stress, through mechanisms that are well-established in the physiological literature. Impaired thermoregulation. The primary way the body cools itself is through sweating and skin vasodilation. Both of these mechanisms are compromised in people with diabetes. Autonomic neuropathy, a common complication of longstanding T2D, reduces sweat gland function, limiting the body's capacity to dissipate heat through evaporative cooling. A comprehensive review (while written some time ago, is still relevant today) in Temperature describes how both sweating capacity and skin blood flow responses to heat are significantly blunted in people with T2D compared to matched controls, and that these impairments worsen with longer duration of diabetes and poorer glycemic control. People with T2D can overheat before they feel hot. Dehydration and glucose fluctuation. Heat causes fluid loss through sweating, reduced as it may be, and through increased insensible losses. Dehydration concentrates blood glucose, raising HbA1c-independent acute hyperglycemia risk. Conversely, some patients on sulphonylureas or insulin who are eating less in the heat, exercising more, or who have reduced appetite during extreme heat events face compounded hypoglycemia risk. A 2025 systematic review in Frontiers in Public Health confirmed that extreme heat events are associated with increased diabetes-related hospitalizations and mortality globally. Cardiovascular vulnerability. T2D is already a major cardiovascular risk factor. Extreme heat places additional stress on the cardiovascular system through increased heart rate, vasodilation, and fluid shifts, a compounding burden for patients already managing hypertension, heart failure, or CKD alongside their diabetes. Hypoglycemia masking. Heat stress and its symptoms, dizziness, weakness, sweating, confusion, overlap substantially with hypoglycemia symptoms. In patients with impaired hypoglycemia awareness (itself more common in longstanding T2D), this masking can delay recognition and response to a low blood glucose event. The Insulin Storage Problem No One Is Talking About One of the most practically urgent, and most commonly overlooked, clinical issues in summer diabetes care is insulin degradation. Insulin is a protein. It is irreversibly damaged by heat. Manufacturers recommend that unopened insulin be stored refrigerated at 2–8°C, and that insulin in use not exceed 30°C for more than 28 days. A 2023 Cochrane systematic review on insulin storage confirmed the temperature sensitivity of human insulin and noted that degradation can occur without any visible change in the insulin's appearance – no cloudiness, no particles, no obvious sign that the medication has lost potency. This matters enormously for patients during heat events. A car parked in the sun can reach 60°C within 20 minutes. A home without air conditioning during a multi-day heat event can sustain indoor temperatures above 35°C for extended periods, exactly the conditions that killed the majority of BC's 2021 heat dome victims, most of whom died inside their own homes. Patients may be injecting degraded insulin, experiencing unexpected hyperglycemia, and not connecting these events to the heat. The medication looks fine. The dose is correct. The blood sugar makes no sense. What to advise patients: Never leave insulin in a parked car, direct sunlight, or near a window in summer Use an insulated medication case or cooling wallet during hot weather (not an ice pack directly on insulin – freezing also destroys it) If insulin has been exposed to sustained heat above 30°C, treat it as potentially compromised and contact their pharmacy or provider GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) are similarly temperature-sensitive – the same guidance applies Wildfire Smoke: A Distinct and Underappreciated Risk for People with T2D Extreme heat and wildfire smoke increasingly co-occur in BC, and their effects on people with T2D compound each other in ways that the clinical literature is only beginning to quantify. Wildfire smoke is dominated by fine particulate matter (PM2.5) at concentrations that can far exceed urban pollution levels even hundreds of kilometres from a fire. When inhaled, PM2.5 penetrates deep into the alveoli, enters the bloodstream, and triggers systemic inflammation, oxidative stress, endothelial dysfunction, and platelet activation, the same biological pathways that drive cardiovascular disease and worsen insulin resistance. A landmark 2024 study published in Diabetes Care, the first large multi-country analysis of its kind, found that short-term exposure to wildfire-specific PM2.5 was associated with a statistically significant increase in diabetes hospitalizations. A concurrent analysis published in PNAS confirmed that long-term wildfire smoke PM2.5 exposure is associated with endocrine disease and diabetes mortality in a dose-dependent relationship across the contiguous United States. The mechanism is clinically coherent: PM2.5 exposure drives insulin resistance through inflammatory cytokine release and impairs microvascular function, exactly the pathophysiology that people with T2D are already managing. For patients with pre-existing endothelial dysfunction, the effect of wildfire smoke exposure is amplified, as confirmed in a 2023 review in Frontiers in Cardiovascular Medicine. For BC providers, this means that a patient presenting with unexplained glycemic deterioration during wildfire season, without changes to diet, medication, or activity, may be experiencing a smoke-driven inflammatory response. This is not yet widely recognized in primary care, and the evidence base is growing faster than clinical awareness. What to advise patients during smoke events: Stay indoors with windows closed when the Air Quality Health Index (AQHI) is high, check weather.gc.ca for real-time BC air quality data Use N95 or KN95 masks if outdoor exposure is unavoidable, standard surgical masks do not filter PM2.5 effectively Increase blood glucose monitoring frequency during prolonged smoke events Advise patients that worsening glycemic control during wildfire season may not be a self-management failure The BC Heat Alert and Response System: What Providers Should Know Following the 2021 heat dome, BC launched the BC Heat Alert and Response System (BC HARS), coordinated by the BCCDC, the Ministry of Health, and Health Emergency Management BC. It operates on two tiers: Heat Warning: issued by Environment and Climate Change Canada (ECCC) when regional temperature thresholds are met; triggers public health actions including activation of cooling centres Extreme Heat Emergency: triggers a Broadcast Intrusive Alert through the Alert Ready system province-wide; activates emergency operations coordination When a Heat Warning or Extreme Heat Emergency is declared, BC HARS activates a series of recommended provider actions, including proactive outreach to high-risk patients. People with diabetes are explicitly named as a high-risk group. Practical steps for providers and practices: Identify high-risk patients on your panel now, before summer heat events begin. Patients on insulin, sulphonylureas, diuretics, or ACE inhibitors face compounded risk Ensure your diabetic patients know how to access cooling centres during heat events. BC's interactive cooling centre map is updated in real time during heat events Review medication lists with heat in mind: diuretics in a heat event can accelerate dehydration; SGLT2 inhibitors increase fluid losses and may compound dehydration risk if patients are not adequately hydrated Brief patients on insulin storage before summer, not during a crisis Know how to refer patients to HealthLink BC (8-1-1) for non-emergency heat-related guidance A Note on Equity The risks of extreme heat and wildfire smoke are not distributed equally. BC's 2021 heat dome analysis confirmed that deaths were concentrated in deprived neighbourhoods without air conditioning or green space. Many of BC's most heat-vulnerable patients, older adults, people in social housing, individuals experiencing housing insecurity, and people in remote and northern communities, are the same populations most likely to have uncontrolled T2D and limited access to emergency resources. Indigenous communities in BC face compounded vulnerability: higher rates of T2D, more frequent exposure to wildfire smoke from fires on or near their traditional territories, and health infrastructure that is often less resilient to climate emergencies. Providers working with these communities should engage with the First Nations Health Authority's climate and environmental health resources and ensure patients have access to FNHA-supported programs and services. Climate change is not a future health issue. For your patients with T2D in British Columbia, it is happening now, this summer, likely this month. The clinical tools to respond are available. The evidence is clear. What's needed is integration of climate awareness into everyday diabetes care. The T2D Network is committed to supporting evidence-informed, equitable diabetes care across British Columbia. Content reviewed for clinical accuracy. For more resources, visit t2dnetwork.ca.

Written by Clare Koning, RN, PhD 6 min read Key Highlights: ✅ T2D prevalence is 244% higher in First Nations individuals on-reserve vs. the general population. ✅ Indigenous peoples are diagnosed younger, with greater severity, and face higher rates of complications. ✅ The disparity is rooted in the legacy of colonization, not individual behaviour. ✅ Cultural unsafety is a documented barrier to care engagement and must be actively addressed. ✅ Evidence-based tools and community-led programs are available, and underused. June is Indigenous History Month in Canada, culminating in National Indigenous Peoples Day on June 21. It is a time to recognize not only the extraordinary cultures, knowledge systems, and contributions of First Nations, Métis, and Inuit peoples across Turtle Island – but also to honestly confront the health inequities that colonization has produced, and that persist today. Type 2 diabetes is one of the starkest examples of this inequity in British Columbia and across Canada. For people working in diabetes care, Indigenous History Month is not a peripheral awareness event, it is a direct call to examine how we provide care, to whom, and with what assumptions. The Indigenous Numbers Tell One Story. History Tells Another. The statistics are well documented: age-standardized diabetes prevalence among First Nations individuals living on-reserve is 17.2%, compared to 5.0% in the general Canadian population – a difference of 244%. Among First Nations individuals living off-reserve the rate is 10.3%, and 7.3% among Métis people. A large Alberta cohort study found that the lifetime risk of diabetes for a First Nations person over 18 is 8 in 10, compared to 5 in 10 for non-First Nations people. These numbers are not explained by genetics or individual lifestyle choices. They are the outcome of policies, residential schools, forced displacement from traditional lands and food systems, the Indian Act's restrictions on economic self-determination, and the chronic underfunding of community health infrastructure, that have systematically produced the conditions in which chronic disease thrives: food insecurity, overcrowded housing, limited access to primary care, intergenerational trauma, and poverty. Before contact, diabetes was effectively absent in First Nations communities. Its emergence is not a natural phenomenon – it is a consequence of colonization. This is the essential context that must sit alongside any clinical conversation about diabetes in Indigenous communities. Complications, Mortality, and a System That Falls Short The disparity does not stop at diagnosis. First Nations individuals with diabetes experience significantly higher rates of complications than non-Indigenous Canadians with the same diagnosis, including chronic kidney disease, lower limb amputation, severe retinopathy, and cardiovascular disease. A population-based study in Ontario tracking outcomes from 1995 to 2014 found that all-cause mortality rates for First Nations people with diabetes remained persistently higher than for other Ontarians throughout the entire 20-year study period, even as overall rates declined. Perhaps most urgently: avoidable mortality, deaths that could have been prevented through timely care, is substantially higher among First Nations people in Canada. These are not deaths from untreatable disease. They are deaths from a care system that fails to reach people equitably. Among youth, the picture is alarming. First Nations individuals diagnosed with diabetes under the age of 20 face 2.6 times higher rates of end-stage renal disease and death compared to non-First Nations youth diagnosed at the same age. Why People Don't Come Back: Cultural Unsafety as a Clinical Issue One of the most consequential, and least discussed, factors shaping diabetes outcomes in Indigenous communities is the experience of the healthcare system itself. Healthcare in Canada has a documented history of harm against Indigenous peoples: coerced sterilization, experimental research, discriminatory treatment, and the pathologization of Indigenous culture and identity. The In Plain Sight report (2020), commissioned by the BC government, documented Indigenous-specific racism as widespread and systemic within BC's health system, not a matter of a few bad actors, but an embedded structural problem. Patients who have experienced or anticipate racism in the healthcare system make rational decisions: they delay seeking care, they don't disclose symptoms fully, they don't return for follow-up, and they disengage from self-management programs. When a provider interprets this as non-compliance or apathy, they are misreading the situation. The Obesity Canada Clinical Practice Guideline names this directly in its Indigenous-specific chapter: what looks like paralysis is often a response to overwhelming systemic stress, compounded by anticipated discrimination. Cultural safety is not a soft skill or a communication preference, it is a clinical determinant of whether people access care at all. Providers who understand this will deliver better outcomes. What the Evidence Recommends The Diabetes Canada Clinical Practice Guidelines Chapter 38, developed collaboratively with Indigenous partners, offers the clearest evidence-based roadmap for clinical care in this population. The Audio version of Chapter 38 can be accessed here. Several recommendations stand out: Screen more frequently. Screening for diabetes in asymptomatic Indigenous adults (>age 18 years) should be considered every 6 to 12 months in those with additional risk factors. Indigenous children at risk should be screened from age 10 or at established puberty. Earlier onset, higher risk, and greater severity at diagnosis make this urgency essential. Address food insecurity directly. Food insecurity is not a background factor, it is a primary driver of poor diabetes self-management in many communities. Research in First Nations communities on-reserve has found that these households experience food insecurity, and diabetes was strongly associated with poorer self-reported health . Ask about food access as part of routine diabetes care. Connect patients to FNHA-supported programs. The First Nations Health Authority's Honour Your Strength: Our Diabetes Wellness Journey is an eight-session, community-delivered diabetes education program co-designed with First Nations people living with diabetes, Knowledge Carriers, dietitians, and nurses across BC. It blends clinical information with storytelling and peer support — an approach the evidence consistently shows is more effective in this population than standard didactic education. Community health teams can access the materials through their FNHA Regional Practice Consultant. Understand Plan W. Providers in BC caring for FNHA-eligible patients should be familiar with Plan W – the First Nations PharmaCare plan administered through Pacific Blue Cross – which covers blood glucose test strips, medications, and other diabetes supplies. Providers can call FNHA directly to activate first-fill coverage for newly diagnosed patients. Removing cost barriers at the point of diagnosis matters. Cultural Safety Is a Skill and It Can Be Learned San'yas Indigenous Cultural Safety Training, delivered by the Provincial Health Services Authority of BC, is the most widely used cultural safety training program in Canada. Over 200,000 people have completed it. It is free for BC health authority and Ministry of Health employees, accredited by the Royal College of Physicians and Surgeons of Canada (up to 10.0 Section 3 credits), and accredited by the College of Family Physicians of Canada (up to 20 Mainpro+ credits). The program covers colonization in Canada, anti-Indigenous racism, stereotyping and discrimination, and the social determinants of Indigenous peoples' health. It is not a one-time checkbox; it is the beginning of an ongoing practice of self-reflection and system change. The College of Physicians and Surgeons of BC has embedded Indigenous collaboration as a core strategic theme in its 2024–2028 strategic plan, and along with 23 other BC health regulatory bodies signed the Declaration of Commitment to Cultural Safety and Humility in 2017. This is not optional professional development for those who have extra time – it is a professional responsibility. A Note on Language and Approach Throughout this post, "Indigenous peoples" has been used as an inclusive term for First Nations, Métis, and Inuit peoples in Canada. When citing specific data, the original study's terminology has been preserved for accuracy. Language matters, and so does acknowledging that Indigenous peoples are not a monolithic group. First Nations, Métis, and Inuit communities each have distinct histories, cultures, languages, and health profiles. Effective care requires curiosity, not assumptions. It is also important to resist a purely deficit-based framing. Research in First Nations communities on-reserve has found that 44% of First Nations individuals with diabetes report being in good health – a finding that speaks to the resilience and self-determination of communities managing significant adversity. Culture, land, language, and community connection are protective factors, not just background context. Resources for Providers and Patients Diabetes Canada CPG Chapter 38 — T2D in Indigenous Peoples FNHA Diabetes Resources — Honour Your Strength program San'yas Indigenous Cultural Safety Training Plan W — First Nations PharmaCare for BC Providers Obesity Canada CPG Chapter 19 — Obesity Management with Indigenous Peoples CPSBC Cultural Safety and Humility Commitment T2D Network — Indigenous Tailored Resources FNHA — Diabetes and Healthy Living Diabetes Canada — Indigenous Communities and Diabetes Indigenous Services Canada — Aboriginal Diabetes Initiative The T2D Network is committed to supporting equitable, culturally safe diabetes care across British Columbia. Content reviewed for clinical accuracy. For more resources, visit t2dnetwork.ca/indigenous-resources. All images have been sourced from CIRA’s Indigenous Stock photo library:

Key Highlights: ✅ Modern drugs improve blood sugar and cardiovascular health ✅ Continuous glucose monitoring enables real-time diabetes insights ✅ Immunotherapy may inform novel type 2 diabetes treatments ✅ Lifestyle + tech empower personalized diabetes management Diabetes management has come a long way. Just a decade ago, options were limited mostly to insulin injections, oral medications, and lifestyle guidance. Today, a wave of innovations, from cutting-edge drugs to smart devices, is reshaping how diabetes is treated and experienced. These advances not only help people control blood sugar but also improve overall health, reduce complications, and even offer hope for reversing or delaying disease progression. Let’s explore the most exciting developments. Understanding Modern Diabetes Treatments For decades, the cornerstone of diabetes care has been balancing medication, diet, and exercise. While these approaches remain essential, research is delivering more targeted treatments that address the underlying mechanisms of diabetes. Modern therapies aim not just to manage blood sugar but to support weight management, reduce cardiovascular risk, and improve long-term outcomes. Today, the emphasis is shifting from a “one-size-fits-all” approach to personalized diabetes management, which tailors therapies to an individual’s biology, lifestyle, and preferences. This means patients can benefit from options that fit their life rather than adjusting their lives around their treatment. GLP-1 and GLP/GIP Combo Medications: A Game-Changer One of the most exciting developments in diabetes pharmacology is the rise of GLP-1 receptor agonists. These have been available in Canada since 2010 and mimic the naturally occurring hormone glucagon-like peptide-1 (GLP-1), which helps regulate blood sugar levels by stimulating insulin release and reducing glucose production in the liver. But they also have a surprising bonus: they reduce appetite and support weight loss, which is particularly beneficial for people with type 2 diabetes. Popular GLP-1 medications include semaglutide and liraglutide. Clinical trials have shown that these drugs not only improve glycemic control but also reduce cardiovascular risk, a critical benefit given that heart disease is a major complication of diabetes. Even more exciting are the GLP-1/GIP dual-agonists, sometimes called “twincretins,” such as tirzepatide. These target two hormones simultaneously, GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), for more robust blood sugar regulation and significantly greater weight loss than GLP-1 agonists alone. Early patient reports indicate noticeable improvements in energy, mood, and confidence, which demonstrates how these drugs are transforming everyday life for people with diabetes. Diabetes Canada has draft a two page quick reference guideline to guide practice of GLP-1s and GLP-1/GIP medication in Canada. Also, see the BC’s Provincial Academic Detailing (PAD) Service information session on Type 2 Diabetes Focused Update: SGLT2 Inhibitors and GLP1 Agonists (last updated Jun 2023). Continuous Glucose Monitoring: Real-Time Insights Continuous Glucose Monitoring (CGM) devices are revolutionizing the way people manage their diabetes. These small sensors measure glucose levels in real-time, often every few minutes, and transmit data to a smartphone or smartwatch. This allows patients to see immediate feedback on how meals, activity, stress, or medications affect their blood sugar. The benefits of CGM are profound. Patients can identify patterns, prevent dangerous spikes or drops, and make informed adjustments to insulin, diet, and exercise. When paired with insulin pumps in closed-loop “artificial pancreas” systems, CGM devices can automatically adjust insulin delivery, reducing the risk of hypoglycemia and giving users more freedom and peace of mind. Beyond individual health, CGM data is increasingly used in clinical settings. Providers can analyze long-term trends, optimize treatment plans, and even predict complications before they occur. The result? Safer, more precise, and more personalized diabetes care. Beyond Medications: Innovative Therapies While drugs and devices dominate the headlines, innovative therapies are pushing the boundaries of what’s possible in diabetes care. Stem Cell Therapy and Beta Cell Regeneration Scientists are exploring stem cell therapy as a potential way to regenerate insulin-producing beta cells in the pancreas. Early trials indicate that transplanting lab-grown beta cells can restore insulin production in patients with type 1 diabetes or advanced type 2 diabetes. While still experimental, this approach could dramatically reduce the need for insulin injections and improve metabolic control. Immunotherapy for Type 1 Diabetes Type 1 diabetes is an autoimmune disease where the immune system attacks beta cells. Immunotherapy aims to retrain or suppress the immune system, preserving the remaining beta cells or even delaying the onset of the disease. Clinical studies are exploring monoclonal antibodies, vaccines, and other immune-targeted approaches. Success in this area could transform type 1 diabetes from a lifelong condition to a manageable or potentially preventable disease. While immunotherapy is primarily focused on type 1 diabetes, research into immune modulation is also shedding light on T2D. In T2D, chronic inflammation and immune system dysregulation contribute to insulin resistance and beta cell stress. Understanding how immune-targeted therapies work in type 1 diabetes could help scientists develop novel interventions for T2D, such as drugs that reduce pancreatic inflammation, improve insulin sensitivity, or preserve beta cell function. By studying these mechanisms, future T2D treatments may go beyond blood sugar control to address underlying inflammation and immune dysfunction, potentially slowing disease progression and reducing complications. Lifestyle and Technology: The Perfect Partners Even with cutting-edge medications and devices, lifestyle remains a cornerstone of diabetes management. The good news is that technology is making healthy living easier and more tailored than ever. Digital Health Apps & Telemedicine: Apps now track blood sugar, diet, medications, and physical activity while offering real-time feedback. Telemedicine connects patients with specialists virtually, improving access to expert care regardless of location. Personalized Nutrition & Exercise: Advanced tools now allow individuals to tailor diets and exercise routines based on genetic, metabolic, and lifestyle factors. This precision approach helps patients achieve better outcomes while maintaining flexibility in their daily routines. By combining personalized lifestyle strategies with medical advances, patients are better equipped to prevent complications, maintain healthy weight, and feel empowered in their care. Looking Ahead: Smart Insulin, Gene Editing, and Precision Medicine The future of diabetes care is even more promising. Researchers are developing: Smart Insulin & Artificial Pancreas Systems: Insulin that activates only when needed could reduce hypoglycemia and simplify daily management, paired with fully automated insulin delivery systems. Gene Editing: CRISPR and other gene-editing technologies hold the potential to correct genetic defects responsible for diabetes, addressing the disease at its source (source). Precision Medicine: Treatments tailored to an individual’s genes, environment, and lifestyle could improve efficacy, minimize side effects, and allow clinicians to anticipate complications before they occur (source). These innovations signal a future where diabetes care is less about managing a chronic condition and more about optimizing health and preventing disease progression. Empowering Patients Through Knowledge and Support The most important tool in diabetes care is knowledge. Staying informed about new treatments, technologies, and lifestyle strategies empowers patients to take control of their health. Engaging with healthcare providers, participating in supportive communities, and leveraging digital health tools can significantly enhance quality of life. In the end, diabetes management is evolving from a reactive, one-size-fits-all model to a proactive, personalized, and integrated approach. With medications, technology, lifestyle strategies, and community support working together, people with diabetes have more opportunities than ever to thrive. For those looking to connect with peers and share experiences, the T2D Network Forum offers a vibrant online community, with a dedicated group for discussing Treatments. Patients can exchange tips on managing side effects, lifestyle adjustments, and success stories, highlighting the importance of social support in diabetes management. If you're wanting more information on drug approval and reimbursement - please consult Canada's Drug Agency (CDA) for the latest information.

Key Highlights ✅ China’s AI hospitals are revolutionizing healthcare delivery. ✅ AI supports diagnostics, chronic disease management, and telemedicine. ✅ Type 2 diabetes care can be personalized and optimized with AI. ✅ Human oversight, ethics, and data security remain essential. Artificial Intelligence is Transforming Healthcare in China Artificial Intelligence (AI) is reshaping healthcare, and nowhere is this more evident than in China. In 2024, Tsinghua University unveiled the world’s first AI hospital, Agent Hospital, a groundbreaking model staffed by AI doctors capable of diagnosing and treating patients across 21 specialties. Trained on half a million synthetic cases, these virtual physicians boast 93% accuracy and can treat thousands of patients in days. By 2025, this model had moved from internal testing to public deployment at Beijing Tsinghua Chang Gung Hospital, where AI now supports everything from digital admissions to radiology, infusion management, and nursing. Even hospital design has been reimagined, blending technology with human-centered architecture. Scaling AI Across China: DeepSeek AI Meanwhile, DeepSeek AI, a locally deployed medical LLM (large language model), has spread to 260 hospitals across 93% of China’s provinces. From analyzing thousands of pathology slides daily to assisting with telemedicine and chronic disease management, it is quietly transforming everyday clinical practice. Together, Agent Hospital and DeepSeek represent two strategies toward the same goal: scalable, sustainable healthcare in a nation facing physician shortages and an aging population. But they also raise critical debates around trust, regulation, and equitable access. As the world watches China’s full-throttle approach to AI in medicine, one thing is certain: the future of healthcare is being built today, and it’s powered by algorithms as much as by humans. AI is Transforming Healthcare AI is rapidly transforming healthcare, offering solutions to global challenges such as the 4.5 billion people lacking access to essential care and the projected shortage of 11 million health workers by 2030. AI technologies are already improving diagnostics, from spotting fractures and interpreting brain scans to detecting early signs of over 1,000 diseases, while digital interfaces and clinical chatbots streamline patient triage and care guidance. AI also has applications in administrative efficiency, traditional medicine, and predicting patient needs, such as ambulance transfers, potentially reducing costs and improving outcomes. However, adoption in healthcare remains slower than in other industries, and challenges persist, including the need for human oversight, ethical use, accurate training, and robust regulation to ensure safety, reliability, and equitable access worldwide. The Promise of AI for Type 2 Diabetes Care Type 2 diabetes (T2D) is one of the most common chronic diseases worldwide, and its management requires ongoing monitoring, lifestyle modification, and clinical support. AI has enormous potential to improve care for people living with T2D. Advanced algorithms can analyze continuous glucose monitoring (CGM) data, predict hyper- or hypoglycemic events, and provide personalized lifestyle recommendations. AI-driven platforms can support medication titration, identify high-risk patients, and even automate parts of routine care, potentially reducing complications such as heart disease, kidney failure, and neuropathy. AI-powered telemedicine and digital twins can expand access to diabetes education and coaching in underserved areas, providing consistent follow-up and personalized interventions. In large-scale healthcare systems like China’s, these technologies could dramatically improve outcomes for millions of patients while easing the burden on healthcare providers. Cautions and Limitations of AI in Diabetes Care Despite the promise, AI in T2D care comes with important limitations. Algorithms are only as good as the data they are trained on, biases in datasets can lead to misdiagnoses or inappropriate recommendations. Human oversight remains essential, particularly when complex comorbidities are present or when patients require nuanced, culturally responsive care. Privacy, security, and ethical concerns around patient data are paramount, as are issues of equitable access, AI should complement, not replace, human clinicians, and must be deployed in a way that benefits all populations. Lessons from China: Building the Future of Healthcare The Chinese experience demonstrates both the potential and the challenges of large-scale AI integration in healthcare. For T2D, AI offers exciting tools for personalized, efficient, and proactive care, but success will depend on careful implementation, robust oversight, and collaboration between humans and machines. As the world watches China’s full-throttle approach to AI in medicine, one thing is certain: the future of healthcare, and the future of chronic disease management like T2D, is being built today, powered by algorithms as much as by humans.

Blog Highlights ✅ GLP-1 RAs manage blood sugar and support weight loss for T2D and obesity. ✅ Approved GLP-1 RAs in Canada include semaglutide, liraglutide, and dulaglutide. ✅ GLP-1 RAs reduce cardiovascular risks but may cause nausea and GI issues. ✅ GLP-1 RA use is rising among non-diabetics, raising concerns about misuse. If you’re living with type 2 diabetes (T2D) or struggling with obesity, you may have heard about a new class of medications called GLP-1 receptor agonists (GLP-1 RAs). These drugs are making headlines for their ability to lower blood sugar and support weight loss — but what are they and how do they work? Let’s break it down. What are GLP-1 Receptor Agonists GLP-1 agonists (short for glucagon-like peptide-1 receptor agonists) are medications that mimic a hormone naturally produced in the gut. This hormone helps regulate blood sugar and appetite, especially after eating. When used as medication, GLP-1 RAs increase insulin production when blood sugar is high, reduce the amount of glucagon (a hormone that raises blood sugar), slow digestion, and increase feelings of fullness; all of which contribute to better blood sugar control and weight management. Most GLP-1 RAs are injectable, but oral options are also available, such as semaglutide tablets. These medications are primarily prescribed for people with T2D who need more than just metformin to control their blood sugar. They are also used for people living with obesity (defined as a body mass index, or BMI, of 30 or more) or overweight individuals (BMI of 27 or more) who have related health issues like high blood pressure or cholesterol. It’s important to note that GLP-1 agonists are not approved for use in Type 1 diabetes in Canada, although they may occasionally be prescribed off-label in unique circumstances. Which GLP-1s are approved in Canada? Medication Brand Name(s) Use Frequency Approved in Canada? Dulaglutide Trulicity® T2D Weekly injection ✅ Yes Exenatide Byetta®, Bydureon® T2D Twice daily or weekly ✅ Yes Liraglutide Victoza® (T2D), Saxenda® (weight loss) T2D, Weight Management Daily injection ✅ Yes Lixisenatide Adlyxine® T2D Daily injection ✅ Yes Semaglutide Ozempic® (T2D), Rybelsus® (oral for T2D), Wegovy® (weight loss) T2D, Weight Management Once weekly (injection) or daily (oral) ✅ Yes (Wegovy approved in 2025) Tirzepatide Mounjaro® T2D (weight loss under review) Weekly injection ✅ Yes (Approved in 2024) Wegovy®, a higher dose of semaglutide used for weight loss, was recently approved by Health Canada. However, due to high global demand, access may be limited in some areas. What are the benefits? The benefits of GLP-1 RAs go beyond just lowering blood sugar. They can also improve other health markers such as blood pressure and cholesterol levels. Some studies suggest that they help reduce the risk of heart and kidney disease, support liver health (especially in people with fatty liver disease), and may delay the progression of diabetic kidney complications. A pivotal 2021 clinical trial of semaglutide showed that participants lost an average of 15% of their body weight over 68 weeks, compared to just 2% in the placebo group. Some individuals even lost up to 20% of their initial weight. More recently, the potential health advantages of these drugs have expanded. Findings from the SELECT trial, published in 2023, revealed that semaglutide reduced the risk of heart attack and stroke by 20% in people with pre-existing cardiovascular disease. Across other large studies, GLP-1RAs showed consistent and significant health benefits beyond glycemic control. A comprehensive cohort study using U.S. Veterans Affairs databases found that GLP-1RA use was associated with reduced risks of major adverse cardiovascular events (MACE), stroke, heart failure, cardiac arrest, and thromboembolic disorders. Neurocognitive benefits included a lower incidence of Alzheimer’s disease, dementia, and psychotic disorders such as schizophrenia. The same study also reported fewer cases of respiratory failure, pneumonia, substance use disorders, and seizures. These findings were echoed in a large-scale adjusted analysis involving 7 million person-years of data. Additionally, a meta-analysis of 26 trials concluded that GLP-1RAs were particularly effective in reducing macrovascular and microvascular complications, positioning them as a strong therapeutic choice for patients at risk of cardiovascular and cerebrovascular disease. What are the risks? As of 28 October 2024, the UK Government's med watch database (MHRA) received over 7,000 reports of gastrointestinal side effects linked to GLP-1RAs, with some resulting in hospitalization. Despite their benefits, GLP-1RAs carry several notable risks. Common ones reported by the Government of Canada include nausea, vomiting, diarrhea, and loss of appetite, especially when starting the medication or increasing the dose. Some people also experience headaches, dizziness, or mild injection site reactions. More serious but rare side effects include pancreatitis, kidney issues, allergic reactions, and possible thyroid tumors (seen in animal studies). These medications are not recommended during pregnancy, and they may increase the risk of hypoglycemia (low blood sugar) when used with insulin or sulfonylureas. Studies have noted higher rates of gastrointestinal disorders, hypotension, syncope, kidney stones (nephrolithiasis), interstitial nephritis, and drug-induced pancreatitis. These findings were confirmed by the observational analysis, which also reported increased musculoskeletal issues such as arthralgias and arthritis. Additionally, other studies have found an elevated risk of thyroid cancer in GLP-1RA users (odds ratio 1.58), further emphasizing the need for careful patient selection. Compared to alternate T2D drugs, GLP-1RAs have a unique adverse effect profile that necessitates individualized prescribing based on tolerability and risk factors. What happens if GLP-1 RAs are stopped? While GLP-1 RA drugs are effective, their high cost ( US$1,350/month) and side effects (nausea, stomach pain, heartburn) raise concerns, especially about what happens after stopping treatment. Numerous studies have investigated this question, and the results are consistent: weight often returns once treatment is stopped. In one trial, participants lost nearly 11% of their body weight with weekly semaglutide injections, dietary changes, exercise, and psychological counseling. However, when a third of the participants were switched to a placebo for the following year, they regained 7% of the weight they had lost. A similar trend was observed in the STEP 1 trial of 2021. After 68 weeks on semaglutide, patients had lost an average of over 15% of their body weight. But within 12 months of stopping treatment, they regained two-thirds of the weight they had lost, along with a significant reversal of improvements in some cardiometabolic markers, such as those related to diabetes and heart disease. The pivotal 2021 clinical trial of semaglutide revealed that nearly 14% of participants were unable to lose even 5% of their body weight, despite being on the medication for over a year. And only around 10% of people were able to maintain all the weight they’ve lost. In another study, patients without T2D were more likely to stop using GLP-1 drugs: about 65% discontinued within a year, compared to 46% of those with type 2 diabetes. After two years, the discontinuation rates rise to 84% for non-diabetic patients and 64% for diabetics. The study highlights that those experiencing fewer side effects are less likely to quit, emphasizing the impact of tolerability and affordability on long-term use. For most, the weight returns quickly, typically within the first 3 to 6 months. This pattern mirrors what’s seen in other chronic conditions, where relapses occur once treatment stops. Understanding why weight regain happens after discontinuing GLP-1 treatment could be crucial for determining their long-term health impacts and the best way to prescribe them in the future. How are GLP-1 RAs Changing T2D Treatment Options Many patients have reported positive experiences with GLP-1 receptor agonists. For instance, those who were previously unable to control their blood sugar levels or face considerable weight challenges have found success with these medications. Patients often highlight the ease of use, GLP-1 receptor agonists can be administered via daily or weekly injections, depending on the specific medication. Additionally, many patients appreciate the positive side effects, such as weight loss, rather than severe drawbacks associated with some diabetes medications. However, these drugs appear to be having a wider impact than the physical state and are reshaping culture and society. An article by Matthew Schneier for New York Magazine explores how the diabetes drug Ozempic, and similar medications, are transforming not just bodies, but the very culture and psychology of eating, thinness, and status. Laila Gohar (artist): “Everyone in L.A. is skinny now... Well, the last few people who weren’t, now are.” Gohar notes the dramatic, visible impact of Ozempic on entire social scenes. The piece investigates how drugs like Ozempic, originally for diabetes, have become status symbols and appetite suppressants among the non-diabetic elite, especially in entertainment and fashion. Quotes from users, doctors, and cultural commentators reveal a landscape where weight loss is now quick, medicalized, and quietly omnipresent; reshaping not just bodies, but the meaning of food, self-control, and social status Dr. Holly Lofton (NYU Langone Health) details the overwhelming demand for these drugs, even among those not strictly medically eligible. “The last six months, I’ve written 1,400 prescriptions for semaglutide... They come in begging for it. If I give them pills, they’re disappointed.” -- Lofton These social and cultural changes have increased demand, motivating illegal methods to obtain the drugs. The UK Government MHRA warns against the misuse of falsified GLP-1RAs, often acquired without a prescription, and the growing trend of using these medications for aesthetic weight loss. Healthcare providers should stress that these drugs should only be obtained from authorized sources and used under medical supervision. Nevertheless, GLP-1 drugs are skyrocketing in popularity even in those without T2D. A 2024 study published in The BMJ reports a staggering 700% increase in the number of U.S. adults without diabetes who began GLP-1RA treatment between 2019 and 2023. According to researchers from the University of Pennsylvania and Cedars-Sinai Medical Center, the number of non-diabetic patients starting these medications jumped from 21,000 in 2019 to over 174,000 in 2023. Using data from over 45 million de-identified patient records, the team found that more than 870,000 people were prescribed a GLP-1RA between 2011 and 2023. Notably, nearly two-thirds of these users did not have diabetes, and the majority (59.6%) were women. The growing demand for pharmacological tools to support weight loss, beyond traditional lifestyle interventions, reflect a broader shift in how these powerful medications are being used in clinical practice. The Future of Diabetes Care with GLP-1 RAs The landscape of diabetes care continues to evolve, and GLP-1 RAs are at the forefront of this transformation. With ongoing research, new formulations, and combination therapies on the horizon, patients can expect even more innovative options for managing their diabetes. Advancements in technology, such as connected pen caps that track medication use and integrate data with smartphone applications, will enhance patient engagement and adherence. Increased awareness about the benefits and accessibility of GLP-1 RAs will also play a significant role in diabetes management moving forward. As we look ahead, it is evident that GLP-1 RAs are revolutionizing diabetes care. Their ability to improve blood sugar control, facilitate weight loss, and significantly impact cardiovascular health sets these medications apart as vital tools in diabetes management. As demand and options are shaped by GLP-1 RAs, a growing need for support is becoming evident. Support groups and communities, like the glp-1 forum, provide patients with a platform to share their experiences and learn from others. This shared knowledge can empower patients in their diabetes management journey. Understanding and utilizing GLP-1 RAs alongside a balanced lifestyle can empower individuals to take control of their diabetes. The integration of technology, community support, and evidence-based medication will shape the future of diabetes care, ensuring better outcomes for patients worldwide. Join our network for more information on T2D.

Key Highlights: ✅ Digital tools empower self-management ✅ Personalized messages boost adherence ✅ Gamification makes care engaging ✅ Wearables improve activity & health ✅ VR enhances education & engagement In today’s healthcare landscape, patient engagement is more important than ever. Engaged patients are more likely to follow treatment plans, attend appointments, and maintain healthier lifestyles. Technology offers innovative tools to enhance this engagement, making healthcare more interactive, personalized, and accessible. This article explores practical ways technology can improve patient engagement, providing examples and actionable recommendations. Enhancing Patient Engagement with Digital Tools Digital tools have transformed how patients interact with healthcare providers. Mobile apps, patient portals, and telehealth platforms allow patients to access their health information, communicate with providers, and manage appointments easily. These tools empower patients to take control of their health and stay informed. For example, patient portals provide secure access to medical records, test results, and medication lists. Patients can review their information anytime, reducing confusion and increasing transparency. Several studies have found that patients with access to patient portals has improved glycemic control outcomes. Telehealth services enable virtual consultations, making healthcare accessible for those with mobility issues or living in remote areas - especially important in Canada in winter.One Canadian study found additional benefits: alongside telemonitoring and digital health records, widespread use of teleconsultations could provide significant advantages for patients, the economy, and Canadian society as a whole. To maximize engagement, healthcare providers should ensure these digital tools are user-friendly and accessible on multiple devices. Offering tutorials or support can help patients who are less tech-savvy. Additionally, integrating reminders for medication, appointments, and health screenings can keep patients on track. The Role of Personalized Communication in Patient Engagement Personalized communication is key to keeping patients engaged. Technology enables tailored messages based on individual health data, preferences, and behaviors. This approach makes patients feel valued and understood, increasing their motivation to participate actively in their care. Automated messaging systems can send customized reminders, educational content, and motivational tips. For instance, a diabetic patient might receive daily blood sugar monitoring reminders and diet suggestions. These messages should be clear, concise, and relevant to the patient’s condition. Healthcare providers can also use data analytics to identify patients at risk of non-compliance or complications. Targeted interventions, such as phone calls or personalized emails, can then be implemented to address specific needs. Using multiple communication channels - SMS, email, and app notifications - ensures messages reach patients in their preferred way. This multi-channel approach improves the chances of engagement and adherence. What is an example of gamification in healthcare? Gamification in healthcare is an innovative strategy that uses game design elements to motivate patients to engage in healthy behaviors. For example, some apps reward patients with points or badges for completing daily health tasks like taking medication, exercising, or logging symptoms. One practical example is a diabetes management app that encourages users to track their blood sugar levels regularly. Patients earn rewards for consistent monitoring and can compete with friends or family members in friendly challenges. This approach makes managing chronic conditions more enjoyable and less burdensome. Research shows that gamification can improve adherence to treatment plans and increase patient satisfaction. It taps into natural human desires for achievement and competition, making health management feel less like a chore. To implement gamification effectively, healthcare providers should ensure the games are simple, relevant, and inclusive. They should also provide clear instructions and feedback to keep patients motivated. Leveraging Wearable Devices for Continuous Engagement Wearable devices such as fitness trackers and smartwatches have become popular tools for promoting patient engagement. These devices monitor physical activity, heart rate, sleep patterns, and other vital signs in real time. Patients receive instant feedback, helping them make healthier choices throughout the day. A recent study, that included many well-known Canadian authors, showed that wearable-based programs like MOTIVATE-T2D can boost exercise adherence, improve clinical markers, and enhance quality of life for people with Type 2 Diabetes, demonstrating both health and long-term management benefits. In future, healthcare providers could integrate wearable data into electronic health records to monitor patient progress remotely. This continuous data stream allows for timely interventions and personalized care adjustments. For example, a patient recovering from surgery might wear a device that tracks blood sugar and alerts the care team if activity levels drop. This proactive approach can prevent complications and support faster recovery. To encourage use, providers should educate patients on the benefits of wearables and how to interpret their data. Offering incentives or challenges can also boost motivation. Using Virtual Reality to Enhance Patient Education and Engagement Virtual reality (VR) is an emerging technology with great potential to improve patient engagement. VR can create immersive educational experiences that help patients understand their conditions and treatments better. For instance, a randomized control trial using a two-week VR exercise program improved blood glucose levels, increased muscle mass, and enhanced exercise engagement in patients with tT2D, making it a highly recommended intervention for managing blood glucose in this population. VR can also be used for pain management, anxiety, and rehabilitation, providing engaging distractions and guided exercises. It has also shown success in patient education. Patients who actively participate in their care through VR are more likely to adhere to treatment plans. Healthcare providers should consider incorporating VR into patient education programs, especially for complex or chronic conditions. Ensuring accessibility and ease of use will maximize its impact. Moving Forward with Technology-Driven Patient Engagement Technology offers numerous opportunities for both diabetes and pre-diabetes. From digital tools and personalized communication to gamification, wearables, and virtual reality. By adopting these innovations, healthcare providers can create more interactive, supportive, and effective care experiences. To succeed, it is essential to focus on usability, personalization, and continuous support. Engaged patients are empowered patients, leading to better health outcomes and satisfaction. Healthcare organizations should stay informed about emerging technologies and be willing to experiment with new approaches. Collaboration with patients to understand their needs and preferences will ensure that technology truly serves its purpose. By embracing these innovative strategies, the future of patient engagement looks promising and patient-centered.

Saskatchewan is a land of vast spaces and stark contrasts, covering an area roughly the size of France. Yet, despite its vastness, access to healthcare for its residents can feel like a distant dream, especially for the 30% of its population living in rural and remote areas. Harsh winters with temperatures reaching -60°C, limited road access to some communities, and logistical challenges make it difficult for patients and healthcare providers to connect. But amid these challenges, innovation is rising to meet the needs of Saskatchewan’s underserved areas. What is the Virtual Health Hub? The Virtual Health Hub (VHH) is an Indigenous-led initiative transforming healthcare delivery for the province’s remote communities. This ambitious project aims to bridge the healthcare gap by leveraging technology and community collaboration to improve access to care. It’s not just a win for rural residents—this groundbreaking approach has the potential to reshape healthcare delivery across the country. The Virtual Health Hub is an innovative, purpose-built facility in Saskatchewan that utilizes state-of-the-art technology to provide real-time virtual care. Designed to serve approximately 90 communities, the hub allows healthcare professionals to remotely assess patients, help with triage, and offer treatment guidance, all from a distance. What makes the VHH stand out is its Indigenous-led approach. With a significant portion of Saskatchewan’s population being Indigenous, 17%.) in 2021, the project is deeply rooted in understanding and integrating Indigenous perspectives and culture into healthcare delivery. This culturally sensitive model ensures that the care provided aligns with the values and traditions of the communities served. 👉 Stay tuned for more exciting news and updates by joining our network Written and clinically validated by Clare Koning, RN, MN, PhD – Supporting evidence-based content at the T2D Network.

Written by Clare Koning, RN, PhD T2D Network | April 2026 | 6 min read Key Highlights ✅ Orforglipron is a once-daily GLP-1 pill: no injections, no food or water timing restrictions ✅ Phase 3 trials showed A1C reductions of 1.3%–1.6% and meaningful weight loss ✅ In a head-to-head trial published in The Lancet, it outperformed oral semaglutide on every key endpoint ✅ Regulatory submissions are underway in 40+ countries: U.S. diabetes approval anticipated later in 2026 ✅ Not yet approved in Canada: but worth knowing about now If you've ever wished the GLP-1 medications that have transformed diabetes care could come in a simple daily pill, without needles, refrigeration, or strict timing around meals, you may be closer to that reality than you think. Orforglipron, an investigational once-daily oral GLP-1 receptor agonist developed by Eli Lilly, has just completed a series of landmark Phase 3 trials. The results are turning heads in the diabetes community, and for good reason. Here's what the evidence actually says, and what it might mean for people living with type 2 diabetes. What Is Orforglipron? GLP-1 receptor agonists (like semaglutide, sold as Ozempic or Rybelsus) work by mimicking a gut hormone that helps regulate blood sugar, suppress appetite, and promote weight loss. Until now, the most effective versions have been injectables. Orforglipron is different. It's a small molecule, meaning it's not a peptide and doesn't break down in the gut the way most protein-based GLP-1 drugs do. That allows it to be taken as a pill, once a day, at any time, without restrictions on food or water intake. That last point matters more than it sounds: existing oral semaglutide (Rybelsus) must be taken 30 minutes before eating, with only a small amount of water, a barrier that can be frustrating in real life. What Do the Trials Show? The data are genuinely impressive. In ACHIEVE-1, the first of seven Phase 3 studies in people with type 2 diabetes, orforglipron reduced A1C by an average of 1.3% to 1.6% across doses compared to placebo at 40 weeks, starting from a baseline of 8.0%. Over 65% of participants on the highest dose achieved an A1C at or below 6.5%, the target many healthcare providers aim for. The pill also produced an average weight loss of about 7.9% (roughly 16 lbs) at the highest dose. Then came ACHIEVE-3, published in The Lancet in February 2026, the first direct head-to-head comparison between two oral GLP-1 therapies. In this 52-week trial of 1,698 people with type 2 diabetes whose blood sugar wasn't adequately controlled on Metformin, orforglipron outperformed oral semaglutide on every primary and secondary endpoint, including A1C reduction and weight loss, with improvements visible as early as four weeks. In ATTAIN-2, which specifically studied people with both obesity and type 2 diabetes (a group for whom weight loss is known to be harder), participants on the highest dose lost an average of 10.5% of body weight (about 23 lbs) over 72 weeks, while also reducing A1C by an average of 1.8%. Across all studies, the safety profile was consistent with the broader GLP-1 class: nausea, diarrhea, and mild gastrointestinal symptoms were the most common side effects, typically occurring during the dose escalation phase. Why Does This Matter for People with T2D? For many people, the barrier to starting a GLP-1 therapy isn't about the medicine itself, it's about the needle. Injection anxiety, needle phobia, and the practicalities of cold storage and travel all limit uptake of otherwise effective treatments. An oral alternative that works as well as or better than existing options, and can be taken as easily as a daily vitamin, has the potential to meaningfully expand access. Researchers at UTHealth Houston described orforglipron's potential to become "the Metformin of obesity", a widely accessible, affordable, and scalable first-line treatment. Whether that vision is fully realized will depend on pricing, insurance coverage, and regulatory outcomes. Where Things Stand Right Now Lilly has submitted orforglipron for regulatory review in over 40 countries. In the U.S., a submission for the weight management indication was made in 2025, with a type 2 diabetes submission planned later this year. Canadian regulatory timelines typically follow U.S. approvals, so Canadians living with type 2 diabetes may be waiting a little longer. It is not yet approved anywhere for type 2 diabetes. But given the strength of the trial data, it's a development worth watching closely. In the meantime, if you're interested in GLP-1 therapies or want to discuss your current diabetes medications, this is a great conversation to have with your healthcare provider. There are already approved options, injectable and oral, that may be right for you now. What Should You Do? Talk to your diabetes care team about whether a GLP-1 receptor agonist is appropriate for you — approved options already exist. Stay informed. The T2D Network will continue to share updates as orforglipron moves through the regulatory process in Canada. Don't discontinue or switch medications without medical guidance. Orforglipron is not yet approved, and self-managing medication changes is never recommended. This blog is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before making changes to your diabetes management.

Written by Clare Koning, RN, PhD May 2026 7 min read Key Highlights ✅ High-quality prospective evidence now links ultra-processed food consumption directly to type 2 diabetes (T2D) risk ✅ Every 10% increase in UPF intake is associated with a 12% to 14% higher risk of developing T2D ✅ The relationship is dose-dependent and holds after adjusting for obesity, diet quality, and lifestyle factors ✅ Not all processed foods are equal: the type of UPF matters as much as the quantity ✅ The NOVA classification system is becoming a practical clinical tool, not just a research framework The term "ultra-processed food" has spent years hovering at the edges of nutrition science, carrying the air of something that sounds alarming but lacks the hard evidence to back it up. That characterisation is no longer accurate. In the past three years, a convergence of large-scale prospective cohort studies and high-quality meta-analyses has moved the science from suggestive to substantial, and the implications for type 2 diabetes prevention and management are difficult to overstate. This is not a fringe position. High-quality meta-evidence now supports a direct, dose-dependent relationship between ultra-processed food (UPF) consumption and the risk of developing type 2 diabetes, independent of obesity, physical inactivity, and overall diet quality. For healthcare providers still reaching for the traditional "eat less sugar and saturated fat" framework, and for patients navigating a food environment dominated by products engineered to displace whole foods, this evidence demands a more specific and more urgent conversation. What Is an Ultra-Processed Food? The term comes from the NOVA food classification system, a framework developed by researchers at the University of São Paulo that categorizes foods not by nutrient content but by the degree and purpose of processing. NOVA divides foods into four groups: unprocessed or minimally processed foods (fresh vegetables, meat, eggs); processed culinary ingredients (oils, flour, salt); processed foods (canned vegetables, cheese, cured meats); and ultra-processed foods. Image taken from: https://www.mdpi.com/2218-273X/15/2/307 Ultra-processed foods are industrial formulations made mostly or entirely from substances extracted from foods, often chemically modified, combined with additives designed to enhance palatability, shelf life, colour, and texture. They include: soft drinks, packaged snack foods, reconstituted meat products, instant noodles, breakfast cereals with added sugars, flavoured yogurts with thickeners, and most ready-to-eat meals. What defines them is not a single "bad" ingredient but the totality of their industrial fabrication and the additives used to make them hyper-palatable and highly convenient. In Canada, as in most high-income countries, UPFs make up a large portion of total caloric intake. Among 33,795 U.S. children and adolescents, ultra-processed food consumption increased to 67% of total energy intake between 1999 and 2018. This is not a marginal dietary pattern. It is the dominant one. What the Evidence Actually Shows The research base has developed considerably in recent years, and the most rigorous findings now represent high-quality evidence by standard epidemiological criteria. A meta-analysis published in Diabetes Care, drawing on three large US prospective cohorts including the Nurses' Health Study I and II and the Health Professionals Follow-up Study (5,187,678 person-years; n = 19,503 T2D cases), found that people in the highest quintile of UPF consumption had the higher risk of developing T2D compared to those in the lowest quintile, after adjusting for multiple confounders. Every 10% increase in the proportion of your diet that comes from ultra-processed foods is associated with a 12% to 14% higher risk of developing type 2 diabetes. The relationship is linear and dose-dependent. A dose-response meta-analysis published in Diabetes Metabolism Journal in 2025, synthesizing 12 prospective cohort studies, corroborated these findings. Each 10% increase in UPF intake was associated with a 14% higher T2D risk, with a potential threshold effect emerging at around 300 grams per day. Importantly, the association was maintained after adjusting for BMI, meaning the pathway between UPF consumption and diabetes is not simply explained by weight gain, though weight gain is one mechanism. A separate updated systematic review and meta-analysis including 14 prospective cohort studies and over 692,000 participants found a pooled hazard ratio of 1.24 (95% CI 1.14 to 1.34) for the highest versus lowest UPF consumption categories, consistent with a clinically meaningful elevation in risk. This means that UPF consumption results in a greater risk of T2D and can contribute to its complications. The Mechanisms: Why UPFs Damage Metabolic Health The biological plausibility of this association is supported by multiple converging pathways. UPFs contribute to diabetes risk through both their nutrient composition and through mechanisms entirely distinct from macronutrient content. On the nutrient side, UPFs are typically high in refined carbohydrates and added sugars that produce rapid postprandial glucose and insulin spikes, and low in dietary fibre, which slows glucose absorption and supports gut microbiome diversity. Both of these profiles directly promote insulin resistance over time. But the UPF story extends beyond nutrients. Research published in Biomolecules in 2025 has identified specific additives in UPFs, including emulsifiers, artificial sweeteners, acrylamide formed during high-heat processing, and bisphenol-A leached from packaging, as independently implicated in disrupting the gut microbiome, promoting low-grade systemic inflammation, and impairing insulin signalling. This suggests that two people consuming similar quantities of sugar and saturated fat will have meaningfully different metabolic outcomes depending on whether those macronutrients arrive in whole foods or ultra-processed vehicles. The gut microbiome dimension is particularly relevant. As reviewed earlier in our blog series, a Westernized dietary pattern dominated by UPFs reduces microbial diversity and promotes the proliferation of pro-inflammatory taxa, while depleting the short-chain fatty acid-producing bacteria associated with improved insulin sensitivity. Not All Processed Foods Are Equal One of the most practically useful findings from this body of research is the evidence on heterogeneity within the UPF category itself. The large US cohort study was able to disaggregate UPF subgroups, and the results are instructive. Refined breads, artificially and sugar-sweetened beverages, sauces and condiments, animal-based processed products, and ready-to-eat mixed dishes were all associated with higher T2D risk. However, some UPF subgroups, including dark and whole-grain packaged breads, plain yogurt and dairy-based products, and some fruit-based products, were associated with lower risk, even though they meet the technical NOVA definition of ultra-processed. This is an important nuance for clinical dietary guidance. The goal is not to create patient anxiety around every food with an ingredient list, but to help people identify the specific categories, sweetened beverages, refined grain products, reconstituted meats, and heavily emulsified savoury snacks, that carry the highest metabolic cost. Reducing ultra-processed food consumption does not require a perfect diet. It requires identifying the highest-risk categories and making targeted, sustainable substitutions. Clinical Implication When reviewing dietary patterns with patients who have T2D or prediabetes, moving beyond the traditional sugar-and-fat framework toward a conversation about food processing level and UPF category is now supported by high-quality evidence. Asking patients about their consumption of sweetened beverages, packaged savoury snacks, and ready-to-eat meals is a specific and evidence-aligned line of clinical enquiry. The Food Environment Problem It would be incomplete to address UPF consumption as though it were purely a matter of individual choice. The food environments in which most Canadians live are designed, deliberately and commercially, to maximize the consumption of ultra-processed products. They are cheaper per calorie than whole foods, more heavily marketed, more convenient, and engineered through flavour science to override satiety signals. The downstream consequence is that people with lower incomes and in food-insecure settings tend to have higher UPF consumption, not because of poor decision-making, but because of constrained access to affordable whole foods. This means UPF exposure is not equally distributed, and any clinical conversation about reducing UPF intake must be sensitive to the social and economic context of each patient's life. The evidence on UPF and T2D risk adds urgency to policy arguments for food labelling reform, front-of-pack warning labels, and pricing interventions that make whole foods more accessible. What This Means for People with T2D For people already living with type 2 diabetes, the evidence on UPFs reinforces priorities that may already be familiar, but with a more specific target. Rather than the general instruction to "eat less processed food," the evidence points toward a handful of high-impact substitutions: replacing sweetened beverages with water, sparkling water, or unsweetened drinks; swapping refined bread products for whole grain versions; choosing minimally processed proteins over reconstituted meat products; and reducing reliance on ready-to-eat and packaged convenience meals in favour of simple whole food preparations. These are not dramatic transformations. They are targeted, evidence-based shifts that reduce UPF exposure at the highest-risk end of the spectrum. For practical guidance on healthy eating with T2D, visit the T2D Network's Healthy Eating page.

Written by Clare Koning, RN, PhD May 2026 7 min read Key Highlights ✅ 79% of people living with diabetes report experiencing diabetes burnout, according to a 2025 IDF survey ✅ 3 in 4 of those affected admit to stopping or interrupting treatment when overwhelmed ✅ Diabetes burnout is distinct from depression and distress, but is often mis-labelled or missed entirely ✅ It is a direct driver of poor glycemic control, medication non-adherence, and reduced quality of life ✅ Healthcare providers have a critical role, and a practical one, in identifying and responding to burnout You are checking your blood sugar. Again. Counting carbohydrates. Again. Navigating a social dinner, an unexpected work trip, a stressful week, a medication refill that didn't come through, and a blood sugar result that makes no sense given everything you did right. And underneath all of it, quietly growing, is the feeling that you simply cannot do this anymore. This is diabetes burnout. And it is far more common, far more clinically consequential, and far more treatable than our healthcare systems typically acknowledge. In a 2024 survey conducted by the International Diabetes Federation spanning thousands of people living with diabetes globally, 79% of respondents reported experiencing diabetes burnout, a state of physical and emotional exhaustion driven by the relentless demands of daily diabetes management. More alarming still: 3 in 4 of those affected admitted to stopping or interrupting their diabetes treatment as a direct consequence of feeling overwhelmed. Those are not peripheral statistics. They are a description of a care crisis happening quietly in clinic waiting rooms and kitchen tables everywhere. What Diabetes Burnout Actually Is, and Is Not The terminology in this space matters, because diabetes burnout, diabetes distress, and depression are three distinct constructs that are frequently conflated in clinical settings, with real consequences for how they are addressed. A scoping review published in eClinicalMedicine clarified these distinctions. Diabetes distress refers to the specific emotional burden arising from the challenges of living with and managing diabetes: worry about complications, frustration with blood glucose variability, concern about the future. It is a condition-specific response, and it fluctuates. Depression, by contrast, is a clinical psychiatric diagnosis with broader symptoms including persistent low mood, anhedonia, and cognitive changes that extend beyond the diabetes experience. Diabetes burnout occupies its own space. It is characterized by a state of physical and emotional exhaustion from the unrelenting self-management demands of a chronic condition. Where distress is worry and frustration, burnout is something more like detachment and resignation. People with diabetes burnout often describe feeling disconnected from their care, not because they don't understand its importance, but because they feel utterly spent by it. As clinical psychologist Dr. William Polonsky, who wrote the foundational text Diabetes Burnout in 1999, describes it: they are at war with their diabetes, and they have run out of fight. In clinical encounters, this often manifests as patients who appear "difficult," "non-compliant," or "unmotivated," and who are sometimes labelled as such in notes and handovers. This framing is both inaccurate and harmful. These are patients who are exhausted, not indifferent. Diabetes burnout is not non-compliance. It is exhaustion from compliance. The distinction matters enormously for how we respond. The Clinical Consequences Are Measurable Burnout is not a soft endpoint. Its downstream effects on health outcomes are clinically meaningful and well-documented. A path analysis study published in PMC examining the predictors of quality of life in people with T2D found that diabetes burnout and distress together significantly reduced self-care behaviours, which in turn were the primary mediators of glycemic control and quality of life. The study found that health literacy, social support, burnout, and distress together accounted for 49% of the variance in diabetes-related quality of life, a remarkably high proportion for a behavioural model, underscoring how central the psychological landscape is to actual health outcomes. Studies consistently show that burnout is associated with barriers to medication adherence. In one study examining medication use in T2D, 36% of participants identified diabetes burnout as a key barrier to taking their medications as prescribed. For a condition where medication adherence is one of the strongest levers for preventing complications, this represents an enormous unmet need in standard care delivery. The relationship between burnout and glycemic control is not simply correlational. A 2026 study published in Frontiers in Endocrinology developing a validated Diabetes Burnout Scale for T2D identified economic pressure, time pressure, and social pressure as key burnout dimensions specifically relevant to people with type 2 diabetes, underscoring how burnout in T2D differs from burnout in type 1 and requires condition-specific clinical tools and responses. Why This Is a System Problem, Not a Patient Problem There is a tendency in healthcare to locate the problem of burnout within the individual. The patient is not coping, not trying hard enough, not engaging with their care plan. But the more honest analysis looks upstream. Managing type 2 diabetes on any given day involves blood glucose monitoring, medication timing, carbohydrate counting, physical activity, sleep, stress management, foot care, medication refills, specialist appointments, and the cognitive labour of integrating all of that into an ordinary life that has its own demands. This is not a simple task. It is a second job, one that never ends, never grants a sick day, and is largely invisible to those who don't live it. Healthcare systems that see patients for 15 minutes every three months and assess quality of care primarily through HbA1c are not designed to detect or address burnout. The IDF's 2025 report was blunt: "While diabetes affects both physical and mental well-being, care often focuses only on blood sugar management, leaving many overwhelmed." What Providers Can Do The good news is that early identification and relatively modest interventions can make a substantial difference. The first step is simply asking, and asking in a way that normalizes the experience. Opening a conversation with a statement like "Many people I see find that living with diabetes is genuinely exhausting at times" before asking how a patient is coping has been shown to create space for disclosure that direct questioning often does not. The 2026 ADA Standards of Care now formally include guidance on behavioural health screening, including referral pathways for diabetes distress and anxiety, reflecting a growing clinical consensus that psychological wellbeing is inseparable from metabolic outcomes. Validated screening tools including the Problem Areas in Diabetes Scale (PAID) and the Diabetes Distress Scale (DDS) can be incorporated into routine care to identify patients at risk before burnout reaches the point of treatment interruption. Practical approaches that have evidence behind them: Reducing the burden of self-management where clinically safe to do so, simplifying medication regimens, extending monitoring intervals, or using technology to reduce cognitive load, can relieve pressure without compromising care quality. Acknowledging that a patient cannot do everything perfectly all the time, and helping them prioritize two or three high-impact actions rather than a comprehensive protocol, reflects person-centred care and can meaningfully re-engage someone who has withdrawn. Referral to a diabetes psychologist or certified diabetes care and education specialist (CDCES) for cognitive behavioural support is appropriate for moderate to severe burnout. Group-based peer support programs have also shown promise, with the shared experience of living with diabetes providing a type of validation that clinical care often cannot replicate. What People Living with T2D Should Know If you recognise yourself in the description above, the most important thing to know is that what you are experiencing has a name, it is not a character flaw, and it is common enough that the world's largest diabetes organizations are now building assessment tools specifically for it. Tell your care team. Not because they will automatically know how to respond, but because naming it creates the possibility of addressing it. And if your current provider does not engage meaningfully with that disclosure, you are entitled to seek one who will. Burnout is not failure. It is a predictable human response to an extraordinary and relentless burden. The T2D Network has resources on diabetes stigma and caregiver support that speak to the emotional dimensions of living with T2D. You are not alone in this.

Written by Clare Koning, RN, PhD | April 2026 | 4 min read Key Highlights ✅ Many early warning signs of T2D show up on your skin, in your sleep, and in your mood, not just your blood sugar ✅ Almost 1 in 4 Canadians who meet the criteria for diabetes don't know they have it ✅ Atypical symptoms like skin changes, recurring infections, and tingling are often dismissed for years ✅ Some signs are visible on the outside of your body long before a blood test is done ✅ Knowing what to look for can get you to a diagnosis years earlier Most people know the classic checklist: excessive thirst, frequent urination, unexplained fatigue. These are the symptoms that appear in every brochure, on every health website, and in every awareness campaign. And they are real. But they are also the symptoms that tend to appear later, once blood sugar has already been elevated for some time. What often comes first are quieter, stranger, and far easier to explain away. A 2025 global study found that 44% of people living with diabetes worldwide don't know they have it. In Canada, government data shows that roughly 1 in 4 Canadians who meet the diagnostic criteria for diabetes remain undiagnosed. The reasons are many, but one of the most consistent is this: the early body signals don't look like "diabetes" to the person experiencing them. They look like tiredness. A skin thing. Getting older. Stress. Here are the signs that are worth paying closer attention to. Dark, Velvety Patches on Your Skin This is one of the most recognizable visible markers of insulin resistance, and one of the least talked about. Acanthosis nigricans is a skin condition that causes dark, thickened, velvety patches to develop in body folds and creases, most commonly on the back of the neck, in the armpits, and in the groin. The skin may also itch or develop small tags. It is not a rash or infection. It is a direct response to high levels of circulating insulin, which stimulates skin cell overgrowth. According to StatPearls, acanthosis nigricans is most commonly associated with insulin resistance and type 2 diabetes. The American Academy of Dermatology describes it as a potential first sign of prediabetes, appearing on the skin often before any other symptom or abnormal blood test result. Many people notice these patches and assume they are cosmetic, a reaction to deodorant, a sensitivity, or simply a feature of their skin. They are worth mentioning to a doctor. What to look for: A darker, thicker, slightly rough or velvety area of skin, usually in a skin fold. It may be subtle, particularly on darker skin tones where it can be less visually pronounced. Cuts and Bruises That Take Too Long to Heal High blood sugar impairs circulation and reduces the efficiency of the immune response. The result is that even small wounds, a papercut, a blister, a shaving nick, take longer to close and longer to clear. Research into atypical presentations of T2D found that delayed wound healing was reported in 16% of newly diagnosed T2D patients, and was particularly common in those with higher BMI who had not yet displayed the classic triad of thirst, urination, and weight loss. In the same study, recurrent skin infections including boils were also noted as frequent early presentations. If you find yourself repeatedly fighting off minor infections, noticing cuts that linger past what seems normal, or dealing with recurring skin or nail fungal infections, this pattern is worth flagging with your healthcare provider. Tingling, Numbness, or Burning in Your Hands and Feet Peripheral neuropathy, nerve damage caused by prolonged high blood sugar, is typically considered a complication of long-standing diabetes. But early, subtle nerve changes can begin before formal diagnosis, particularly in people who have been living with undetected elevated blood sugar for years. Diabetes Canada estimates that up to 50% of people with diabetes develop some degree of neuropathy over time. Tingling or "pins and needles" in the extremities, a burning sensation in the feet, or reduced sensitivity in the toes can be early signals. These symptoms are also associated with other conditions, including vitamin B12 deficiency, thyroid disorders, and poor circulation. But they should not be written off without investigation, particularly if you carry other risk factors for T2D. Recurring Yeast or Urinary Tract Infections Elevated glucose in the body creates a feeding environment for yeast and certain bacteria. Women in particular may experience recurring vaginal yeast infections or urinary tract infections as an early signal that something is metabolically off, long before blood sugar reaches the diagnostic threshold for diabetes. In a clinical case series of newly diagnosed T2D patients, 24% of women reported recurrent vaginal candidiasis as one of their presenting symptoms. For many, this had been treated repeatedly as an isolated gynecological issue before the underlying blood sugar connection was identified. If you have been treated multiple times for yeast or urinary infections without a clear explanation, it is worth asking your doctor about a blood sugar check. Blurred Vision That Comes and Goes The lens of the eye is sensitive to fluid shifts driven by blood sugar levels. When glucose rises, fluid is pulled from the lens, altering its shape and temporarily impairing focus. This is reversible in the short term, but it is a physical sign of fluctuating blood sugar. The Canadian Diabetes Risk Assessment data and clinical guidelines both note visual changes as an early symptom. Unlike the permanent vision changes caused by diabetic retinopathy (a long-term complication), this early blurring is often dismissed as eye strain, screen fatigue, or a need for new glasses. All of those things may also be true. But if blurring is intermittent and not explained by your optometrist, it is worth investigating metabolically. Fatigue That Sleep Doesn't Fix This is different from being tired after a poor night's sleep. This is a pervasive, unrestorative fatigue that persists regardless of how much rest you get. It often comes with difficulty concentrating, a kind of cognitive sluggishness sometimes described as "brain fog." When blood sugar is elevated, glucose cannot efficiently enter cells to be used as fuel. The result is a paradox: the body has high blood sugar, but cells are energy-deprived. This metabolic fatigue is one of the most commonly reported but most frequently dismissed early symptoms of T2D. It is worth distinguishing from depression, thyroid problems, anemia, and sleep disorders, all of which share similar presentations and all of which can coexist with T2D. But fatigue that does not resolve with rest, especially alongside any of the other signs above, deserves a metabolic workup. What to Do If Any of These Signs Sounds Familiar You do not need to have all of these signs, or even most of them. One or two, in combination with risk factors like family history, carrying weight around the waist, or being over 40, is enough to warrant a conversation with your doctor and a simple blood test. The test is straightforward: either a fasting blood glucose test or an HbA1c (3-month blood sugar average). It takes minutes and can either reassure you or give you information that changes the trajectory of your health. Take the CANRISK questionnaire to assess your personal risk in under five minutes. If your score suggests elevated risk, bring the result to your next appointment. If you've already been told your blood sugar is elevated, visit our prediabetes guide for clear next steps. And explore the T2D Network's for resources tailored to wherever you are in your health journey.

Written by Clare Koning, RN, PhD May 2026 7 min read Key Highlights ✅ Short sleep is now a recognized, modifiable risk factor for type 2 diabetes ✅ Just one week of sleeping five hours a night reduces insulin sensitivity by approximately 25% ✅ Postmenopausal women face up to a 20% increase in insulin resistance with chronic mild sleep restriction ✅ Obstructive sleep apnea is both a consequence and a driver of poor glycemic control ✅ Sleep screening is now embedded in the 2026 ADA Standards of Care for people with diabetes There is a version of diabetes prevention that almost never appears in clinical brochures, public health campaigns, or the standard advice handed out at diagnosis. It doesn't involve a new medication, a dietary overhaul, or a gym membership. It involves going to bed. Sleep has long occupied a peripheral position in diabetes care conversations, mentioned briefly after the headline topics of diet and exercise, often as an afterthought. That is now changing. A growing and increasingly robust body of evidence positions chronic insufficient sleep as an independent, modifiable risk factor for type 2 diabetes, one that operates through mechanisms distinct from, and additive to, the effects of poor diet and sedentary behaviour. The 2026 ADA Standards of Care have formalized this shift, embedding sleep screening as a routine recommendation for people with diabetes and those at risk. This is not a soft lifestyle topic. It is metabolic science. What Happens in the Body When You Don't Sleep Enough The relationship between sleep and glucose regulation is deeply biological. During normal slow-wave sleep (the deep, restorative N3 stage), the brain's metabolic rate drops, peripheral tissues clear glucose efficiently via the GLUT4 transporter system, and hormonal systems governing hunger and energy balance are calibrated. When this architecture is disrupted, the consequences for glucose metabolism are rapid and measurable. Laboratory studies of healthy young adults subjected to partial sleep restriction demonstrate decreased glucose tolerance and reduced insulin sensitivity within days. The mechanisms are multiple and synergistic: GLUT4 transporter activity at the cell surface decreases, reducing the efficiency of glucose uptake in skeletal muscle. Free fatty acids, which compete with glucose for oxidation and directly impair insulin signalling, rise. Inflammatory cytokines including interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-alpha) increase, exacerbating insulin resistance at the receptor level. And cortisol, which rises with sleep deprivation and directly antagonizes insulin action in peripheral tissues, reaches levels that impair glucose homeostasis throughout the following day. The net effect is striking. Researchers from the University of Chicago's sleep laboratory have reported that one week of restricting sleep to five hours a night reduces insulin sensitivity by 37%, an effect that directly impacts body weight gain through increased appetite and altered glucose levels. For someone whose insulin sensitivity is already compromised, this is a clinically meaningful shift, one large enough to push a person with prediabetes across the clinical threshold for type 2 diabetes. Hunger regulation is disrupted in parallel. Sleep loss decreases leptin, the hormone that signals satiety, and increases ghrelin, the hormone that drives appetite. This neuroendocrine shift promotes increased caloric intake and weight gain, further amplifying insulin resistance through a secondary route. Poor sleep is not simply a consequence of poor metabolic health. It actively produces it. The Epidemiological Picture Large-scale prospective cohort data align with the laboratory findings. The Nurses' Health Study, the Sleep Heart Health Study, and multiple European cohort studies consistently find that habitual short sleepers, defined as sleeping under six hours per night, have 1.5 to 2 times the incidence of type 2 diabetes over five to ten year follow-up periods, after adjusting for BMI, diet, physical activity, and other confounders. The relationship is U-shaped: very long sleep duration (over nine hours) is also associated with elevated risk, likely because it reflects underlying illness, depression, or sleep-disordered breathing rather than being causal in its own right. The risk window is clear: six to eight hours of quality sleep sits at the metabolically optimal range for most adults. A Critical Note for Clinical Practice These associations hold after adjusting for BMI. That matters. It means the sleep-diabetes relationship is not simply mediated by obesity, though sleep deprivation and weight gain reinforce each other. Sleep duration and quality are independently relevant to metabolic risk, and should be assessed independently in clinical encounters, not subsumed under general lifestyle advice. Women, Menopause, and a Specific Warning Signal The evidence on sleep restriction and insulin resistance carries a particularly pointed message for women in midlife and beyond. A study published in Diabetes Care and conducted by researchers at Columbia University enrolled 40 women aged 20 to 75 with healthy baseline sleep patterns. Participants underwent two 6-week phases: one with normal sleep (averaging 7.5 hours per night) and one with sleep restricted to 6.2 hours per night, mirroring the average sleep duration of American adults reporting insufficient sleep. The effects were significant across the group, but the postmenopausal subgroup showed the most severe response. Restricting sleep to 6.2 hours led to a 14.8% increase in insulin resistance across all participants. In postmenopausal women specifically, that figure rose to 20.1%, with increases in both fasting insulin and fasting glucose levels, independent of changes in body weight. The study's lead author, Dr. Marie-Pierre St-Onge of Columbia University, noted: if these effects are sustained over time, chronically insufficient sleep among individuals with prediabetes could accelerate the progression to type 2 diabetes. For postmenopausal women already navigating declining estrogen, shifting fat distribution, and rising cardiometabolic risk, disrupted sleep is not merely a quality-of-life issue. It is a metabolic one. The Sleep Apnea Link Any discussion of sleep and T2D is incomplete without addressing obstructive sleep apnea (OSA). OSA affects a disproportionately high proportion of people with T2D, yet it remains underdiagnosed in this population, particularly in women, in whom the classic presentation of loud snoring is less common. The relationship is bidirectional. OSA fragments sleep architecture, suppresses slow-wave sleep, activates the sympathetic nervous system, and elevates cortisol, all of which worsen insulin resistance. Conversely, obesity and central adiposity, common in T2D, worsen OSA by increasing pharyngeal collapsibility. Effective CPAP treatment for OSA has been shown to improve glycemic control, and in some studies to reduce HbA1c, though effect sizes vary. Clinical Implication Any patient with T2D presenting with unexplained poor glycemic control, fatigue, morning headaches, or a bed partner reporting apneic episodes should be screened for OSA. This applies with equal urgency to women who may not report the "classic" symptoms. What This Means in Practice For healthcare providers, the message is to make sleep a clinical vital sign in diabetes care, not a bonus topic if time allows. Ask about sleep duration and quality at every diabetes review. Screen for OSA using a validated tool such as the STOP-BANG questionnaire. Address sleep health as a co-equal component of the metabolic risk conversation alongside diet, exercise, and medication adherence. For people living with T2D or at risk of it, the evidence is equally clear. Chronic short sleep is not a neutral background condition. It is actively working against your blood sugar management, your hunger regulation, and your cardiovascular risk profile. The goal is not perfection. It is recognizing that the hours between midnight and seven in the morning are as metabolically important as what you eat for breakfast. Practical targets supported by evidence: Getting 7 to 9 hours of sleep per night is the recommended range for adults. Maintaining consistent sleep and wake times supports circadian alignment, which itself influences glucose metabolism independently of total sleep duration. Limiting screen exposure before bed, keeping the bedroom cool and dark, and avoiding caffeine in the afternoon are all supported as part of sleep hygiene practice. If you consistently wake unrefreshed, snore, or feel excessively sleepy despite adequate time in bed, discuss OSA screening with your provider. For more on managing type 2 diabetes holistically, visit the T2D Network's Healthy Lifestyle and Monitoring & Medication pages.

Written by Clare Koning, RN, PhD | April 2026 | 4 min read Key Highlights ✅ In Canada, roughly 1 in 4 people with diabetes have not yet been diagnosed ✅ T2D can be present and causing damage for up to 10 years before symptoms appear ✅ Risk factors go well beyond weight and family history ✅ Certain ethnic backgrounds carry significantly higher risk at a younger age ✅ A simple blood test is all it takes to find out You feel fine. You are not unusually thirsty, you are not losing weight without trying, nothing feels obviously wrong. And yet, right now, there is a real chance that your blood sugar has been quietly elevated for years. Type 2 diabetes is, in many cases, a completely silent condition in its early stages. The body compensates for rising blood sugar remarkably well for a long time, producing no dramatic symptoms and sending no clear alarm. Meanwhile, that elevated glucose is doing slow, cumulative damage to blood vessels, nerves, and organs. According to Diabetes Canada, roughly 10% of Canadians currently live with diagnosed diabetes. When undiagnosed cases are included, that figure climbs to approximately 15%. More than 600,000 Canadians are currently living with diabetes without knowing it. Understanding your personal risk is not about anxiety. It is about information. And the earlier you have it, the more you can do with it. The Risk Factors Most People Know A few risk factors for T2D are widely recognized, and worth stating clearly. Family history is one of the strongest individual predictors. If a parent, sibling, or child has type 2 diabetes, your lifetime risk increases by two to six times compared to someone with no family history. This is not a certainty, it is not a life sentence, but it is information that should translate into regular screening even in the absence of symptoms. Excess weight around the abdomen is directly linked to insulin resistance. Fat stored around the waist and internal organs, as opposed to the hips and thighs, is metabolically active in ways that interfere with how cells respond to insulin. The CDC identifies overweight and physical inactivity as among the most significant modifiable risk factors for T2D. Age is also a factor, with risk rising sharply after 40 in most populations. But this is not the full story, particularly in certain communities. The Risk Factors That Are Less Talked About Ethnicity and Earlier Onset T2D does not affect all populations equally, and this is one of the most clinically important and under-communicated aspects of risk. Diabetes Canada's guidelines and international evidence consistently show that people of South Asian, East Asian, African, Hispanic, Indigenous, and Middle Eastern descent face significantly elevated T2D risk at lower body weights and at younger ages than people of European descent. For these communities, the standard age-40 threshold for screening may be too late. In Canada, early screening is recommended for people from these higher-risk ethnic backgrounds. If you fall into one of these groups and have not been screened, this is worth raising with your provider. Gestational Diabetes If you had gestational diabetes during pregnancy, your lifetime risk of developing type 2 diabetes is substantially elevated, even if your blood sugar normalized completely after delivery. Studies show that women with a history of gestational diabetes have a significantly higher likelihood of developing T2D within 10 years. Postpartum screening at 6 to 12 weeks is recommended, but follow-up beyond that is inconsistent. If you had gestational diabetes and have not had metabolic screening in the past year or two, this is a gap worth closing. Polycystic Ovary Syndrome (PCOS) PCOS is closely linked to insulin resistance, which is both a feature of the condition and a driver of elevated T2D risk. Women with PCOS have a significantly higher lifetime risk of type 2 diabetes, independent of weight. This connection is frequently underdiscussed in PCOS management, with the focus remaining on reproductive symptoms. If you have PCOS, regular metabolic screening including blood glucose and HbA1c should be part of your routine care. High Blood Pressure and Abnormal Cholesterol These are not simply comorbidities. They are part of a cluster of metabolic changes collectively known as metabolic syndrome, which increases T2D risk substantially. If you have been told your blood pressure is elevated, your HDL (good cholesterol) is low, or your triglycerides are high, these are signals that the same underlying metabolic processes that drive T2D may already be in motion. Prediabetes If you have been told you have prediabetes, an A1C between 5.7% and 6.4% or a fasting blood glucose between 6.1 and 6.9 mmol/L, you are in the window with the greatest opportunity to act. A European study cited by the Public Health Agency of Canada found that among adults aged 45 and older with prediabetes, the lifetime risk of progression to type 2 diabetes was 74%, underscoring just how seriously this intermediate state deserves to be taken. It also underscores how much can be changed with early action. The evidence on lifestyle modification and prediabetes reversal is strong. That window matters. So, What Are Your Actual Risk Factors? Rather than running through a mental checklist, you can get a personalized picture in under five minutes using the CANRISK questionnaire, the Canadian Diabetes Risk Assessment tool developed specifically for the Canadian population. It asks about age, ethnicity, family history, gestational diabetes, blood pressure, physical activity, and waist circumference. The result will tell you whether your risk is low, moderate, or high, and give you a concrete starting point for a conversation with your healthcare provider. What Happens After a Diagnosis? If a test confirms elevated blood sugar or a diabetes diagnosis, the most important thing to know is that this is manageable. Many people with T2D lead full, active lives with good glycemic control. And when caught early, the opportunities for lifestyle-based intervention are at their greatest. The T2D Network exists to support people at every stage of this journey, from understanding risk and navigating diagnosis, to managing day-to-day life with T2D for the long term. Take the CANRISK test today. Visit our Learn More page to understand your risk factors in more depth. Or if you have already received a high blood sugar result, our T2D resources have you covered.

Written by Clare Koning, RN, PhD | April 2026 I 6 min read Key Highlights ✅ Women with T2D have higher heart disease mortality but are underrepresented in research ✅ GDM signals long-term T2D and CVD risk beyond pregnancy ✅ Perimenopause is a key window as BP risk rises early ✅ Women are often under-prescribed CVD therapies ✅ Sex-specific BP targets and screening improve care There is a persistent gap in how women with type 2 diabetes (T2D) and hypertension are understood, diagnosed, and treated, and it has real consequences. For decades, landmark studies enrolled predominantly male participants, and clinical guidelines were built on that evidence base. Women were assumed to respond similarly. They do not. That assumption is now being corrected, but the pace of change in research has not yet translated into clinical practice. Women with T2D remain at disproportionately elevated cardiovascular risk , and the systems designed to protect them frequently fall short. Understanding why, and what to do about it, is one of the most urgent challenges in cardiometabolic care today. A Higher Risk, a Lower Priority The statistics are stark. Women with T2D face a substantially greater relative increase in cardiovascular disease (CVD) risk compared to men with T2D, research suggests women lose more of the cardiovascular protection that typically accompanies female sex than men do when diabetes enters the picture. Put simply: diabetes erases more of women's biological advantage. Despite this, women remain more likely to have their cardiovascular symptoms attributed to anxiety or non-cardiac causes, to wait longer for diagnosis and intervention, and to receive guideline-directed therapies at lower rates. The result is a care gap that compounds an already elevated biological risk. Diabetes erases more of women's cardiovascular advantage , yet clinical systems have been slower to respond to female-specific risk than the evidence demands. Hormonal Life Events: More Than Reproductive Milestones One of the most clinically important, and historically underappreciated, areas is the role of hormonal transitions in shaping cardiometabolic risk in women. These are not just reproductive events. They are metabolic inflection points. Gestational Diabetes: The Signal That Persists Gestational diabetes mellitus (GDM) affects approximately 16% of pregnancies globally and has long been treated as a transient condition, something that resolves after delivery. It does not. Women who experience GDM have a significantly elevated lifetime risk of developing T2D, and carry an independent increased risk of hypertension and cardiovascular disease that extends decades beyond the pregnancy. Studies show that women with a history of GDM are nearly twice as likely to develop cardiovascular disease compared to those with normoglycemic pregnancies, even in the absence of a subsequent T2D diagnosis. Clinical Implication A GDM diagnosis should trigger ongoing postpartum follow-up: glucose testing at 6–12 weeks post-delivery , annual or biennial metabolic screening, and early cardiovascular risk assessment, not a single post-delivery check and discharge. Perimenopause: The Window We Have Been Missing Perimenopause, the years-long hormonal transition before menopause, is emerging as one of the most significant and underutilized windows for cardiovascular prevention in women. Blood pressure begins to rise during this period, driven by declining estrogen, sympathetic nervous system activation, and changes in vascular tone and body composition. This rise frequently predates the onset of recognizable symptoms and can go undetected for years. For women who already carry T2D or are at cardiometabolic risk, this hormonal-vascular interaction creates a compounding hazard . The traditional model of cardiovascular screening at midlife, waiting for menopause to arrive before assessing BP trajectory, misses the moment of greatest intervention potential. Menopause and Beyond The post-menopausal period brings a further shift. Loss of estrogen's vasodilatory and anti-inflammatory effects accelerates arterial stiffening and increases both systolic BP and LDL cholesterol. Women with T2D entering menopause face the convergence of insulin resistance, hypertension, dyslipidemia, and weight redistribution, often simultaneously and often without adequate clinical recognition. The picture is further complicated by symptom presentation. Women are more likely to present with atypical cardiovascular symptoms , fatigue, jaw or neck pain, nausea, shortness of breath, that are less likely to trigger cardiac investigation than the "classic" chest pain presentation more common in men. The Under-Prescribing Problem for Women Vanita Aroda, MD, Associate Professor of Medicine at Harvard Medical School, and Katherine Tuttle, MD, Professor of Medicine at the University of Washington, discuss current disparities in the treatment of women with type 2 diabetes and cardiorenal risk despite the evidence and breadth of available agents. They discuss that women are less likely to receive guideline-directed medical therapy, including both older and newer agents, and less likely to enroll in clinical trials, as well as the need to recognize and address these disparities. Recorded during 2023 CMHC's Women's Health Masterclass, August 19, 2023. Even when cardiovascular risk is identified in women with T2D, the therapeutic response is often inadequate. Multiple studies and registries have documented that women are less likely to receive guideline-directed pharmacological therapies, including ACE inhibitors, statins, and antiplatelet agents, at rates comparable to men, even when clinical indications are equivalent. This is not a minor discrepancy. These are medications with demonstrated mortality benefit. Under-prescribing in this population translates directly into preventable cardiovascular events. Therapy Evidence in T2D + CVD Documented Gap in Women Statins Reduces major cardiovascular events by 20–25% Women prescribed at lower rates despite equal benefit ACE inhibitors / ARBs Renoprotective & cardioprotective in T2D Under-initiated, particularly in younger women SGLT2 inhibitors Proven CV and renal benefit in T2D Evidence base and precribing historically male-dominant GLP-1 receptor agonists CV risk reduction & weight benefit Emerging sex-specific response data needed Systemic Barriers to Equitable Care The care gap is not only clinical, it is systemic. Women face a cluster of barriers that compound their biological risk. These include greater likelihood of dismissal of cardiovascular symptoms, lower rates of referral to cardiac rehabilitation, financial and caregiving responsibilities that reduce capacity to engage with follow-up care, and implicit bias in clinical assessment that continues to shape referral and prescribing patterns. Research representation has also been structurally inequitable. For decades, women, particularly women of reproductive age, were routinely excluded from cardiovascular and metabolic trials. The evidence base that informs current guidelines was built largely on male physiology. This is beginning to change, with regulatory agencies and funders increasingly mandating sex-disaggregated data, but the downstream effect on clinical practice will take years to fully materialize. What Providers Can Do for Women Today Closing the care gap does not require waiting for new research. There are practical, evidence-supported steps that clinicians can implement now to better serve women with T2D and cardiovascular risk. Take GDM Seriously as a Long-Term Signal Implement structured postpartum follow-up protocols for all patients with GDM history: glucose tolerance testing at 6–12 weeks, annual metabolic review, and early CVD risk stratification. Do not let the post-delivery window close without establishing a long-term care pathway. Begin BP Monitoring at Perimenopause – Not After For women with T2D, metabolic syndrome, or cardiometabolic risk factors, begin proactive BP monitoring and cardiovascular risk assessment at the first signs of perimenopausal transition, typically the mid-40s. Don't wait for menopause to act on BP trajectory. Apply Sex-Informed BP Targets Emerging evidence suggests women may benefit from tighter BP targets than have historically been applied. Until sex-specific guidelines are updated, consider the lower end of recommended BP ranges for women with T2D and additional cardiovascular risk factors. Audit Prescribing Patterns for Equity Conduct regular practice audits comparing guideline-directed therapy prescribing rates between male and female patients. Where gaps exist, examine the clinical rationale, and in the absence of contraindications, close them. Educate Patients on Atypical Symptom Presentation Women need to know that heart attack and cardiovascular crisis can present differently in them, and that fatigue, nausea, and jaw pain are symptoms that warrant urgent attention, not a low threshold for dismissal. This conversation belongs in routine clinical care, not only in the acute setting. Research Is Catching Up – Practice Must Follow The scientific community has recognized the gap and is working to close it. Sex-disaggregated analyses are becoming standard in major cardiovascular trials. Hormonal transitions are being studied as cardiometabolic inflection points rather than reproductive footnotes. Female-specific CVD risk calculators are in development. But research findings take time to reach clinical practice, and women with T2D are navigating the healthcare system now. The steps outlined above are not aspirational, they are feasible within current clinical frameworks, supported by existing evidence, and overdue.

Written by Clare Koning, RN, PhD T2D Network | April 2026 | 6 min read Key Highlights ✅ A high blood sugar result or a prediabetes diagnosis is not a life sentence. It's a signal. ✅ Prediabetes affects an estimated 1 in 3 Canadian adults, most of whom don't know they have it ✅ With lifestyle changes, up to 58% of people with prediabetes can return to normal blood sugar levels ✅ The window between prediabetes and type 2 diabetes is your most powerful opportunity to act ✅ You don't have to do this alone. Here's exactly what to do next. Maybe it was a routine blood test. Maybe your doctor mentioned your A1C was "a little elevated." Maybe the words prediabetes  or borderline diabetes  came up, and you left the appointment with more anxiety than answers. If that sounds familiar, you're not alone, and you're in the right place. Getting news that your blood sugar is higher than it should be can feel scary, confusing, and even a little unfair, especially if you weren't expecting it and feel mostly fine. But here's the thing: this result, uncomfortable as it is to receive, is actually one of the most valuable pieces of health information you can get. Because at this stage, you still have significant power to change where this is headed. Let's walk through what it all means, and what to do next. First: What Do the Numbers Actually Mean? Blood sugar is typically measured in one of three ways. Here's how the results are categorized: Test Normal Prediabetes Diabetes Fasting blood glucose Below 6.1 mmol/L 6.1–6.9 mmol/L 7.0+ mmol/L A1C  (3-month average) Below 5.7% 5.7%–6.4% 6.5%+ 2-hour glucose tolerance Below 7.8 mmol/L 7.8–11.0 mmol/L 11.1+ mmol/L (Note: Canadian and American diagnostic thresholds differ slightly. Your doctor will use Canadian guidelines.) Prediabetes means your blood sugar is higher than normal, but not yet high enough to be diagnosed as type 2 diabetes. It's a warning signal, not a diagnosis of diabetes itself. "But I Feel Fine. Is This Really That Serious?" This is one of the most common reactions, and it makes total sense. Prediabetes almost never causes noticeable symptoms. That's precisely what makes it so easy to miss, and why so many people are caught off guard. But feeling fine doesn't mean nothing is happening. Over time, persistently elevated blood sugar damages blood vessels and nerves quietly, long before symptoms appear. People with prediabetes already carry an elevated risk of cardiovascular disease, even if they never go on to develop type 2 diabetes. The 30-year follow-up of the Da Qing Diabetes Prevention Study , one of the longest-running diabetes prevention trials ever conducted, found that without intervention, the vast majority of people with impaired glucose tolerance eventually progressed to type 2 diabetes. That's the honest reality of prediabetes left unaddressed. But here's the equally honest flipside: the same study, and many others, showed that early action dramatically changes the trajectory. Can Prediabetes Actually Be Reversed? Yes, and the evidence for this is strong. The landmark Diabetes Prevention Program (DPP) , a major randomized controlled trial, found that lifestyle modification reduced the risk of progression from prediabetes to type 2 diabetes by approximately 58% , making it more effective than medication alone. Crucially, lifestyle changes also showed something medications didn't: the benefits were sustained long after the intervention ended, because the changes became embedded in how people lived. A 2025 review published in Cardiovascular Diabetology  found that structured lifestyle programs can achieve reversion to normal blood sugar levels in up to 58% of participants, with physical activity being one of the most powerful individual predictors. People who exercised more than 150 minutes per week were four times more likely  to reverse their prediabetes than those who didn't. Across studies, between 18% and 59%  of people with prediabetes return to normal blood sugar levels within five years. The opportunity is greatest when you act early, before blood sugar has climbed further and before the prediabetes state has persisted for years. Image: ParticipACTION This is your window. Right now. What Actually Moves the Blood Sugar Needle? You don't need a perfect diet, a gym membership, or a complete lifestyle overhaul overnight. The research is clear that modest, consistent changes  drive the most significant results. 1. Move More, Especially After Meals Physical activity is one of the most potent tools for improving insulin sensitivity. Your muscles use glucose directly during movement, without needing insulin, which is why even a short walk after eating can meaningfully reduce post meal blood sugar spikes. The target supported by the evidence is at least 150 minutes of moderate activity per week , roughly 30 minutes, five days a week. Brisk walking, swimming, cycling, and dancing all count. You don't need to go hard; you need to be consistent. 2. Reduce Refined Carbohydrates and Ultra-Processed Foods You don't have to eliminate carbohydrates entirely. The research shows it's the type  of carbohydrate that matters most. Refined carbs like white bread, white rice, sugary drinks, and packaged snacks spike blood sugar rapidly. Replacing them with fibre-rich whole foods such as legumes, vegetables, oats, and whole grains slows glucose absorption and improves insulin response. The 2026 ADA Standards of Care  highlight Mediterranean-style and low-carbohydrate eating patterns as having the strongest evidence for preventing progression to type 2 diabetes. 3. Aim for Modest Weight Loss If Relevant You don't need to lose a lot. Research consistently shows that losing 5–7% of body weight  significantly reduces progression risk. For someone who weighs 200 lbs, that's just 10–14 lbs. The mechanism isn't cosmetic: excess weight, especially around the abdomen, is directly linked to insulin resistance, and even modest loss reduces that burden substantially. 4. Prioritize Sleep This one often surprises people. Poor sleep raises cortisol and disrupts insulin sensitivity, and chronically bad sleep has been shown to increase diabetes risk independently of diet and exercise. Aim for 7–9 hours of quality sleep per night. If you snore heavily or wake unrefreshed, ask your doctor about screening for sleep apnea, which is particularly common in people with prediabetes and directly worsens metabolic control. 5. Manage Stress Chronic psychological stress raises blood cortisol, which in turn raises blood glucose. This isn't just about feeling calmer; it's about your body's chemistry. Stress management strategies, whether that's exercise, mindfulness, social connection, or time in nature, have measurable effects on metabolic health. What About Medication? Lifestyle change is the first-line recommendation for prediabetes, and for good reason. But medication isn't off the table. Metformin, a long-established and well-tolerated diabetes medication, is sometimes recommended for people with prediabetes who are at particularly high risk, who have not responded to lifestyle changes alone, or who were diagnosed at a younger age. Your doctor can discuss whether this is appropriate for you. Newer medications including GLP-1 receptor agonists are also being studied in prediabetes prevention contexts, with promising early results. This is a rapidly evolving space, and your care team is your best guide for what makes sense in your specific situation. 5 Practical Things to Do This Week You don't need a plan for the next decade. You need a plan for the next seven days. Here are five concrete steps you can take right now: Book a follow-up appointment  with your family doctor or primary care provider to review your results in detail and discuss next steps. Ask for a referral to a diabetes education centre.  In most provinces, you don't need a diabetes diagnosis to access free diabetes education programs. Prediabetes qualifies. These programs offer registered dietitians, nurses, and educators who specialize in exactly this. Track your meals for three days,  not to judge yourself, but to get an honest picture of where your biggest blood sugar opportunities are. Even simple notes on your phone work. Add one 15-minute walk after dinner this week.  Just one. Then build from there. Tell someone you trust.  Having a support person, whether a partner, friend, or family member, who knows what you're working toward significantly improves long-term success. A Note on How You're Feeling Right Now Receiving health news you weren't expecting can bring up a lot: anxiety, denial, frustration, even grief for the lifestyle you thought you had. All of those reactions are completely normal. What's important is that this result doesn't define you, and it doesn't determine your future. It's data. Data that arrived at exactly the right time to give you the chance to do something about it. The T2D Network exists for moments like this one. Whether you're newly diagnosed, supporting someone who is, or just trying to understand your risk, you'll find resources, community, and practical guidance throughout our website. You don't have to navigate this alone. Ready to learn more? Visit the T2D Network's Learn More  page, take the CANRISK assessment  to better understand your risk, or explore our Healthy Eating  and Healthy Lifestyle  resources.

Written by Clare Koning, RN, PhD T2D Network | April 2026 | 6 min read Key Highlights ✅ The gut microbiome, the trillions of bacteria living in your digestive tract, plays a meaningful role in blood sugar regulation ✅ People with type 2 diabetes consistently show distinct gut microbiome patterns compared to those without ✅ Diet is one of the most powerful ways to shape your microbiome in a beneficial direction ✅ Probiotics, prebiotics, and even fecal microbiota transplantation are under active investigation ✅ This science is promising but still evolving, here's what's ready for real life and what's still in the lab You probably know that what you eat affects your blood sugar. But did you know it also shapes the trillions of microorganisms living in your gut, and that those microorganisms, in turn, may be influencing your blood sugar too? The relationship between the gut microbiome and type 2 diabetes is one of the most rapidly growing areas of metabolic research. It's complex science, but the core idea is surprisingly intuitive: the bacteria in your digestive system are not passive passengers. They actively communicate with your body's metabolic systems, including the ones that regulate insulin and glucose. What Is the Gut Microbiome? Your gastrointestinal tract is home to an estimated 38 trillion microorganisms , bacteria, fungi, and viruses, collectively known as the gut microbiome. These microbes play critical roles in digesting food, producing vitamins, training the immune system, and regulating inflammation. The composition of your microbiome is shaped by genetics, age, medication use, environment, and, most powerfully, what you eat. What Does the Research Say About T2D? The connection between gut bacteria and type 2 diabetes is well-established in scientific literature, even if it's not yet widely discussed in clinical practice. Large-scale metagenomic studies  consistently find a reproducible pattern in people with T2D: a depletion of bacteria that produce short-chain fatty acids (SCFAs) , particularly butyrate, alongside an increase in opportunistic, pro-inflammatory microorganisms. SCFAs are important because they help regulate insulin sensitivity, reduce gut permeability ("leaky gut"), and suppress systemic inflammation. Research published in Cell Metabolism  in 2025 identified specific gut-produced metabolites  that travel from the intestine to the liver and appear to influence how the body handles energy and responds to insulin, findings that could open new avenues for treatment. A 2026 review published in Frontiers in Endocrinology , a scoping review of systematic reviews and meta-analyses, concluded that modulating the gut microbiome through dietary, probiotic, or pharmacological means shows promising effects on fasting glucose, HbA1c, and inflammatory markers in people with T2D, though the evidence remains heterogeneous and long-term data are still needed. What Can You Do About It? Here's the good news: your diet is one of the most powerful tools you have for shaping your microbiome, and that's within your control today, not waiting for clinical approval. Eat More Plants Diets rich in plant foods consistently promote greater microbial diversity and support the growth of SCFA-producing bacteria. Research shows  that Mediterranean-style eating patterns, built on vegetables, legumes, whole grains, olive oil, and fish, are associated with a more diverse and metabolically beneficial microbiome, and reduced risk of T2D complications. A Western-style diet heavy in saturated fats, refined sugars, and ultra-processed foods does the opposite: it reduces microbial diversity and promotes pro-inflammatory bacteria. Prioritize Fibre Fibre is the preferred fuel for beneficial gut bacteria. Most Canadians consume far less than the recommended 25–38 grams per day. Legumes, oats, barley, flaxseed, and most vegetables are excellent sources. Consider Fermented Foods Yogurt, kefir, kimchi, sauerkraut, and miso are natural sources of live bacteria. While the evidence for specific probiotic strains in T2D is still being refined, general consumption of fermented foods is consistently associated with greater microbial diversity and reduced inflammatory markers. What About Probiotics and Supplements? This is where things get more nuanced. A systematic review published in Cureus  in 2025  found that microbiome-targeted interventions, including probiotics, prebiotics, and dietary strategies, show meaningful effects on glycemic outcomes and complication risk. One bacterium in particular, Akkermansia muciniphila , has attracted significant interest: in a controlled trial, pasteurized A. muciniphila  improved insulin sensitivity by nearly 29% and reduced fasting insulin levels significantly. That said, a 2026 narrative review published in Nutrients  offered an important caveat: while RCTs show positive signals, heterogeneity across studies and short follow-up periods mean that there isn't yet enough evidence to recommend specific probiotic supplementation as a standard therapy for T2D. Standardized protocols, larger trials, and longer-term safety data are all still needed. The bottom line: over-the-counter probiotic supplements are generally safe, but the specific strains, doses, and durations that benefit T2D most are still being worked out. Don't rely on a supplement to replace the dietary foundations. What About Fecal Microbiota Transplantation (FMT)? FMT: the transfer of stool from a healthy donor into a recipient's gut, is an active area of research for T2D. Early results are intriguing, but the field is still in early clinical stages. It is not a standard treatment for diabetes and should not be sought outside of clinical trials. The Big Picture The gut microbiome is not a magic lever you can simply pull to fix blood sugar. But it is a real and increasingly well-understood part of the metabolic picture, one that responds meaningfully to lifestyle choices you're likely already thinking about. For now, the most evidence-supported actions remain: eat more fibre and plant-based foods, follow a Mediterranean-style dietary pattern, limit ultra-processed foods, stay physically active, and sleep well. These habits don't just improve blood sugar directly, they also feed a healthier gut ecosystem that, in turn, supports better metabolic health. As this science matures, we're likely to see more targeted interventions, personalized to an individual's specific microbial profile, emerge as a genuine complement to existing diabetes care. Want to learn more about healthy eating for type 2 diabetes? Visit the T2D Network's Healthy Eating  page for evidence-based guidance. Your gut bacteria may be playing a bigger role in your blood sugar than you think. Here's what the latest science says, and what you can do about it today.

Written by Clare Koning, RN, PhD T2D Network | April 2026 | 5 min read Key Highlights ✅ The 2026 ADA Standards of Care now recommend CGM for people with T2D, even those not on insulin ✅ Real-world evidence shows CGM reduces HbA1c by 0.6%–0.9% and cuts diabetes-related hospitalizations by up to 67% ✅ CGM helps you understand how food, exercise, and stress affect your glucose in real time ✅ Over-the-counter CGM options now make this technology more accessible than ever ✅ Talk to your care team, coverage and eligibility criteria in Canada are evolving For most of the history of continuous glucose monitoring (CGM), the technology was primarily associated with Type 1 diabetes and people on intensive insulin therapy. If you had Type 2 diabetes and weren't on insulin, a CGM was seen as a "nice to have", not a clinical priority. That's changed in 2026. The American Diabetes Association's updated Standards of Care , the most widely referenced clinical guidelines in diabetes, now recommend CGM from the time of diagnosis and at any point thereafter, including for people with type 2 diabetes who are on non-insulin therapies . This marks a significant shift, and it has real implications for how you and your care team might approach your diabetes management. Here's what you need to know. What Is a CGM? A continuous glucose monitor is a small wearable sensor, typically worn on the arm or abdomen, that measures glucose levels in the fluid just beneath the skin and transmits readings to your smartphone or a small receiver, usually every few minutes, around the clock. Unlike traditional fingerstick testing, which gives you a snapshot at one moment, a CGM gives you a continuous picture: you can see whether your glucose is rising, falling, or stable, how quickly it's changing, and how it responds to specific foods, physical activity, stress, or sleep. Why Does This Matter for T2D? Most people with type 2 diabetes don't use insulin, and historically, that meant many weren't considered candidates for CGM. But the benefits of real-time glucose feedback go beyond just informing insulin dosing. The evidence for CGM in non-insulin-using T2D has been building steadily: A real-world study published in Scientific Reports  found that CGM use in primary care patients with T2D on non-insulin or basal insulin therapy was associated with a significant HbA1c reduction of 0.62%  at three months, along with meaningful improvements in time-in-range (from 39.7% to 61.9%) and reductions in time spent at elevated glucose levels. A large retrospective study using Aetna insurance data  found that after starting CGM, people with diabetes — including T2D patients not on insulin — showed an average A1c improvement of 0.9% , alongside a 67% reduction in diabetes-related hospitalizations  and a 40% drop in emergency department visits. A meta-analysis published in Diabetologia  confirmed a consistent, modest reduction in HbA1c across people with T2D regardless of whether they were on insulin, together with a 6.4% improvement in time in range . These are clinically meaningful numbers. And beyond the blood sugar metrics, CGM data gives people insight into their own patterns — showing, for instance, that a particular food causes a glucose spike, or that a 20-minute walk after dinner makes a real difference. That kind of real-time, personalized feedback is hard to replicate with periodic fingerstick measurements. As the 2026 ADA Standards note , the benefits of CGM have been shown regardless of age, sex, education, income level, or baseline diabetes characteristics. What's Changed in the 2026 Guidelines? The 2026 ADA Standards of Care  made two particularly notable updates: CGM is now recommended at diabetes onset , not just after a patient has been struggling to reach glycemic targets. The recommendation now explicitly includes people with T2D on non-insulin therapies , not just a soft "consider" but a genuine recommendation when CGM would aid management. The guidelines also removed intermittently scanned CGM from the list of recognized current technologies, reinforcing real-time CGM (rtCGM)  as the standard of care. Real-time systems continuously transmit data and can alert you to dangerous highs or lows proactively, a meaningful safety advantage over systems that only record data when you scan them. What Are the Options? CGM devices have expanded considerably in recent years: Dexcom G7 : widely available, 10-day wear, known for accuracy and real-time alerts Abbott FreeStyle Libre 3 Plus : one of the most widely used globally, compatible with automated insulin delivery systems Eversense 365 : an implantable CGM with a one-year sensor life, for those seeking minimal day-to-day device management Some CGMs are now available over-the-counter (OTC) in the U.S. without a prescription, dramatically lowering the access barrier. Canadian availability and coverage criteria are evolving, check with your pharmacist or diabetes care team for the most current information. What Should You Ask Your Care Team? If you're managing type 2 diabetes and haven't tried a CGM, these are worth raising at your next appointment: Am I eligible for CGM coverage  through my provincial drug plan, extended benefits, or diabetes education program? Would CGM help me understand a specific pattern , like post meal spikes, overnight trends, or the impact of exercise? Which device would work best for my lifestyle? Do I need training?  Most diabetes education centres and primary care networks can walk you through setup and interpretation. The technology is not a replacement for your medications, healthy eating, or physical activity. But as a real-time mirror for your metabolic health, it can be a remarkably powerful complement, giving you and your care team better information to make better decisions. Interested in learning more about monitoring and technology? Visit the T2D Network's Monitoring & Medication  page.

Written by Clare Koning, RN, PhD T2D Network | April 1, 2026 | 5 min read Key Highlights: ✅ Lancets, alcohol swabs, and ketone strips now covered under PharmaCare ✅ A hybrid closed-loop insulin pump covered for eligible people with Type 1 diabetes ✅ People on Plans C, F, and W receive 100% coverage at no cost ✅ Funded via National Pharmacare agreement: up to $670 million over three years ✅ Register for Fair PharmaCare to access income-based coverage If you've been managing diabetes in British Columbia, today is a day worth marking on your calendar. As of April 1, 2026, the province has expanded PharmaCare coverage for a range of diabetes-related supplies and devices, changes that could save you anywhere from a few hundred to several thousand dollars a year. This builds on coverage announced earlier this year for a wide range of diabetes medications, including many insulins, Metformin, and newer agents like Dapagliflozin and Empagliflozin. Today's update goes a step further, bringing everyday testing supplies and advanced insulin delivery technology into the coverage fold. Here's what you need to know. What's Newly Covered? Everyday Testing Supplies Managing blood sugar at home requires tools. And for many people with diabetes, those tools come with a monthly price tag that adds up fast. Starting today April 1, 2026, more British Columbians are eligible for PharmaCare coverage of: Lancets  (up to 400 per year) Alcohol swabs  (up to 300 per year) Blood or urine ketone strips  (up to 100 per year) These three items together form the core of an at-home diabetes testing kit. Depending on the brands you use and how often you test, this could represent savings of $30 to $100 every month . Coverage is processed directly at your pharmacy counter. You'll just need to present your B.C. Services Card. Important:  To be eligible, you must have received training from a diabetes education centre or primary care network, the same requirement that applies to blood-glucose test strips. If you haven't connected with a diabetes education program yet, this is a great reason to do so. A Hybrid Closed-Loop Insulin Pump – A First for PharmaCare This one is a game-changer for people with Type 1 diabetes who meet certain clinical criteria. The Ypsomed mylife Ypsopump  is now the first hybrid closed-loop (HCL) insulin delivery system to receive PharmaCare coverage in B.C. When paired with the Dexcom G6 continuous glucose monitor and a compatible smartphone app, it creates a system that continuously monitors glucose levels and automatically adjusts insulin delivery in real time. Product Image Ypsomed For those who qualify, PharmaCare will cover up to $7,000  for the pump (which carries a five-year warranty). Other HCL technologies are currently under review. Dr. Tom Elliott, medical director of B.C. Diabetes, called it "great news" while framing it as one step toward the best possible care for people living with diabetes in B.C., and we agree. Automated insulin delivery technology has the potential to reduce the cognitive load of constant glucose monitoring and improve time-in-range outcomes significantly. Who Is Covered and How? Coverage flows through existing PharmaCare plans: Plan Who It Covers Coverage Level Plan C Income Assistance and Family Services recipients 100% Plan F Children in the At-Home Program 100% Plan W First Nations Health Authority members 100% Plan B Long-term Care residents (pump only) 100% Fair PharmaCare All other B.C. residents Based on family income If you're not currently enrolled in Plan C, F, or W, registering for Fair PharmaCare  is the key step. It's free to sign up, and your coverage level is determined by your household income, meaning lower-income families pay less. Why This Matters Living with diabetes is expensive. Test strips, lancets, swabs, and devices quietly drain household budgets, and for people managing diabetes on a fixed income or dealing with other financial pressures, these costs can lead to rationing supplies or skipping tests altogether. That has real consequences for blood sugar control, and downstream, for long-term complications. Federal Health Minister Marjorie Michel acknowledged this directly: "Many British Columbians are feeling the pressure of daily expenses, including the high cost of managing chronic diseases like diabetes." This expanded coverage, funded through the federal-provincial National Pharmacare agreement signed in March 2025, which provides up to $670 million over three years  (including approximately $37 million specifically for diabetes devices and supplies), is a meaningful step toward reducing that burden. What Should You Do Next? Here's a quick action list: Check your PharmaCare plan.  Log in at gov.bc.ca/nationalpharmacare  or call your pharmacy to confirm your coverage. Register for Fair PharmaCare  if you're not on Plan C, F, or W. Registration is based on your most recent tax return and takes only a few minutes online. Talk to your diabetes care team.  If you haven't received training at a diabetes education centre or primary care network, you'll need to do so before claiming lancets, swabs, or ketone strips. Ask your endocrinologist or diabetes specialist  whether you meet the clinical criteria for the Ypsopump if you have Type 1 diabetes. Bring your B.C. Services Card  to the pharmacy. Coverage is applied at the counter. The Bigger Picture This coverage expansion is part of a broader shift in how Canada is approaching diabetes care. Since March 1, 2026, hundreds of thousands of British Columbians have already gained access, at no cost, to menopausal hormone therapy, contraceptives, and a suite of diabetes medications under the National Pharmacare Plan (Plan NP). Today's announcement adds supplies and devices to that list, moving care beyond the prescription pad and toward the full toolkit that people actually use every day. There's still work to be done, access to diabetes education, equitable coverage of CGM technology, and support for underserved communities remain ongoing priorities. But as Dr. Elliott noted, today is a step in the right direction. We'll be watching for further updates as additional HCL systems and devices are reviewed for coverage. Stay connected with the T2D Network for the latest news, resources, and community support. For more information, visit gov.bc.ca/nationalpharmacare  and https://news.gov.bc.ca/releases/2026HLTH0030-000334 or s peak with your healthcare provider or pharmacist.

Blog Key Insights ✅Our umbrella review found that culturally tailored, community-based interventions are most effective for preventing and managing T2D in South Asian populations. ✅ In Surrey, BC, we’re bringing diabetes screening and education into trusted community spaces, with a focus on early detection, culturally adapted tools, and stigma reduction. ✅ Joy, our patient partner and a South Asian woman living with T2D, shares her lived experience in a powerful video that highlights the importance of culturally informed care. ✅ Our work is about more than healthcare — it's about inclusion, representation, and making diabetes support truly accessible. Type 2 Diabetes Mellitus (T2D) continues to rise at an alarming rate across the globe, but its impact is not evenly distributed. South Asian populations, including those from India, Pakistan, Bangladesh, and Sri Lanka, are among the most disproportionately affected, developing T2DM earlier, and often with more severe complications, than other ethnic groups. The South Asian community has grown significantly in the last 25 years, according to Stats Canada - the majority of whom were immigrants. Image: Stats Canada: South Asian Immigration to Canada An Ontarian study examined how many of these South Asian immigrants had diabetes and found a rate of 15.9%; higher than the 11.6% prevalence in the non-immigrant population. The study also found that men had higher rates of diabetes than women in each South Asian group. Sociodemographic factors, such as income, education, English proficiency, and refugee status, were also associated with higher diabetes prevalence. This elevated risk is shaped by a complex intersection of genetic predisposition, cultural dietary habits, socioeconomic stressors, and access barriers that demand not only clinical attention but also a deep understanding of the community context. Why Focus on South Asian Communities? Studying this population isn’t just about numbers, though the numbers are striking. In Canada alone, over 2 million people identify as South Asian, making up the largest racialized group in the country. In 2021, South Asians made up 7.1% of Canada's total population, representing over a quarter (26.7%) of the visible minority group. British Columbia is home to nearly half a million individuals of South Asian descent, many of whom live in cities like Surrey, where cultural and religious institutions serve as anchors of community life. Despite these numbers, South Asian communities remain underrepresented in health research and underserved in preventive and diabetes care. We believe that addressing diabetes disparities in this group is about more than improving clinical outcomes. It's about equity, representation, and inclusion. Culturally relevant approaches aren't just “nice to have”, they're essential to building trust and delivering care that makes sense in people’s daily lives. Focusing on this population allows us to spotlight solutions that are tailored, respectful, and sustainable. What We Learned: Our Umbrella Review To better understand what works in preventing and managing T2DM in South Asian populations, our team conducted an umbrella review , a rigorous synthesis of 21 existing systematic reviews, including 7 meta-analyses. This review, recently published in the Clinical Journal of Diabetes Care and Control  (September 2024) , highlights the critical role of culturally tailored, community-based interventions. We found that interventions are far more effective when they align with people’s lived realities, whether that means incorporating traditional foods into dietary plans, respecting religious practices such as fasting during Ramadan, or providing materials in a person’s first language. The most impactful programs were those that combined practical lifestyle guidance with accessible self-management education and supportive technology, such as mobile health apps and reminder systems. Importantly, the review emphasized the power of multidisciplinary, community-anchored care. Programs that engaged dietitians, pharmacists, nurses, family members, and community health workers were more likely to foster ongoing participation and behavior change. This evidence gave us the confidence to move from academic findings to real-world action, creating a bridge between research and community empowerment. Bridging Research and Reality: Our Community-Based Initiative in Surrey, BC Inspired by the findings of our umbrella review, we launched a project in Surrey, BC. Surrey is home to one of Canada’s largest South Asian communities; 37.8% of the Surrey population was South Asian ( 2021 census ). This project, running from March to August 2025, is a collaboration between a local pharmacy, the Canada Indian Network Society (CINS) , and several South Asian community organizations. Our approach is simple but powerful: meet people where they are. We’ve brought diabetes screening directly into temples, gurdwaras, mosques, and community centres, trusted spaces where individuals feel comfortable and respected. Our mobile screening clinics aim to reach up to 300 people every two months, with a focus on early detection and rapid follow-up. Those identified as at risk are immediately linked to primary care, reducing the typical wait time and barriers that often prevent timely diagnosis. But this initiative is more than a screening campaign. It’s a community-driven model of care. In collaboration with the Institute for Personalized Therapeutic Nutrition ( IPTN), we’re developing culturally adapted self-management tools, including visual guides, recipe cards, and bilingual digital resources, co-created with input from South Asian individuals living with diabetes. These materials are designed not only to inform but also to reflect the cultural values, family dynamics, and everyday challenges that people face. We’ve also embedded a stigma-reduction strategy into this work. Too often, diabetes is perceived as a personal failure or something to hide, especially among older adults and women. By engaging patient partners and community influencers, we’re starting conversations that de-stigmatize the disease and encourage proactive care-seeking. What we learnt from Joy, our patient partner, and her lived experience Meet Joy, a vibrant voice in our community and a passionate patient partner. Joy is of South Asian descent and has been living with type 2 diabetes. In this video, she opens up about her personal journey, the challenges, the turning points, and the strength she’s found along the way. Through her story, we gain insight into the lived experience of managing diabetes and the power of culturally informed care. Let’s hear from Joy. What This Means for Healthcare Providers and the Public For healthcare providers, this work is a reminder that culturally informed care is more than translation. It’s about listening, collaborating, and designing interventions that are grounded in people’s lived experience. Providers must consider cultural norms, family roles, and socioeconomic realities when offering care plans. Small changes, such as integrating traditional foods into meal planning or using familiar metaphors to explain blood sugar, can have a profound impact on trust and engagement. For the South Asian public, our message is this: diabetes is not a life sentence, and you are not alone. Early screening, culturally relevant information, and community-based support can dramatically reduce your risk and help you live well with diabetes. Our work is about making those tools truly accessible, not just available in clinics, but embedded in the fabric of community life. Taking the Next Step The burden of T2D in South Asian communities is significant, but so is our opportunity to respond with compassion, evidence, and creativity. Our project in Surrey is just one example of how research can move off the page and into action. It shows what’s possible when academic rigor meets grassroots collaboration. We are also one of the few websites for T2D support that have a dedicated webpage focusing sorely on South Asian resources. We’re committed to continuing this work, expanding partnerships, and sharing what we learn. We hope others, whether researchers, policymakers, practitioners, or community members, will join us in reimagining what diabetes care can look like: inclusive, personalized, and rooted in equity. This isn’t just about fighting a disease, it’s about affirming the right to good health for all.

Key Highlights: ✅ Technology transforms diabetes self-management ✅ Apps and devices support real-time monitoring ✅ AI predicts glucose trends and patterns ✅ Adoption varies by population and region ✅ Digital tools improve clinical outcomes Managing type 2 diabetes used to mean daily fingerstick glucose checks and routine office visits. Today technology is playing a major role in how people monitor, track, and make decisions about their health outside of the clinic. Consumer apps, connected devices, continuous glucose monitoring, remote coaching, and even artificial intelligence systems have become part of diabetes care. These digital tools promise to improve self-management and clinical outcomes. Researchers around the world are studying how these tools can be most effective and how adoption varies by population group and region. Why Digital Tools Matter in Diabetes Care Digital tools, including apps, wearables, and connected devices, help people self-manage more effectively. Research shows mobile health tools can improve short-term blood glucose control when integrated with professional guidance. Mobile health interventions with personalized feedback have been linked to short-term reductions in hemoglobin A1c, a key blood sugar marker. A 2025 systematic review highlights that digital tools are increasingly part of diabetes care globally, but evidence for long-term effectiveness remains limited. Who Is Using Digital Tools and Where Adoption of digital tools is influenced by age, education, income, and geography. Younger adults and those comfortable with technology are more likely to use smartphone apps, wearables, and connected devices. A mixed-methods study found that over 60% of participants tracked at least two factors such as blood glucose, diet, or physical activity, with higher engagement among those with greater digital literacy. In this survey of 61 respondents , most had type 2 diabetes (72%), used insulin (59%), and had experience with CGMs (56%), with high digital literacy evidenced by widespread use of health apps (87%) and activity trackers (59%). Participants mainly used apps to guide dietary choices and preferred passively collected, integrated, visually clear, and customizable data for broader self-management. In Canada, the diabetes technology market is expanding rapidly, particularly among adults under 65 who are comfortable with mobile apps and wearable trackers. Urban areas have higher adoption rates than rural regions, highlighting disparities related to access and broadband infrastructure. Popular Digital Tools in Diabetes Care Apps for Tracking and Management Popular apps for logging blood glucose, meals, medications, and physical activity include OneTouch Reveal, Social Diabetes, mySugr, Tactio SALUD, and Diabetes:M. Explore more free T2D apps available in Canada . Continuous Glucose Monitoring (CGM) CGM devices like Dexcom CGM and FreeStyle Libre provide real-time glucose readings and trend data. Studies indicate CGM users experience improved time in range and fewer hypoglycemic episodes compared to traditional fingerstick monitoring. Wearables and Activity Trackers Devices such as Fitbit, Apple Watch, and Garmin help monitor steps, heart rate, and sleep. Research shows that integrating wearable data into self-management routines supports physical activity adherence. AI-Driven and Personalized Systems AI platforms analyze user data to offer personalized insights, insulin dosing suggestions, or proactive alerts. Early studies suggest AI-driven recommendations can help anticipate glucose trends and improve self-management. Evidence on Effectiveness There is a growing body of scientific evidence showing that digital tools can meaningfully improve clinical outcomes for people living with type 2 diabetes, particularly when used as part of structured care rather than in isolation. A l arge systematic review and meta‑analysis of 118 randomized controlled trials involving more than 21,000 participants found that digital health interventions significantly r educed hemoglobin A1c (HbA1c) , fasting blood glucose, and postprandial blood glucose compared with usual care, with some online and remote monitoring platforms producing the largest effects on glycemic control. Other meta‑analyses focusing specifically on app‑based lifestyle interventions have shown clinically relevant reductions in HbA1c. One pooled analysis across 23 studies reported that patients using app‑based digital tools experienced an average HbA1c reduction of about 0.36 percentage points compared with control groups receiving usual care, and nearly 0.8 percentage points reduction within intervention groups over three to twelve months. Home‑based digital diabetes management technologies that combine frequent self‑monitoring of blood glucose (SMBG), remote data upload, and personalized clinician feedback have also demonstrated significant improvements in HbA1c , fasting glucose, and 2‑hour postprandial glucose, along with modest reductions in BMI , compared to standard home glucose self‑monitoring. A broader 2025 review of digital diabetes management technologies, including mobile apps, continuous glucose monitoring (CGM), telemedicine, and personalized feedback systems, concluded that these tools are consistently associated with improvements in key glycemic measures such as HbA1c and postprandial glucose , and that mobile applications and CGM systems are among the most effective types of interventions studied to date. Taken together, these findings support the growing consensus that digital health tools can enhance glycemic control and support diabetes self‑management when they are well designed, integrated into routine care, and supported by healthcare professionals. However, variations in intervention design, duration, and intensity mean that not all digital programs produce the same level of benefit, and long‑term outcomes beyond one year remain an area of active research. Current Limitations in Digital Diabetes Care Despite their promise, digital tools for type 2 diabetes face several significant limitations. Access disparities  remain a major barrier, as lower‑income individuals and those living in rural or remote areas may lack reliable broadband or devices capable of supporting advanced apps and connected systems, limiting adoption and equity in care. In one study of 422 participants , smartphone ownership among adults with type 2 diabetes increased from 87% in 2017–2018 to 98% in 2020–2021, with corresponding growth in health app use from 49% to 70%. However, this study found that disparities persist by income and health literacy, showing that owning a device alone does not guarantee engagement with health apps. Digital literacy challenges  also persist; older adults and people unfamiliar with technology often struggle to use apps effectively, and complex interfaces such as nutritional databases or glucose‑tracking dashboards can make sustained engagement difficult. Even among users with access and literacy, long‑term engagement  is a challenge, many download apps enthusiastically but discontinue use after a few months, reducing the potential for ongoing clinical benefit. One notable problem for App users is linking tracked behaviors to glycemic and diabetes self-management goals. Additionally, barriers such as difficulty understanding and using apps, interpreting data, and navigating interfaces are frequently reported in studies of digital health technology use among adults with diabetes, and these challenges are linked to lower engagement and less effective self‑management. Privacy and trust concerns  further limit adoption, as users are often unaware of how their personal health data is stored or shared, and few diabetes apps have undergone clinical certification, which can undermine confidence in their accuracy and safety. Finally, evidence gaps  remain. There is a pressing need for standardized outcome measures and large‑scale, long‑term studies in diverse populations to determine which digital tools provide truly meaningful benefits for diabetes management. What the Future Holds for Digital Diabetes Care Looking ahead, the next generation of digital diabetes tools promises to go beyond tracking and reminders toward true prediction and personalization . Artificial intelligence and machine learning systems are increasingly able to analyze massive amounts of glucose, activity, and contextual data to anticipate glucose trends before they occur , offering proactive lifestyle or clinical recommendations rather than reactive alerts. A 2025 study  demonstrated that AI models trained on continuous glucose monitoring and lifestyle data could predict glucose excursions hours in advance with clinically useful accuracy, opening the door to truly anticipatory diabetes care. Researchers are also working toward integrated platforms  that combine multiple streams of health data , glucose, diet, physical activity, sleep, and stress, into a unified dashboard accessible by both patients and clinicians. Early prototypes of these multimodal systems show promise for helping clinicians see the “whole picture” of a person’s daily rhythms and tailor interventions more precisely than ever before. A recent Journal of Medical Internet Research   article highlights how such integrated systems are being tested for both usability and clinical relevance in chronic disease populations. Another promising trend is the move toward clinical prescription of digital tools . Some health systems and payers have begun to formally reimburse evidence‑based diabetes apps and digital therapeutics as part of covered care, similar to medications or medical devices, which could significantly increase access and reduce disparities. A 2025 policy analysis  discussed emerging programs in North America and Europe where digital diabetes tools are reimbursed based on real‑world effectiveness data. Despite these advances, experts emphasize the ongoing need for standardized evidence and clinical guidelines . Large, long‑term randomized controlled trials that measure clinically meaningful outcomes (such as complications, hospitalizations, and quality of life) are essential to determine which tools provide the greatest benefit across diverse populations. While the research community has called for harmonized outcome measures to allow meaningful comparisons across digital interventions, progress has been slow, and studies still vary widely in design, duration, and metrics, making it difficult to determine which digital tools consistently improve clinical outcomes and self-management for diverse populations. Summary Digital tools are reshaping type 2 diabetes care, providing patients with more data, insight, and control than ever before. Evidence shows that apps, wearables, CGM, and AI systems can improve short-term outcomes, particularly when integrated with clinical support. Challenges remain, including access, digital literacy, sustained engagement, privacy, and the need for standardized evidence. As technology and research advance, the future of diabetes care promises to be increasingly personalized, connected, and effective for diverse populations living with type 2 diabetes. The T2D Network does not actively promote any one specific App. We recognize that different Apps may meet different users’ needs, and encourages people to choose tools that best fit their lifestyle, health goals, and clinical guidance.

Key Highlights ✅ Early symptoms include thirst, fatigue, blurred vision, and slow healing ✅ Timely detection prevents serious complications ✅ Healthy diet, exercise, and support improve blood sugar control ✅ Routine check-ups and blood sugar monitoring are essential ✅ Community resources and education enhance diabetes management Living with diabetes or supporting someone who does requires understanding the early signs that indicate a change in health. Recognizing these signs early can lead to timely management and better health outcomes. This article explores the key indicators of diabetes, practical steps to take if you notice symptoms, and how to access helpful resources. Common Signs of Type 2 Diabetes Type 2 diabetes often develops gradually, and its symptoms can be subtle at first. JAMA Patient Page has a great review of what type 2 diabetes is, the risk factors, and recommendations. The Centers for Disease Control and Prevention and Diabetes Canada outline the following common symptoms. Being aware of these signs can help you or your loved ones seek medical advice promptly. Increased thirst and frequent urination: When blood sugar levels rise, the kidneys work harder to filter and absorb the excess glucose. This can lead to dehydration, causing increased thirst and more frequent urination. Fatigue: High blood sugar affects the body's ability to use glucose for energy, leading to persistent tiredness. Blurred vision: Elevated glucose levels can cause fluid to be pulled from the lenses of the eyes, affecting the ability to focus. Slow-healing sores or frequent infections: High sugar levels can impair the body's natural healing process and immune response. Unexplained weight loss: Despite eating normally, some people may lose weight because the body cannot properly use glucose and starts breaking down muscle and fat for energy. These signs often overlap with everyday health issues, which can delay diagnosis – a challenge noted in recent clinical observations. If you notice any of these symptoms, it is important to consult a healthcare professional for evaluation and testing. Checking blood sugar levels with a glucometer Understanding Why Early Detection Matters Early recognition of symptoms allows for timely intervention, which can prevent serious complications such as heart disease, nerve damage, kidney disease, and vision loss –risks highlighted in recent diabetes care research. Routine screening is recommended for adults with risk factors (such as age, obesity, or family history) because early diagnosis improves disease management and quality of life. A recent community‑based review underscores that accessible early detection programs – including point‑of‑care screening and risk questionnaires – can reduce undiagnosed cases and improve outcomes. Lifestyle Changes to Support Management Once diagnosed, adopting healthy habits is crucial. Here are some practical recommendations: Balanced diet: Focus on whole grains, lean proteins, healthy fats, and plenty of vegetables. Limit processed foods and sugary drinks. Regular physical activity: Aim for at least 150 minutes of moderate exercise per week, such as walking, cycling, or swimming. Weight management: Losing even a small amount of weight can improve blood sugar control. Stress reduction: Techniques like meditation, yoga, or deep breathing can help manage stress, which affects blood sugar. Medication adherence: Follow your healthcare provider’s instructions regarding medications or insulin therapy. Support from family, caregivers, and healthcare professionals can make these changes more sustainable. Recent trials, such as the PREDIMED‑Plus study, found that combining a Mediterranean‑style diet with lifestyle changes can significantly lower the risk of developing type 2 diabetes. Healthy meal plate supporting diabetes management When to Seek Medical Advice If you experience any of the signs mentioned earlier or have risk factors, schedule an appointment with your healthcare provider. They may perform blood tests such as fasting glucose or HbA1c to assess your blood sugar levels. Regular check-ups are essential for monitoring your condition and adjusting treatment plans. If you notice new symptoms like numbness, chest pain, or vision changes, seek medical attention promptly. Accessing Reliable Resources and Support Managing diabetes is a continuous journey that benefits from education and community support. Many organizations offer digital tools, educational materials, and peer support groups tailored to people living with diabetes in Canada. Online platforms provide access to meal planning guides, exercise tips, and medication reminders, like the T2D Network. Healthcare providers can connect you with dietitians, diabetes educators, and support programs. Community groups offer opportunities to share experiences and learn from others facing similar challenges. Utilizing these resources can enhance self-management and improve overall well-being. Recognizing the early signs of type 2 diabetes is the first step toward effective management and a healthier life. Stay informed, seek support, and take proactive steps to maintain your health.

Key Highlights ✅ Sex hormones influence cardiovascular risk in type 2 diabetes ✅ Metabolomic signatures improve early prediction of T2D ✅ Patients prioritize usability in digital health tools ✅ Oral Ozempic tablets change diabetes treatment options Diabetes care is undergoing subtle but important shifts. While much of the clinical conversation remains focused on glucose targets and cardiovascular protection with established therapies, recent research suggests that risk prediction, personalized cardiovascular risk profiles, and technology adoption may redefine how we approach both prevention and long‑term management. A few key studies point toward advances that could reshape practice, especially for high‑risk populations and those with subclinical disease. Let’s unpack them. Cardiovascular Risk in Type 2 Diabetes (T2D): Sex Hormones May Matter Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in people with T2D, but the risk isn’t uniform across patient populations. A large new study from Johns Hopkins Medicine  sheds light on why heart disease risk differs between men and women with T2D, and it points to the role of sex hormones. In people with T2D, higher testosterone in men was associated with lower  heart disease risk. Rising estradiol levels correlated with greater  cardiovascular risk. Surprisingly, these hormone‑risk patterns were not seen in women with diabetes, suggesting that hormone‑driven mechanisms might influence risk differently by sex. Clinical Implications These findings highlight that, beyond traditional risk factors like LDL, blood pressure, and smoking status: Hormonal milieu may contribute to cardiovascular risk stratification. For men with T2D, low testosterone could signal elevated CVD risk independent of glycemia, a nuance worth considering when interpreting risk or planning preventive strategies. For women, the absence of the same hormone associations suggests other mechanisms may dominate CVD risk. While we’re not yet at the point of routinely measuring sex hormones for risk prediction, this study invites clinicians and researchers to explore more personalized risk profiles in cardiovascular care for diabetes. Metabolomic Signatures Could Sharpen Early T2D Prediction Traditional risk prediction models rely on age, BMI, family history, and fasting glucose or A1c. But a large new international study , tracking over 23,000 individuals across 10 cohorts with up to 26 years of follow‑up, has identified a blood‑based metabolomic signature that improves prediction of future T2D beyond conventional factors. Researchers identified specific small molecule metabolites in blood that correlate with future onset of diabetes. When integrated into predictive models, this metabolomic signature outperformed traditional predictors alone. These metabolites also reflect genetic and lifestyle influences on disease risk, suggesting that biological pathways of risk go beyond simple glucose measures. Potential Clinical Impact Earlier identification of high‐risk individuals could allow for earlier, more aggressive prevention, including lifestyle change or pharmacotherapy. Because the study spanned diverse ethnic backgrounds, the findings may be more generalizable than many prior biomarker studies limited to single populations. This research hints at a future where a patient’s metabolomic profile becomes part of routine risk stratification, particularly for those in the gray zone of prediabetes. Digital Health Engagement: What Patients Actually Want Clinical innovation isn’t just about biomarkers and drugs, it’s also about how patients interact with care tools. A new systematic review published January 2026 examined patient experiences and perceptions of digital health technologies (like mobile apps and web‑based platforms) for T2D management. Insights From the Review Digital tools hold promise for improving self‑management , education, and engagement. However, the human experience often differs from theoretical potential: patients report barriers such as: Usability issues Lack of sustained motivation with apps Integration gaps with clinical workflows Effective digital adoption is not automatic, it requires clinician guidance, easy‑to‑navigate design, and integration with real‑world needs. As more digital tools enter the marketplace, clinicians will increasingly need to curate and recommend solutions backed by evidence, not just popularity. Understanding patient perceptions helps frame shared decision‑making around tech use, and may improve engagement and outcomes. Ozempic Pills Are Here, What Should Clinicians Know? In regulatory news that will affect prescribing patterns, the FDA has approved oral formulations of Ozempic (semaglutide tablets) in multiple doses, set to launch in the second quarter of 2026. Clinical Context These tablets represent an additional option for GLP‑1 therapy, especially for patients who struggle with injectables. The new doses are bioequivalent to existing semaglutide formulations, offering flexibility in titration and patient preference discussions. Higher doses pending review (like a 25 mg tablet) may further widen therapeutic uses. While many clinicians are already comfortable prescribing injectable semaglutide, the oral option may reduce barriers to initiation and adherence. Conversations about GLP‑1 therapy should evolve to include both efficacy and delivery modality preferences. Genetic Signals Hidden from Standard Blood Tests in T2D In another intriguing finding published January 2026 , researchers uncovered that standard blood tests miss key genetic causes in up to 85 % of type 2 diabetes cases, meaning many genetic drivers of disease risk are invisible with routine testing. This highlights the limitations of traditional biomarkers and suggests that genetics and underlying biology may remain undetected until disease manifests. It supports the earlier theme of incorporating novel biomarkers (like metabolites or genetic profiles) into more predictive models. Diabetes care is moving toward precision diagnosis and more individualized treatment. Cardiovascular risk assessment may soon go beyond traditional markers like lipids and blood pressure, incorporating hormone levels and personal metabolic signatures for more accurate risk profiling. Metabolomic and genetic tools also promise better prediction and earlier intervention, allowing prevention strategies to be tailored sooner. At the same time, digital health will only succeed when tools are genuinely usable for patients and supported by clinician, not just novel. Finally, therapeutic flexibility is expanding, with options like oral semaglutide broadening access to GLP-1 therapy and creating new opportunities for engagement and long-term adherence. Clinically, this means considering sex-based differences in cardiovascular risk, staying aware of fast-evolving prediction tools, actively supporting patients using digital platforms, and preparing for new formulations and delivery methods in diabetes pharmacotherapy.

From Superior GLP‑1 Combos to Oral Ozempic and Cytokine Targets. Key Insights ✅ CagriSema outperforms single GLP‑1 therapies. ✅ Oral Ozempic improves patient adherence significantly. ✅ IL‑32 identified as kidney disease target. ✅ Diabetes care shifting toward personalized, mechanistic treatments. In the fast‑moving world of diabetes medicine, the early weeks of 2026 are already shaping up to be a watershed moment. Recent clinical trial data and biotech insights are pointing toward new treatment paradigms that may soon change how we manage type 2 diabetes, and even its complications. This post unpacks the latest evidence (all within the last week) and places it into clinical context for healthcare professionals. We’ll explore novel drug combinations, formulations, and emerging molecular targets, each backed by new, relevant data. The Novo Nordisk logo is used for informational purposes only. This blog is not affiliated with or endorsed by Novo Nordisk , and all trademarks remain the property of their respective owners. CagriSema: A GLP‑1 Combination That Outperforms the Current Standard A late‑stage trial of a novel diabetes drug combination called CagriSema (cagrilintide plus semaglutide) has just released (Feb 2026) compelling data suggesting it may be superior to the current GLP‑1 agonist benchmark, Wegovy (semaglutide alone). What the Data Shows In a trial with 2,728 adults with type 2 diabetes, CagriSema delivered ~14.2% average weight loss over 68 weeks vs. ~10.2% with Wegovy. It also produced slightly better HbA1c reductions, nearly 1.91% vs. 1.76% with semaglutide alone. These results suggest that dual‑mechanism therapies could become a new therapeutic class with enhanced glycemic and weight benefits. Why It Matters for Clinicians Combining multiple hormonal pathways (glucagon‑like peptide effects with amylin‑like signaling) may offer more robust metabolic control with acceptable tolerability. If regulatory approval follows, CagriSema could become a go‑to option for patients who aren’t achieving targets with mono‑agonists. Oral Ozempic Tablets: A Game Changer for Adherence In another major development in February 2026, Novo Nordisk announced FDA approval of an oral Ozempic  tablet  that’s expected to launch in mid‑2026. Key Features Approved doses include 1.5 mg, 4 mg, and 9 mg of semaglutide in tablet form. These tablets are bioequivalent to injectable semaglutide formulations that we’re already familiar with. Higher doses (up to 25 mg) are under review for later in the year. Clinical Significance Oral GLP‑1 therapy may dramatically improve patient adherence, particularly for those with needle aversion or logistical challenges with injectables. Given the strong cardiovascular and renal benefits seen with injectable semaglutide, the oral formulation could broaden the reach of this class. Expect questions in clinic about how oral semaglutide compares with existing formulations, especially regarding onset of action, GI tolerability, and cardiovascular outcomes data. IL‑32: A Novel Inflammatory Target in Diabetic Kidney Disease A team led by Dr. Justin Chun at the University of Calgary has identified a protein called IL‑32 that may play a key role in kidney damage caused by diabetes. Their study, published in Inflammation Research (2026) , looked at human kidney tissue and found that kidney cells build up lipid droplets coated with IL‑32. This suggests a direct link between metabolic problems and inflammation in diabetic kidney disease (DKD). Why This Matters Diabetic kidney disease is a leading cause of chronic kidney problems worldwide. I nflammation and fat buildup in kidney cells contribute to disease progression. IL ‑32 co uld become a new therapeutic target, opening the door to treatments that slow or prevent kidney damage beyond simply controlling blood sugar. While this work is still early and primarily molecular, it highlights a broader shift: moving past glucose and toward immunologic drivers of complications. What These New Findings Mean for Practice Combination therapies like CagriSema could redefine glycemic and weight‑loss goals. If approved, clinicians will need to learn how to integrate these agents into existing treatment frameworks and manage nuanced adverse effect profiles. Oral semaglutide formulations may significantly reduce barriers to GLP‑1 therapy, especially for patients who struggle with injectables, potentially improving both engagement and outcomes. Emerging molecular targets such as IL‑32 reflect a broader trend in diabetes research: targeting the drivers of complications at a biologic level, not just metabolic symptoms. Clinical Takeaways Start thinking ahead about patient selection for combination therapies like CagriSema, especially those with suboptimal response to current GLP‑1 monotherapies. Discuss oral GLP‑1 options with patients now, preparing them for what’s coming in the market. Be aware of evolving science in inflammatory regulation of complications, even if it hasn’t yet translated into available therapeutics. These advances reflect a broader transformation in diabetes care, one where personalization, convenience, and deeper mechanistic targeting are becoming the norm.

Key Insights into Blood Sugar Management ✅ Blood sugar responses differ greatly between individuals. ✅ “Carb-response types” reflect metabolism, not just food. ✅ Insulin-resistant people may not benefit from fiber/protein preloads. ✅ Molecular and gut microbiome profiles influence glucose spikes. ✅ Precision nutrition using CGM and metabolic data is the future. An interesting study published in Nature Medicine on June 4, 2025, is changing how we think about blood sugar after meals. Traditionally, foods have been labeled by their glycemic index, suggesting a “one-size-fits-all” approach. However, this research shows that your body’s response to food, particularly your post-meal blood sugar spike, is shaped more by your metabolism than by the food itself. This insight could transform how we prevent and manage type 2 diabetes (T2D) and cardiovascular disease. How the Study Was Conducted Fifty-five adults without diabetes participated in a carefully designed study. Researchers used Continuous Glucose Monitors (CGMs) to track real-time blood sugar changes as participants ate seven carbohydrate-rich meals. These meals included rice, bread, potatoes, pasta, grapes, beans, and mixed berries. Each meal contained 50 grams of carbohydrate, and participants repeated meals to ensure consistent results. Beyond monitoring blood sugar, the team measured metabolic health using gold-standard tests for insulin resistance and beta cell function. They also collected detailed molecular data from blood and stool samples to uncover links between glucose responses, metabolites, fats, proteins, and even gut microbes. Individual Variability in Blood Sugar Responses One of the most striking findings was the variability in responses. Some people had high spikes after rice, while others spiked after potatoes or bread. Researchers categorized participants into different “carb-response types” based on which foods triggered the largest glucose increase: Rice-spikers Potato-spikers Grape-spikers Bread-spikers Interestingly, these patterns reflected each person’s underlying metabolism. Potato-spikers tended to have higher insulin resistance, while grape-spikers were more insulin sensitive. Bread-spikers had higher blood pressure. Rice-spikers, the largest group, included many individuals of Asian descent. This clearly shows that blood sugar responses are a personal signature of your physiology, not a fixed property of the food. The Impact of Metabolic Health on Meal Responses The study also explored whether adding fiber, protein, or fat before a high-glycemic meal could blunt the sugar spike. The results were fascinating. People who were insulin sensitive saw real benefits; fiber and protein reduced their glucose peaks. However, for those who were insulin resistant, these strategies had little effect. In other words, the very people most at risk for high blood sugar may not respond to generic dietary tricks. To give some numbers, potato spikes were 179% higher in insulin-resistant individuals than in insulin-sensitive ones, and pasta spikes were 152% higher. The research also highlighted a simple clinical metric, the Potato vs. Grape ratio , that may help identify insulin resistance in a non-invasive way, potentially serving as a game-changing tool for clinicians. Molecular Insights and Future Directions This study didn’t stop at blood sugar. Molecular profiling revealed distinct metabolic signatures. Potato-spikers had higher triglycerides and fatty acids, while bread-spikers showed elevated N1-Methyladenosine, which is linked to high blood pressure. Certain gut microbes also correlated with individual glucose responses, emphasizing the role of the microbiome in metabolism. A particularly cutting-edge aspect is the idea that combining CGM data with multi-omics profiling could allow for truly precision nutrition plans. Imagine a future where your meals are optimized not just by calorie or carbohydrate content, but by your unique metabolic and molecular profile—a personalized diet for preventing diabetes before it starts. More Evidence on Blood Sugar Responses An earlier study in 2019 showed the same key principle: post-meal glucose responses vary widely between people, and generic dietary advice may miss the mark. In this study of adults without diabetes, researchers found that men and women responded differently to the same meal. Their postprandial glycemic responses (PPGRs), as measured with CGMs , diverged substantially depending on nutrients and sex, not just the carbohydrate content. Another strong body of evidence comes from a landmark “real-world meals” study 01481-6?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867415014816%3Fshowall%3Dtrue) from 2015. In this study, a large cohort of ~800 people logged almost 47,000 meals while wearing CGMs. The authors demonstrated very high inter-individual variability in PPGRs to identical meals. They built a machine-learning model that integrated personal blood parameters, dietary habits, anthropometrics, physical activity, and gut microbiome data. This model achieved much better prediction of PPGRs than traditional carbohydrate-counting or calorie-based approaches. The success of this study in predicting individual glycemic responses and improving them through personalized diet interventions strongly supports the concept advanced by the 2025 paper: PPGRs are not simply about the food, but about “who’s eating it.” Together, these findings build a strong case for a shift toward precision nutrition. This involves using CGM, phenotyping %20and%20environmental%20factors.) and possibly microbiome data .) to tailor dietary advice individually, rather than relying on generic glycemic index tables or broad dietary recommendations. The Importance of Personalized Nutrition For individuals managing their blood sugar, the key takeaway is that your response is unique. What works for someone else might not work for you. Monitoring your own glucose can guide smarter food choices. Simple strategies like adding fiber or protein can help, but only if your body is responsive. For healthcare providers, this research highlights the limitations of generalized dietary advice. Understanding each patient’s metabolic phenotype can help design personalized nutrition interventions that may be far more effective for preventing or managing T2D and related conditions. These studies provide strong evidence that post-meal glucose spikes are deeply individual and rooted in measurable metabolic and molecular traits. This opens the door to truly personalized nutrition strategies . Blog topic suggested by Sean McKelvey from the Institute for Personalized Therapeutic Nutrition .

February is Heart Month in Canada. This is a time to raise awareness about cardiovascular health. For those living with diabetes, heart disease is the leading cause of death . Adults with diabetes are more than 3 times more likely to die from heart disease than those without diabetes ( 65-80% ). These statistics are alarming, but the situation is even more concerning. A nationwide Danish study published (2025) in the European Heart Journal found that people with T2D were 6.5 times more likely to experience sudden cardiac death (SCD) than those without diabetes. Individuals with type 1 diabetes faced a 3.7-fold increased risk. Among adults under 50, the relative risk was even higher. Younger patients living with diabetes experienced a sevenfold increase in SCD compared to their peers. Several mechanisms contribute to this heightened risk. Diabetes accelerates the development of ischaemic heart disease, which can lead to fatal arrhythmias. Episodes of hypoglycemia and cardiac autonomic neuropathy further increase the likelihood of dangerous heart rhythm disturbances. On a population level, diabetes also shortens life expectancy. The same Danish study reported that type 1 diabetes reduces average life expectancy by 14.2 years, and type 2 diabetes by 7.9 years, with SCD accounting for a notable proportion of these lost years. Exercise as a Key Strategy to Reduce Cardiovascular Risk Lifestyle modification, particularly structured exercise, is one of the most effective strategies for reducing cardiovascular risk in people with T2D. A 2025 systematic review published in Diabetology compared the effects of aerobic, resistance, and combined exercise training on cardiovascular outcomes in adults with T2D. The review found that aerobic exercise alone can reduce systolic and diastolic blood pressure by 6 mmHg and 3 mmHg respectively. It also improves cholesterol levels, including an 8% reduction in LDL and a 5% increase in HDL. Resistance training improves lean muscle mass, insulin sensitivity, and contributes modestly to lowering inflammation. The most pronounced cardiovascular benefits were observed with combined aerobic and resistance training. This approach achieved larger reductions in blood pressure, LDL cholesterol, and inflammatory markers, alongside a 15% improvement in heart rate variability. These findings underscore the value of a holistic exercise program as a cornerstone of cardiovascular prevention in T2D. Source: https://www.mdpi.com/2673-4540/6/5/38 Rethinking Risk Screening: Why Traditional Tools Can Miss Heart Events While diabetes significantly increases heart risk, standard screening tools may still miss many individuals at risk for acute events. An 2025 open-access study in JACC : Advances highlighted that nearly half of patients presenting with their first myocardial infarction had low or borderline ASCVD risk scores. Most experienced no symptoms until just before their cardiac event. The study emphasized that both ASCVD and newer risk calculators, such as the PREVENT tool , fail to identify many at-risk individuals under 66 years old. Notably, 60% of participants did not develop symptoms until within 48 hours of their event. These findings reveal a critical gap in traditional, risk-based screening. They underscore the importance of proactive lifestyle interventions, personalized care, and, where appropriate, imaging-based assessment of subclinical atherosclerosis. Personalized Interventions & Clinical Guidance Effective cardiovascular prevention in diabetes requires an integrated approach. Structured exercise combining aerobic and resistance training, early optimization of medications such as SGLT2 inhibitors, GLP-1 receptor agonists, and statins, and advanced cardiovascular monitoring can all contribute to reduced risk. Younger adults, particularly those with type 1 diabetes, may benefit from early intervention and personalized treatment strategies. Practical Cardiac Resources for Canadian Healthcare Providers Healthcare providers in Canada can access practical resources for assessing and managing cardiovascular risk in patients with diabetes. The Canadian Cardiovascular Society (CCS) calculators and forms provide validated tools for risk assessment tailored to Canadian populations. The Heart & Stroke Foundation Risk Screening offers an interactive tool for evaluating patient risk and generating personalized recommendations. CardioRisk Calculator ™ is a clinical tool to streamline heart disease risk assessment based on national Canadian dyslipidemia guidelines. Additionally, the CCS Companion Resources provide infographics, algorithms, and printable handouts to support guideline implementation. Clinicians can also utilize Hypertension Canada’s clinician resources for guidance on managing a major modifiable risk factor in diabetes. Protecting Your Heart with Diabetes For patients, key steps include monitoring blood sugar, blood pressure, and cholesterol regularly. Maintaining an active lifestyle with combined aerobic and resistance exercise is crucial. Engaging in ongoing discussions with healthcare providers about preventive strategies and advanced monitoring is also essential. These proactive steps, along with evidence-based treatment and personalized interventions, can significantly reduce cardiovascular risk and improve long-term health outcomes in people with diabetes.

Key Insights ✅ GLP-1s help lower blood sugar and shed weight in T2D. ✅ Benefits often fade after stopping, and weight can return. ✅ Muscle loss is possible; exercise helps. ✅ Best results come from combining medication with lifestyle support. Weight-loss medications, especially GLP-1–based drugs like semaglutide and tirzepatide, have transformed obesity treatment. Double-digit percentage weight loss, rapid metabolic improvements, and strong cardiovascular signals have driven unprecedented demand. But a crucial question has lingered behind the headlines: what happens when people stop taking these drugs? A major new BMJ systematic review and meta-analysis (January 2026) offers the clearest answer yet, and the findings should reshape how clinicians, policymakers, and patients think about weight-loss medications. In this review of 37 studies covering over 9,300 participants found that after stopping weight-loss medication, people regain weight at an average of ~0.4 kg per month, returning to baseline weight in about 1.7 years. For newer GLP-1 medications, regain can be even faster, around 0.8 kg per month. Even though these drugs produce larger initial weight losses than lifestyle programs, the rebound is steeper. Behavioral programs like diet and exercise interventions may produce slower initial losses, but they also teach coping skills that help maintain weight loss longer, often nearly twice as long as medication alone. Graphical abstract West et al. 2026 Weight loss isn’t the only thing that reverses. GLP-1s improve key cardiometabolic markers, including blood sugar, blood pressure, and cholesterol, but these benefits largely disappear within 12–18 months of stopping treatment. This challenges the idea that a period of drug-induced weight loss can “reset” metabolic risk permanently. Why Stopping GLP-1s Matters for People with T2D For people with T2D, these findings are particularly important. Diabetes is a chronic, progressive condition, and GLP-1s are a management tool, not a cure. Stopping medication often means both weight and blood sugar levels rise again, potentially undoing months of effort. Muscle loss is another consideration. Up to 40% of the weight lost on GLP-1 therapy may come from lean body mass. Without resistance training and proper nutrition, repeated cycles of weight loss and regain could lead to sarcopenic obesity, especially in older adults. Lifestyle Still Matters We've said it before and here it is again. The evidence reinforces a simple truth: medication alone is rarely enough. Lifestyle interventions, structured nutrition, regular exercise, stress management, remain essential for lasting benefits. Think of GLP-1s as powerful tools that work best when integrated into a long-term metabolic health plan. Without a long-term strategy, weight-loss drugs alone are unlikely to solve a chronic problem. One of the most revealing aspects of the study is its comparison with behavioural weight management programmes (BWMPs) such as diet and physical activity interventions. Although medications led to greater initial weight loss, the rebound was much steeper: Even after adjusting for how much weight people lost initially, regain was consistently faster after medication than after behavioural programmes. Intervention Monthly weight regain after stopping GLP-1a Time to return to baseline weight prior to GLP-1a Weight-loss medication ~0.4 kg/month ~1.7 years Behavioural programmes ~0.1 kg/month ~3.9 years Weight loss is real. Regain is real too. And for people with T2D, planning for both is the key to sustained health. What Other GLP-1 Evidence Shows: Beyond the Headlines It’s worth looking at what peer‑reviewed science tells us about GLP‑1 medications and weight rebound. Multiple systematic reviews and meta‑analyses confirm that significant weight regain tends to occur after stopping GLP‑1 receptor agonists, including semaglutide and tirzepatide. One meta‑analysis found that after discontinuation, participants regained several kilograms of body weight proportional to the amount lost on therapy, underscoring the biologic drive to return to prior weight without ongoing medication support. Moreover, structured analyses show that not only does weight return, but cardiometabolic markers such as HbA1c, blood pressure, and lipid levels also deteriorate once treatment stops, particularly in people with T2D or obesity. This metabolic rebound highlights that the advantages gained during active therapy are not always durable unless sustained by long‑term intervention. However, the story isn’t entirely one‑sided. Other research suggests that combining GLP‑1 therapy with lifestyle modification, like diet and exercise, produces larger and more favorable effects on weight and cardiometabolic biomarkers than medication alone, pointing to the powerful synergy between drugs and behavior change. Rethinking Duration, Expectations, and T2D Management Recognizing T2D as a chronic, progressive disease means asking different questions about GLP‑1s: Should these medications be used long‑term or even lifelong for many patients? What strategies help preserve metabolic gains if therapy is tapered or stopped? Some analyses argue that short‑term courses may fall short for lasting benefit unless paired with sustained lifestyle changes and realistic planning around discontinuation. It’s also important to tailor expectations: while GLP‑1s are highly effective tools for lowering blood sugar and reducing weight, they are not a cure for the underlying metabolic dysfunction of T2D. Durable improvements most often come from comprehensive care plans that integrate medication, nutrition, physical activity, and behavior support over years, not just months. Toward Better Long‑Term Support GLP-1 medications are transformative for glycemic control, weight loss, and cardiovascular risk in T2D, but only while they’re taken. Long-term success depends on combining medication with lifestyle support and realistic planning around discontinuation. Looking ahead, r esearchers continue to explore how to optimize GLP‑1 use in chronic care. This includes studying whether extended treatment durations, tapering strategies, or combined therapeutic approaches could lessen rebound effects after stopping, or even transform how we think about long‑term T2D and obesity management. In the meantime, the weight loss is clear, and so is the challenge of maintaining it. For people with T2D, the best outcomes usually emerge when GLP‑1 medications are part of a broader, sustained plan that includes lifestyle support, realistic expectations, and ongoing conversations between patients and clinicians about goals, duration of therapy, and what happens next.

Key Insights ✅ GLP-1s improve blood sugar and support weight loss. ✅ They reduce cardiovascular risk in people with T2D. ✅ Stopping therapy often leads to weight regain and metabolic rebound. ✅ Muscle loss can occur without resistance training. ✅ Lifestyle support is crucial for lasting benefits. In the last few years, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shifted from a relatively niche treatment for Type 2 diabetes to a household name. In fact, reports suggest about 1 in 8 adults in the U.S. has tried or uses a GLP-1 medication , with roughly a quarter of those using it for weight loss rather than strictly for diabetes control. Originally developed to help manage blood glucose and reduce cardiovascular risk in people with type 2 diabetes (T2D), these drugs have remarkable effects on hunger, appetite, and body weight, and that’s part of why they’re suddenly everywhere. But as we’ll see, their benefits and risks are deeply tied to how they’re used, why they’re used, and what happens when they’re stopped. How GLP-1s Work: Appetite, Weight Loss, and Metabolic Health GLP-1 medications, such as semaglutide  (Ozempic, Wegovy) and tirzepatide  (Zepbound, Mounjaro), mimic a hormone our bodies naturally produce. They slow gastric emptying, reduce hunger signals to the brain, and help lower blood sugar levels, a triple benefit that’s perfect for managing T2D and promoting weight loss . Clinical trials show these drugs can lead to significant weight loss, often 1 0 – 20 % of body weight , while improving glycemic control and lowering cardiovascular risk. This has made them transformative for many people with diabetes who also struggle with obesity. But real-world evidence suggests that not everyone experiences dramatic weight loss, and many people discontinue treatment within the first year. GLP-1s and Type 2 Diabetes: Promise and Practical Reality For people with T2D, GLP-1 medications are more than a weight-loss tool, they’re a metabolic therapy. Long-Term Benefits Large outcome trials h ave shown that GLP-1 RAs not only lower HbA1c but also reduce the risk of major cardiovascular events in people with diabetes and overweight or obesity. This is important because diabetes is not just about blood sugar, it’s about reducing complications that affect the heart, kidneys, and overall longevity. Real-World Patterns Despite their benefits, many people stop taking GLP-1s within a year. A study involving 125,475 adults , both with and without type 2 diabetes, found that 46–65% of those prescribed GLP-1 receptor agonists stopped treatment within 12 months. Reasons range from cost and side effects (nausea, gastrointestinal discomfort) to difficulty with regular injections or insurance coverage. This pattern of starting and stopping matters, especially because the biology, metabolism, and long-term outcomes are not static once you stop. What Happens When You Stop GLP-1 Medications One of the most talked-about topics online, and for good reason, is what happens after stopping GLP-1 therapy. Weight Regain Is Common A growing body of evidence suggests that significant weight regain usually follows GLP-1 discontinuation .  Meta-analyses and clinical trials consistently find that many people regain much of the weight they lost once medications are stopped. Some data estimate weight can return at up to 0.5 kg per month , with people often reaching or nearly reaching pre-treatment weight within 1–2 years. Even large observational analyses indicate that while a minority might maintain some weight loss after stopping, the typical experience is weight recurrence without sustained lifestyle changes.  Metabolic Rebound Beyond Weight It’s not just about pounds on the scale. When people stop GLP-1 medications, glycemic control and other cardiometabolic measures tend to worsen . In T2D, HbA1c levels can rise, undoing some of the drug’s benefits. This underlines an important point: T2D is a chronic, progressive condition. GLP-1 RAs don’t cure it; they help manage it. Stopping therapy often reveals the underlying metabolic dysfunction that led to weight gain and diabetes in the first place. Beyond Weight: Muscle, Sarcopenia, and Body Composition Recent research highlights another layer of complexity: not all weight lost on GLP-1 medication is fat. A considerable portion, up to 40 % in some analyses, comes from lean body mass (including muscle) . That’s concerning because muscle is metabolically active tissue. Losing muscle while dieting (medically or otherwise) can affect strength, mobility, and long-term metabolic health. There’s increasing interest in whether repeated cycles of weight loss and rebound, common with intermittent GLP-1 use, might increase the risk of sarcopenic obesity  (high fat, low muscle) especially in older adults. Exercise, particularly resistance training, becomes a crucial part of minimizing muscle loss, but many real-world users do not get that integrated support , which can make muscle preservation more difficult and lead to nutritional deficiencies. Lifestyle Medicine Still Matters Lifestyle medicine advocates remind us that medication alone rarely solves a chronic condition. And the World Health Organization released a guideline stating that using GLP-1s without structured nutrition, physical activity, stress management, and behavior change often leads to disappointment when the drugs are stopped. This is true whether the goal is diabetes control or weight management. Think of medications as tools, powerful ones, but not substitutes for the habits and routines that sustain health over decades, not months. Where We Stand: A Balanced Perspective So what does all this mean for someone thinking about GLP-1 therapy? They can be transformative for glycemic control and weight loss, especially in people with Type 2 diabetes. Stopping them often leads to weight regain and a return of metabolic risk factors unless lifestyle changes are well-established. Body composition changes matter, not just weight on a scale. Lifestyle support is vital for long-term success, whether continuing medication or not. At the end of the day, GLP-1 medications are not a quick fix , they’re part of a broader, chronic disease management plan, especially when Type 2 diabetes is involved. Their real value comes when treatment integrates metabolic medicine with lifestyle interventions, not one instead of the other.

Key Insights ✅ ~20% of adults with T2D have thyroid dysfunction, mostly subclinical hypothyroidism and hypothyroidism. ✅ Hypothyroidism worsens insulin resistance and lipid metabolism; hyperthyroidism increases insulin needs. ✅ Even minor TSH or thyroid hormone changes can affect A1C, weight, and metabolic control. ✅ Screening and monitoring thyroid function in select patients with T2D is important for integrated care and complication prevention. Introduction Thyroid disorders and type 2 diabetes (T2D) often overlap, a reality with important clinical implications. Emerging evidence suggests that even subtle changes in thyroid hormone levels may influence the risk of developing T2D, affect glycemic control, and contribute to diabetes‑related complications. As providers working at the interface of metabolic care, recognizing and addressing this overlap can improve early detection, optimize diabetes management, and reduce complications. Here we review recent evidence on the association between thyroid dysfunction and T2D, discuss potential mechanisms, and outline practical considerations for clinical practice. What Does the Evidence Show? A recent meta‑analysis of prospective observational studies found that individuals with higher baseline thyroid-stimulating hormone (TSH) had a 17% higher risk  of developing T2D compared with those who had normal TSH levels; in the same analysis, low free T3 (FT3) and low free T4 (FT4) were also significantly associated with increased T2D risk. This relationship held even after adjustment for common risk factors, suggesting that thyroid hormone imbalance may independently contribute to diabetes risk. Notably, the associations followed a U‑shaped (or J‑shaped) pattern: both high TSH and low thyroid hormone levels were linked to greater risk, emphasizing that even modest thyroid dysfunction, or hormone values at the less favorable end of the “normal” range, may be clinically relevant . Supporting this, a recent systematic review and meta-analysis (2024) reported that thyroid dysfunction remains relatively common among adults with T2D. This review of 38 studies found that thyroid dysfunction (TD) affects about 20% of people with T2D, with subclinical hypothyroidism (12%) and hypothyroidism (8%) being most common. Prevalence was higher in Asia and Africa, and risk factors included female sex, poor glycemic control (HbA1c ≥ 7%), long diabetes duration, family history of TD, central obesity, smoking, and presence of diabetic complications like retinopathy and neuropathy. Beyond risk of diabetes onset, thyroid dysfunction may also worsen metabolic control among people with existing T2D. A 24‑month prospective study found that patients with T2D had significantly lower free T3 levels and altered thyroid hormone ratios compared with controls, a pattern that could influence insulin sensitivity, lipid metabolism, and overall metabolic balance. Another cross-sectional study focusing on euthyroid men with T2D demonstrated that subtle variations in thyroid hormone levels were associated with differences in body fat content and lipid metabolism, suggesting thyroid hormones remain metabolically important even when overt dysfunction is absent. Taken together, these findings support the view that thyroid status and glucose metabolism are closely intertwined, a connection that seems relevant across the spectrum from subclinical thyroid variation to overt thyroid disease. Physiological Mechanisms: Why Thyroid and Diabetes Intertwine The biological plausibility of a thyroid–diabetes link is high. Thyroid hormones are central regulators of basal metabolic rate, thermogenesis, lipid turnover, and protein synthesis, all processes intimately tied to insulin sensitivity and glucose metabolism. Hormonal imbalance in either direction can thus disrupt metabolic equilibrium . In hypothyroidism , reduced thyroid hormone activity may slow metabolic rate, impair insulin-mediated glucose uptake, and alter lipid metabolism, all of which can promote insulin resistance. Conversely, in hyperthyroidism, increased thyroid hormone action can accelerate glucose absorption, increase hepatic glucose output, enhance insulin clearance, and raise gluconeogenic and catecholamine activity, potentially driving hyperglycemia and insulin resistance. Moreover, in diabetes, metabolic stress, hyperinsulinemia, or insulin resistance may impair the conversion of T4 to active T3 (via deiodinase enzyme dysregulation), leading to lower circulating T3 despite “normal” thyroid function tests, a phenomenon that might further contribute to metabolic derangement. Thus, the relationship appears bidirectional : thyroid dysfunction may predispose to insulin resistance and T2D, while impaired glucose metabolism in diabetes may disrupt thyroid hormone balance. Clinical Implications for Diabetes Care Given the evidence, healthcare providers should consider thyroid function in patients with T2D, especially in those whose glycemic control, lipid profile, weight, or energy levels change without clear explanation. Even modest deviations in thyroid hormone levels could meaningfully influence metabolic stability. When thyroid testing is indicated , interpreting TSH, FT4, and FT3 in the context of a patient’s overall metabolic picture is critical. “Normal” thyroid values may not guarantee metabolic neutrality; high‑normal TSH or low-normal free thyroid hormone values may warrant closer monitoring or endocrinology referral, especially if metabolic derangement exists despite appropriate diabetes therapy. For patients with T2D and newly identified thyroid dysfunction, overt or subclinical, collaborative care may benefit metabolic outcomes. Coordinating with endocrinology to determine whether thyroid hormone replacement (or suppression) is appropriate may improve insulin sensitivity, lipid metabolism, and potentially reduce risk of complications. Moreover, patient education is essential. Explaining to patients how thyroid imbalance can affect their blood sugar, weight, energy level, and cardiovascular risk may improve adherence to monitoring, medication, and lifestyle interventions. For patients with both diabetes and thyroid disease, integrated care that attends to both hormonal axes, thyroid and pancreas, can help avoid treatment “silos.” Limitations, Uncertainties, and What We Still Don’t Know Despite suggestive data, the association between thyroid function and T2D is not definitively causal. Many studies are observational, and confounding factors, including age, BMI, baseline metabolic risk, and medication use, may influence results. Some analyses suggest the association is stronger in certain subgroups (e.g., normal-weight individuals), while others find no association once obesity or other confounders are accounted for. Long-term, randomized studies assessing whether treating mild/subclinical thyroid dysfunction improves glycemic control, insulin sensitivity, or reduces diabetes incidence are lacking. The optimal thresholds for “thyroid-normal but metabolically suboptimal” remain unclear. Future research should aim to clarify whether thyroid hormone modulation, through treatment or other interventions, can meaningfully alter diabetes risk or outcomes, and to define which patients benefit most from thyroid screening or therapy. Summary Thyroid dysfunction, overt or subtle, and T2D frequently intersect. Emerging evidence suggests that thyroid hormone imbalances may not only increase the risk of developing T2D, but also worsen metabolic control and complicate management. As healthcare providers, maintaining a high index of suspicion for thyroid dysfunction in people with T2D, interpreting labs in the context of metabolic health, and pursuing integrated care when indicated can help optimize outcomes. While more research is needed to determine whether treating mild thyroid abnormalities improves diabetes outcomes, current data justify a proactive, nuanced approach: thyroid health matters in diabetes, and addressing it could yield significant patient benefits.

Key Insights ✅ Nutrition and exercise are key for managing T2D. ✅ Combined aerobic and resistance training improves blood sugar. ✅ Gym-based resistance training is most effective. ✅ Canadians are mostly sedentary; fruit and vegetable intake low. ✅ Small, practical goals improve adherence and long-term success. Practical guidance, evidence, and Canadian context Living with type 2 diabetes (T2D) means managing blood glucose, body weight, cardiovascular risk, and quality of life, and two of the most powerful tools for doing that are what you eat and how you move. Nutrition and physical activity work together: food choices affect blood glucose and weight, while exercise improves insulin sensitivity, cardiovascular fitness and the way your body uses carbohydrates. This article pulls together current evidence and practical, person-centered advice for people with T2D, highlights Canadian statistics about diet and activity, and links to key research and guideline resources so you can read the original studies if you’d like. Why diet and exercise matter in T2D T2D is fundamentally a condition of insulin resistance and relative insulin deficiency. Nutrition and physical activity influence the two core problems; how the body responds to insulin and how much glucose is available in the bloodstream. Weight loss (when needed) improves insulin sensitivity; dietary patterns that lower post-meal glucose spikes reduce glycemic variability; and both aerobic and resistance exercise increase glucose uptake by muscle even without insulin. Clinically meaningful improvements in HbA1c (average blood glucose over 2–3 months) have been demonstrated with combined lifestyle interventions and with specific dietary patterns such as Mediterranean-style diets , while structured exercise programs (aerobic, resistance, or combined) consistently lower HbA1c and improve fitness and body composition. What Canadian guidelines recommend Canadian recommendations for people with diabetes mirror international guidance: aim for regular aerobic exercise (the typical target is at least 150 minutes per week of moderate-intensity activity, spread over at least 3 days, with no more than two consecutive days without activity) plus resistance training at least twice weekly to maintain or increase muscle mass and strength. Diabetes Canada’s clinical practice guidelines emphasize that smaller amounts of activity are still beneficial and that recommendations should be individualized to fitness level, comorbidities and treatment plan (for example, insulin therapy may change the approach to exercise and hypoglycemia prevention). The guidelines also describe nutrition therapy as individualized, there is no single “diabetes diet”, but recommend energy balance for weight management, focus on whole foods (vegetables, fruits, whole grains, legumes, nuts), emphasis on unsaturated fats, and limiting refined carbohydrates and sugar-sweetened beverages. How much activity are Canadians getting? Understanding population-level behaviour helps shape realistic clinical and public-health goals. Recent Canadian data show room for improvement: ParticipACTION’s national summary reports that roughly 49% of Canadian adults meet the 150 minutes/week moderate-to-vigorous physical activity guideline (measured by questionnaire). This leaves about half of adults below recommended levels, with variations by age and sex. National surveillance using device-based measures (accelerometers) from the Canadian Health Measures Survey indicates differences by age and shifting trends; direct-measure reports emphasize that many Canadians spend large portions of the day sedentary and that youth activity is declining. Between 2022 and 2024, Canadian adults averaged 9.3 hours of sedentary time per day , with only about 42% meeting recommended limits. Men were less likely than women to meet the guideline, with 35% versus 49% compliance, respectively. These objective measures often show lower compliance with guidelines than self-reported estimates. On the nutrition side, Statistics Canada and other national reports document that many Canadians do not meet recommended intakes of fruits and vegetables and that obesity prevalence has been rising ( over 30% of adults living with obesity in recent profiles). In fact, in 2023 , only 1 in 5 Canadians aged 12+ consumed fruits and vegetables five or more times per day. Intake was lowest among 18–34-year-olds (17.8%) and highest in adults 65+ (25.6%), showing a clear trend of increasing consumption with age. Younger Canadians continue to fall short of recommended fruit and vegetable intake. These population patterns are important because excess weight and suboptimal diet quality are major contributors to diabetes development and complications. Physical activity: what type, how often, and why it helps Aerobic exercise  (walking, cycling, swimming, brisk housework) improves cardiorespiratory fitness and insulin sensitivity. A general target is ≥150 minutes per week  of moderate-intensity aerobic activity (or 75 minutes vigorous, or a combination), in sessions of at least 10 minutes if needed. For blood-glucose control, timing matters: exercising after meals often lowers post-prandial (after-eating) glucose more effectively than before meals for many people. Resistance training  (weights, resistance bands, bodyweight exercises) increases muscle mass and strength; muscle is a major sink for glucose, so more and stronger muscle helps with glucose disposal. Most guidelines recommend 2 or more sessions per week, targeting major muscle groups. Recent meta-analyses show resistance training reduces HbA1c in people with T2D; supervised, gym-based programs tend to achieve higher effect sizes (potentially due to better adherence and progressive overload). Combined training  (aerobic + resistance) often provides the best of both worlds: improved glycemic control, improved body composition, and cardiovascular benefits. Systematic reviews and meta-analyses that pool many trials show clinically meaningful reductions in HbA1c with combined programs, and improvements in blood pressure and lipid profiles. While not for everyone, high-intensity interval training (HIIT) has also shown promising glucose benefits in trials - safety, preference and baseline fitness determine appropriateness. Free Exercise Videos from Diabetes UK Practical points Start where you are: any increase from sedentary is beneficial. Even short, frequent walks reduce post-meal glucose spikes. Aim for consistency: frequent, moderate sessions are better than long sessions once per week. Consider supervised or group programs, which improve adherence for many people. Tailor exercise to medications: people on insulin or sulfonylureas should monitor for hypoglycemia and may need carbohydrate adjustments when exercising. Discuss medication timing and blood-glucose targets with your care team. Nutrition approaches with the greatest evidence in T2D There is no single “best” diet universally, individual preferences, cultural foods, affordability and comorbidities all matter. Still, several dietary patterns and principles have strong evidence for preventing or managing T2D: 1. Mediterranean-style dietary patterns Consistent evidence links Mediterranean-style diets ( high in vegetables, fruits, legumes, whole grains, fish, nuts, and olive oil; moderate dairy and limited red meat and sugars) with lower diabetes risk and improved glycemic control in people with T2D. Multiple meta-analyses and systematic reviews report benefits for HbA1c, cardiovascular risk factors and weight when compared to lower-quality diets. The pattern is flexible, palatable and compatible with many cultural foods. 2. Energy-restricted diets for weight loss For people living with overweight/obesity, calorie reduction with a structured plan often produces meaningful weight loss and HbA1c reduction. Weight loss of 5–10% of body weight can improve glycemic control and some cardiovascular risk factors; larger weight losses can produce diabetes remission in some individuals (especially with greater early weight loss or with surgical approaches). Individualize the rate of loss, ensure adequate protein and micronutrients, and include behaviour support. 3. Lower-carbohydrate options Moderate carbohydrate reduction (not extreme restriction) can reduce postprandial glucose excursions and sometimes HbA1c, particularly in the short term. Evidence for very-low-carbohydrate diets shows early glucose improvements and weight loss, but long-term sustainability, safety and effects on lipids vary between studies. Shared decision-making is key: if a lower-carb approach helps a person adhere and achieve goals safely, it can be used with monitoring. 4. Plant-forward and higher-quality carbohydrate choices Emphasize whole grains, legumes, vegetables, and fruit rather than refined carbohydrates and sugary drinks. Dietary fibe r is beneficial for glycemic control and satiety. Swapping refined grain products for wholegrain alternatives and prioritizing legumes and non-starchy vegetables helps moderate post-meal glycemic responses. Putting it into practice: a realistic, person-centered plan Set one small nutrition goal for 2–4 weeks Example: add a vegetable to two meals per day, swap sugary drinks for water or unsweetened tea, or replace white rice with a legume-and-vegetable mix twice weekly. Small wins build confidence and create momentum. Start with achievable movement If you’re mostly sedentary, start with 10–15 minute brisk walks after meals (this helps post-prandial glucose). Gradually increase duration and frequency until you reach ~30 minutes most days. Add two short resistance sessions per week (bodyweight squats, push-ups against a wall, resistance-band rows) to begin building strength. Combine strategies for better results If weight loss is a goal, combine moderate energy restriction with higher-protein meals to preserve lean mass, add resistance training, and use behavioural supports (goal-setting, self-monitoring, and structured follow-up). Plan for medication interactions If you take insulin or insulin-stimulating medicines (sulfonylureas), learn how to check glucose before and after exercise and carry quick-acting carbohydrate to treat hypoglycemia. Review medication timing with your prescribing clinician when you start a new exercise program. Use community resources Consider diabetes education programs, supervised exercise classes, or working with a registered dietitian or exercise physiologist. Group classes and supervised programs increase adherence and safety, especially when starting out or when there are comorbidities. Barriers and how to overcome them Common barriers include pain or mobility limitations, fear of hypoglycemia, time constraints, cost, low confidence, and lack of culturally relevant guidance. Practical solutions: Choose low-impact activities (cycling, water aerobics) if joint pain is a problem. Start with short sessions and build up gradually to manage time barriers. Use free local resources (walking groups, community rec centres) and online guided sessions. Seek culturally sensitive nutrition advice, healthy patterns can be adapted to many cuisines (e.g., Mediterranean principles can be applied using local staples). If hypoglycemia is a concern, plan snacks or adjust medication timing in conversation with your healthcare team. Monitoring progress and safety Track outcomes that matter to you: blood glucose patterns (particularly fasting and post-prandial values), weight (if relevant), waist circumference, energy/fatigue, sleep quality, and mood. HbA1c remains the standard for average glycaemia, but daily patterns and how you feel are critical for day-to-day decisions. If you have cardiovascular disease, proliferative retinopathy, severe neuropathy, or other complications, get medical clearance for high-intensity exercise and tailor programs accordingly. Final thoughts For people living with T2D, nutrition and exercise are not optional extras - they are foundational therapies that reduce blood glucose, lower cardiovascular risk and improve overall wellbeing. The best plan is one you can follow long-term: a pattern of whole, minimally processed foods tailored to your needs, plus regular aerobic and resistance activity that fits your life.

2025 was a remarkable year for the T2D Network’s vodcast series. With an emphasis on innovation, equity, mental health, and patient engagement, the vodcasts provided clinicians, educators, researchers, and patient partners with actionable insights, inspiration, and real-world strategies to improve type 2 diabetes care. Whether exploring the integration of health information systems, challenging stigma, or amplifying patient voices, each episode offered depth, nuance, and practical guidance. Meet the hosts: Krista Lamb , host of the main vodcast series, is a healthcare professional and educator with extensive experience in diabetes care. She brings thoughtful questions, clinical insight, and a patient-centered perspective to each episode. Shelley Tice , host of the Patient Partner Series, is an advocate for patient engagement and co-design in healthcare. Shelley expertly guides conversations with patient partners to highlight lived experiences, insights, and the collaborative process of developing meaningful healthcare resources. Main Vodcast Series Diversity in Research In this compelling vodcast, Krista Lamb sits down with Dr. Baiju Shah  to unpack why diversity matters in diabetes research. Dr. Shah dives into how inclusive, culturally sensitive studies can reveal health inequities that are often hidden in aggregate data, and why these insights are essential to designing interventions that actually work for everyone. He emphasizes the importance of combining large-scale population data with the real stories and experiences of people from different communities to challenge assumptions, improve accuracy, and ultimately drive more equitable diabetes care. Full Vodcast: https://youtu.be/SGIGsDJCV2g Teaser clip: https://youtu.be/eZLy9BaMSEA Active Transportation & Positive Nudges in Type  2  Diabetes Care In this engaging vodcast, Krista Lamb sits down with Dr. Jon McGavock to explore how active transportation, like walking, biking, and using public transit, can be a powerful tool for increasing physical activity among people with type 2 diabetes. They delve into how small behavior “nudges” and thoughtfully designed environments support movement in everyday life, beyond structured exercise routines. Dr. McGavock shares research-backed insights on how urban planning, safe infrastructure, and community support can help reduce sedentary behavior and bolster self‑management of diabetes. Krista leads the conversation toward practical strategies for clinicians and educators, focusing on how to encourage patients to integrate more movement into their daily routines in a sustainable way. Full vodcast:   https://youtu.be/sif1T3egTjY Teaser clip: https://youtu.be/IvoYds0JoLM Empowering Diabetes Care: Integrating Health Information In this vodcast, Krista Lamb sits down with Dr. Shazhan Amed to explore the transformative power of integrated health information systems in diabetes care. They examine how digital tools, electronic health records, and patient-accessible data can bridge care gaps, improve patient engagement, and streamline communication between care teams and patients. This conversation goes beyond technology, exploring how clinicians can leverage information integration to anticipate patient needs, personalize care plans, and ultimately enhance outcomes for people with type 2 diabetes. Full vodcast:   https://youtu.be/EazxubOu9bc Teaser clip :   https://youtu.be/AtFozhED35Y Challenging Stigma This powerful compilation brings together key moments from the T2D Network series that explore how stigma affects people living with type 2 diabetes. In this short video, three leading experts share their perspectives on stigma in healthcare and why it matters. Dr. Diane Finegood explains how stigma creates barriers that prevent people from accessing the care they need. Dr. David Campbell highlights how stigma often shows up in subtle ways within clinical settings, shaping both provider attitudes and patient experiences. Dr. Ian Patton discusses practical strategies to reduce stigma through empathy, inclusion, and systemic change. Together, they call for more patient-centered approaches that break down stigma and lead to better health outcomes. Compilation Clip: https://youtu.be/SnEVbPD-Yu0 Tackling Diabetes and Inequity with Dr David Campbell Krista Lamb hosts Dr. David Campbell in a compelling discussion on the intersection of diabetes and social inequities. They explore how homelessness, food insecurity, and systemic barriers contribute to disparities in diabetes care and outcomes. Dr. Campbell shares innovative knowledge mobilization strategies, including photo-voice exhibits and short films, to bring visibility to under-served populations. This vodcast challenges viewers to consider how equity-informed practices and community engagement can reshape diabetes care delivery at every level. Full vodcast:   https://youtu.be/Rqt4yiNJW-s Teaser clip:   https://youtu.be/9KAkBITmCLI More Science, Less Stigma – A Conversation with Obesity Canada In this episode with Krista Lamb, the T2D Network engages Dr. Ian Patton from Obesity Canada to examine how weight bias and stigma affect diabetes care. The conversation delves into evidence-based approaches for reducing stigma in clinical settings, the use of respectful language, and the importance of understanding obesity as a chronic condition rather than a personal failure. This vodcast equips healthcare professionals with strategies to foster a supportive, patient-centered environment that encourages adherence, engagement, and improved health outcomes. Full vodcast:   https://youtu.be/cKXASZ-kcIw Teaser c lip:   https://youtu.be/Z1gnbqJ7EKg Understanding Stigma in T2D Krista Lamb speaks with Dr. Diane Finegood about the pervasive stigma surrounding type 2 diabetes and its impact on patients’ mental health, self-management, and engagement with healthcare providers. They discuss actionable steps clinicians can take to recognize and reduce stigma in their practice, including communication strategies, culturally sensitive education, and policy-level interventions. This vodcast is a must-watch for anyone committed to creating a more compassionate and equitable diabetes care environment. Full vodcast:   https://youtu.be/6iw6ttLu8Dc Teaser clip:   https://youtu.be/1QgfkRiokiU Diabetes and Mental Health: Exploring the Connection In this panel discussion moderated by Krista Lamb, Dr. Mahavir Agarwal and Dr. Diana Sherifali explore the often-overlooked link between type 2 diabetes and mental health conditions, such as anxiety, depression, and stress. The conversation emphasizes how mental health profoundly influences self-management, adherence, and overall quality of life. Panelists offer practical guidance for integrating mental health support into diabetes care, encouraging clinicians to adopt a holistic, patient-centered approach. Full vodcast:   https://youtu.be/0YCp3U6ABhA Short clip Dr. Mahavir Agarwal:   https://youtu.be/zOr0S76u0NM Short clip Dr. Diana Sherifali:   https://youtu.be/fhDlY6n2sSI Patient Partner Series: Joy’s Story (Three-Part Series) Part 1: My Journey Hosted by Shelley Tice, this episode introduces Joy, a patient partner, as she recounts her journey living with type 2 diabetes. Joy reflects on the challenges she faced navigating complex information and engaging with the healthcare system. Her candid story underscores the importance of including patient voices in the design of educational resources and digital health tools. Watch here:   https://youtu.be/9VvVgT72HYE Part 2: First Impressions Joy shares her first experiences collaborating with the T2D Network team. She talks about being welcomed as an equal contributor, the value of co-design, and how patient perspectives can shape content, accessibility, and usability. This episode emphasizes the mutual learning that occurs when patients and professionals work together. Watch here:   https://youtu.be/wWIlnhLE2c0 Part 3: Designing Together The final episode in the series highlights the co-design process in action. Joy details how she helped shape content, refine language, and ensure the final resources genuinely meet patient needs. Her reflections illustrate the tangible impact of patient partnership on creating meaningful, user-friendly digital tools. Watch here:   https://youtu.be/DpJsR4B1ZBg The 2025 vodcast series from the T2D Network masterfully blended clinical expertise, patient perspectives, and actionable strategies for improving diabetes care. From integrating health information systems to tackling stigma and mental health, and showcasing patient co-design, these episodes offered a rich learning experience for healthcare providers and patient partners alike.

Key Insights ✅ T2D care is shifting from glucose control to holistic metabolic health. ✅ 75+ companies are developing 80+ pipeline therapies for T2D. ✅ New treatments target weight, insulin resistance, and organ protection. ✅ Precision medicine and AI enable earlier, personalized interventions. ✅ Digital tools support monitoring, adherence, and lifestyle integration. If you’ve been working in type 2 diabetes (T2D) care for some time, you’ll likely recall the older script: diet + exercise, metformin, maybe a sulfonylurea, then insulin when things got worse. But that story is shifting. What we’re seeing now is a move toward metabolic health , not just glucose numbers. T2D is no longer simply about “high blood sugar” - it’s about weight, insulin resistance, cardiovascular and kidney risk, lifestyle, and the way all these intersect. A recent review in the European Journal of Medical Research  outlines how new drug targets (miRNAs, mitophagy, immune modulation) and precision approaches are converging in T2D care. For clinicians, this means your conversations with patients look different. Instead of “let’s focus on your HbA1c”, the next question might be: what does your weight trajectory look like? How is your kidney function? What is your cardiovascular risk profile? What are your lifestyle supports? The innovations being developed now are reshaping both the “what” and the “how” of T2D care. What Innovation Looks Like Today The old algorithm of “metformin → add one drug → insulin” is now being expanded. For example, the rise of GLP‑1 receptor agonists and SGLT2 inhibitors has already changed practice. A recent article titled New Molecules in Type 2 Diabetes: Advancements, Challenges and Future Directions  discusses how these newer drugs bring cardiovascular and metabolic benefits beyond simple glucose lowering. A clear signal of how fast things are evolving comes from the recent industry intelligence report titled “ Type 2 Diabetes – Pipeline Insight, 2024: Comprehensive Insights About 75+ Companies and 80+ Drugs ”  which outlines more than 75 companies and 80 distinct pipeline therapies in development for T2D. This dizzying number reflects the scope of work across stages - from discovery through Phase III - and across many modalities: oral agents, injectables, small molecules, biologics, even gene or peptide‑based therapies. The report details drug profiles, mechanism of action, development stage, collaborations/licensing deals and more, giving a full picture of where R&D is moving. Drugs like LY‑3209590 (a once‑weekly basal insulin) and HU6 (a metabolic accelerator aimed at fat loss and lean mass preservation) are in development. Imagine a drug that doesn’t just lower glucose, but also optimizes metabolism, enhances insulin sensitivity, and protects organs. That’s where we’re going. In practical terms for clinicians and patients, this means the next decade could bring multiple new options beyond the current standard of care, better tailored therapies, fewer side‑effects, different routes of administration (e.g., oral where we currently use injections), and potentially more precise matching of therapy to patient phenotype. Five Key Pipeline Therapies In drug development, “pipeline therapy” refers to a medicine or treatment that is actively being researched and developed but is not yet widely available or fully approved. Essentially, it’s a drug “in the pipeline” of the pharmaceutical development process. Image credit: Friedreich's Ataxia Research Alliance. Here are five of the most promising pipeline therapies  for T2D, with details on mechanism, stage of development and clinical implications: Insulin efsitora alfa (LY‑3209590)  - Developed by Eli Lilly and Company, this is a once‑weekly basal insulin fusion protein (single‑chain insulin variant + human IgG2 Fc domain) designed to provide stable insulin levels, lower variability and reduce injection burden. It’s currently in Phase 3 for adults with T2D. Clinical implication : If approved, this therapy could simplify basal insulin regimens (fewer injections), potentially improve adherence, and reduce glycemic variability for people with T2D who require basal insulin. Note : Early trials suggest it’s non‑inferior to once‑daily degludec in HbA1c reduction, but there remains some concern about hypoglycaemia risk. HU6  - Developed by Rivus Pharmaceuticals, this is an oral “Controlled Metabolic Accelerator (CMA)” in Phase II that works by mitochondrial uncoupling to increase resting metabolic rate, promote fat loss while preserving lean muscle mass, and thus address metabolic dysfunction. Clinical implication : A therapy like HU6 may expand the treatment paradigm from glucose‑centric to metabolic‑centric (addressing fat metabolism, lean mass, and energy expenditure), offering additional benefit for patients with T2D and overweight/obesity. Consideration : Novel mechanism: will require careful monitoring for safety (e.g., metabolic stress, mitochondrial effects) and long‑term outcomes. AZD‑5004 (ECC5004)  - A small‑molecule GLP‑1 receptor agonist developed by AstraZeneca and Eccogene, currently in Phase II for obesity and T2D. Clinical implication : If successful, the oral GLP‑1RA class may provide more convenient alternatives to injectable GLP‑1 therapies, improving uptake and adherence among people with T2D. Consideration : Oral delivery of peptides/agonists poses formulation challenges; long‑term comparative effectiveness will be key. XW014   - An oral small‑molecule GLP‑1 receptor agonist from Sciwind Biosciences, currently in Phase I for obesity and T2D. Clinical implication : This agent represents an early look into next‑generation GLP‑1 therapies with improved convenience (oral), potentially lower cost and combination potential with other therapies. Consideration : Still early stage; many “first in class” oral analogues have hurdles in bioavailability, durability, and regulatory approval. THDB0206 (BC Lispro)  - From Tonghua Dongbao Pharmaceutical, this insulin analog is designed for ultra‑rapid‑acting post‑meal insulin delivery (mimicking early‑phase insulin secretion) and is in Phase III for T2D. Clinical implication : As many patients with T2D struggle with post‑prandial glucose excursions and early‑phase insulin deficiency, a targeted ultra‑rapid analog may improve glycemic control with less risk of late hypoglycemia. Consideration : Insulin-related therapies still carry hypoglycemia risk and injections may remain a barrier; patient education and monitoring remain critical. Prevention & Precision Medicine The future isn’t just “treat T2D better”, it’s “prevent T2D before it happens, intervene earlier, tailor treatment smarter.” Case in point: in 2025, the UK’s NHS trialed an AI tool that uses routine ECGs to predict T2D risk up to 13 years out. On the precision medicine side, the r eview in the European journal highlights miRNA‑based therapies, epigenetic interventions and novel biomarkers. In practical terms, this means we might soon stratify patients by risk not just by BMI or HbA1c, but via gut‑microbiome profiles, wearable data, digital phenotyping, and genetic markers - then match them to the right therapy early. It’s moving toward “which patient gets which therapy when” rather than “what is the next drug”. The Future: What Might It Look Like? Let’s imagine five to ten years ahead, in a clinic you’re working in. A patient presents with newly‑diagnosed T2D. Rather than the standard checklist, you begin with a metabolic‑health profile: weight history, fat distribution, liver status, kidney and cardiovascular risk, lifestyle context, genetic/biomarker screen. You select a therapy that not only lowers glucose but also targets insulin resistance, preserves β‑cells and supports weight loss. They are prescribed not only a drug but a connected app, CGM, sensor wearables, remote coaching, and a care plan that adapts in real time. Because the drugs are more refined (dual agonists or metabolic accelerators) and the tech more robust, that patient makes better headway: fewer hypoglycemic episodes, less weight gain, reduced variability in glucose, fewer complications. Monitoring becomes dynamic rather than static; decisions are data‑driven and adaptive. Over time, the hope is that fewer patients progress to advanced disease or need multiple therapies. Moreover, care moves from reactive (“you’ve developed complications”) to proactive (“how can we prevent progression?”). That’s the promise. And the research backs it: pipeline analyses show over 160 drugs targeting GLP‑1 receptors alone in development for T2D therapies. These aren’t incremental tweaks - they represent a wholesale re‑imagining of T2D treatment. Some Important Considerations Of course, innovation comes with caveats. Access and equity remain critical - new therapies and tech can widen disparities if not thoughtfully implemented. Data overload is real: clinicians and patients will need help interpreting digital data streams. The evidence, while promising, still has gaps: many digital interventions need longer‑term outcomes. And cost, reimbursement and system integration are non‑trivial issues. Final Thoughts What we’re witnessing in T2D care is not just an evolution - it’s a transformation. The pieces are already falling into place: smarter drugs, integrated tech, personalised care, early intervention. For clinicians, that means broadening our lens and embracing a more holistic metabolic approach. For patients, it means better possibilities and greater engagement in their care. In short, the future of T2D is less about “getting the HbA1c under target” and more about “optimizing metabolic health, preserving organs, improving quality of life, and preventing complications.” It’s an exciting time to be in diabetes care.

Key Highlights: ✅ Oral GLP-1 drugs improve sugar, weight, and heart health. ✅ Canadian Ozempic generic will boost access. ✅ Tirzepatide supports strong blood sugar control and weight loss. ✅ Prediabetes can reverse without weight loss. ✅ AI tools predict risk and guide care. ✅ OTC CGMs offer real-time glucose tracking. Type 2 diabetes (T2D) remains a significant global health challenge, but recent advancements in treatment and management offer new hope for both healthcare providers and patients. This article explores the latest developments in T2D, focusing on 2025 innovations from Canada and around the world, setting the stage for 2026. Breakthrough Treatments Orforglipron: A Promising Oral Alternative Eli Lilly has announced (Oct 15, 2025) promising results from its experimental oral GLP-1 receptor agonist, orforglipron . The oral medication, orforglipron, is intended to replicate the appetite-reducing effects of the GLP-1 hormone, which is also the target of the company’s successful injectable drug tirzepatide, marketed as Mounjaro and Zepbound. In late-stage clinical trials, orforglipron demonstrated superior blood sugar control and weight loss compared to existing treatments (metformin). Patients taking the highest dose of orforglipron experienced an average A1C reduction of 2.1% and a 10.5% reduction in body weight over 72 weeks. These results position orforglipron as a potential game-changer in T2D management. Lilly plans to submit orforglipron for the treatment of T2D to global regulatory agencies in 2026, while submission for obesity treatment is set to occur by the end of 2025. Rybelsus: Expanding Cardiovascular Benefits Novo Nordisk's oral GLP-1 medication, Rybelsus , has received approval from the European Medicines Agency to include cardiovascular benefits in its label. Clinical trials have shown a 14% reduction in cardiovascular deaths, heart attacks, and strokes among patients with T2D taking Rybelsus. This approval makes Rybelsus the first GLP-1 drug - a naturally occurring gut hormone that regulates blood sugar and suppresses appetite - available in the EU for T2D with demonstrated cardiovascular benefits, potentially paving the way for FDA approval in the U.S. later in 2025. Generic Ozempic: Making Treatment More Accessible Toronto-based Vimy Pharma  is preparing to produce a Canadian-made generic version of Ozempic, aiming to make this widely used diabetes medication more affordable and accessible. Founded by former Novo Nordisk Canada executives Dave Suchon and Farris Smith, the company plans to launch the generic as the patent for Ozempic nears expiration. Ozempic, and its related drug Wegovy, contain semaglutide, which helps regulate blood sugar, support weight loss, and improve cardiovascular health. Nearly one million Canadians currently use these medications, and Vimy Pharma expects access to expand significantly once a generic is available. The company will manufacture the drug in partnership with Applied Pharmaceutical Innovation in Edmonton, with funding from Canadian investors, reflecting a new chapter in Canada’s long history of diabetes innovation. Dual-Incretin Receptor Agonists: Enhancing Glycemic Control and Weight Loss Recent developments in diabetes management have introduced dual-incretin receptor agonists , such as tirzepatide, which combine GLP-1 and GIP receptor agonism. This combination results in increased insulin secretion, decreased glucagon release, and significant weight loss, offering a promising approach for enhancing treatment outcomes in T2D patients. A recent Phase 3 tria l (published Oct 2025) demonstrated that tirzepatide reduced A1C by an average of 2.2% in children and adolescents with T2D, highlighting its potential across various age groups. Additionally, the trial reported a 7.4% reduction in BMI among participants, with 79% achieving A1C levels below 6.5% and 53% reaching levels below 5.7%, indicating remission or prediabetes levels. These findings could support tirzepatide as a potential safe and efficacious treatment option for youth-onset T2D. Once-Monthly Anti-Obesity Medication: Potential Benefits for T2D Patients A novel, dual-action anti-obesity medication, maridebart cafraglutide ( MariTide ), has shown effectiveness with once-monthly dosing in reducing weight in patients with obesity, including those with T2D. In an Amgen led Phase II clinical tria l, participants experienced up to 17% average weight loss and significant improvements in HbA1c levels over 52 weeks. This less frequent dosing schedule may improve patient adherence to treatment regimens. The trial demonstrated that MariTide led to substantial weight loss without a plateau, indicating the potential for further weight loss beyond 52 weeks. Additionally, participants with T2D achieved up to 2.2 percentage points reduction in HbA1c, highlighting the medication's efficacy in managing blood glucose levels. AI Advancements Machine Learning Framework for Therapeutic Target Discovery A novel machine learning framework integrating predictive modeling with gene-agnostic pathway mapping has been introduced to identify high-risk individuals and uncover potential therapeutic targets for T2D. This approach provides mechanistic insights without requiring direct molecular data, advancing precision medicine in diabetes care. The framework employs logistic regression and t-tests to identify critical predictors such as pregnancies, glucose levels, skin thickness, insulin, BMI, and diabetes pedigree function. When this model was used to identify key predictors of T2DM, it yielded an overall model accuracy of 78.43% . By mapping clinical predictors to biological pathways, the framework offers a comprehensive understanding of T2D pathogenesis and potential intervention points. Predicting Mortality Risk in T2D Patients Using AI Models Researchers have developed an explainable artificial intelligence model that can predict the risk of death in people with type 2 diabetes over time. They studied 554 adults with diabetes for up to 17 years, tracking who survived and who did not. The model uses ten key health factors (like age, blood sugar, body weight, and other clinical measures) to estimate a person’s risk. What makes this model special is that it’s “explainable”- it doesn’t just give a number, it shows which factors are contributing most to a person’s risk. This can help doctors understand why a patient might be at higher risk and adjust treatments or interventions accordingly. The model was very accurate, especially for predicting 5- to 15-year outcomes, and could eventually be used at the bedside to help guide personalized care for people with T2D. Lifestyle Research Lifestyle Changes Can Reverse Prediabetes Without Weight Loss A r ecent study from the German Center for Diabetes Research (Sept 2025) shows that people with prediabetes can return their blood sugar to normal levels and lower their risk of developing type 2 diabetes - even without losing weight. In the study, about 22% of participants who didn’t lose weight during a one-year lifestyle program still achieved normal glucose levels, and over a ten-year follow-up, they had a 71% lower risk of developing diabetes compared to those who stayed prediabetic. The researchers found that the key difference wasn’t overall weight, but where the body stored fat. People who went into remission stored more subcutaneous fat (under the skin), while those who didn’t remission accumulated harmful visceral (abdominal) fat. Remission was also linked to better insulin sensitivity, improved pancreatic function, and stronger responses to the hormone GLP-1. These findings suggest that focusing on normalizing blood sugar and metabolic health - not just weight loss - can be a highly effective strategy for preventing T2D. So don't focus too much on the scale - focus on the small daily changes that can lead to improved health in the long term. Product News Over-the-Counter Continuous Glucose Monitoring Becomes More Accessible Abbott's Lingo , an over-the-counter continuous glucose monitor (CGM), is now available in over 3,500 Walmart locations across the United States (Oct 2025). This marks a significant step in making advanced health technology more accessible to the general public. Previously, Lingo was only available through select online platforms. The device allows individuals to monitor their glucose levels non-invasively, providing real-time insights into their metabolic health. This development is particularly beneficial for individuals with T2D or those at risk, as it enables more proactive management of their condition without the need for prescriptions or insurance coverage. In Canada, while Abbott's FreeStyle Libre series of CGMs are widely available and covered by most provincial health plans for individuals with diabetes, the Lingo device is not yet approved for sale. Currently, Canadian consumers can purchase the Lingo biosensor directly from Abbott's official website, but it is only compatible with iPhones and is not reimbursed by insurance. This means that, unlike in the U.S., Canadians must pay out-of-pocket for the device, and its use is limited to those who have access to compatible technology. Additionally, the Lingo app is not yet available for Android devices in Canada. The introduction of Lingo in the U.S. highlights a growing trend towards consumer-accessible health technology. However, for Canadian consumers, the availability and accessibility of such devices remain limited. As the demand for non-invasive glucose monitoring tools increases, it is hoped that regulatory bodies in Canada will consider expanding access to devices like Lingo to support individuals in managing their metabolic health more effectively. A New Era in T2D Care The landscape of type 2 diabetes management is rapidly evolving, with innovations spanning medications, digital health tools, AI-driven models, and lifestyle interventions. From oral GLP-1 agonists and dual-incretin therapies to machine learning frameworks that personalize treatment, these advances are providing healthcare providers with more precise and effective ways to manage T2D. At the same time, research shows that even small, targeted lifestyle changes - such as improving blood sugar regulation without necessarily losing weight - can significantly reduce the risk of progression from prediabetes to diabetes. For patients, accessible technologies like continuous glucose monitors empower daily self-management, offering actionable insights and greater control over their health. Together, these developments signal a shift toward personalized, proactive, and accessible care, where both clinicians and individuals can make informed decisions that improve long-term outcomes and quality of life for those living with T2D. Follow us on social media and sign up for our newsletters and feature articles here

Key Insights ✅ GLP‑1 drugs, once for T2D, now lead a $58 B weight loss market. ✅ Patients can lose 15–25% of body weight with lifestyle support. ✅ Dual benefits: improved blood sugar, heart, and kidney health. ✅ Weight loss improves mobility, sleep, and daily functioning. ✅ Obesity is recognized as a chronic condition needing medical management. ✅ Risks include drop-outs, weight regain, GI side effects, and cost barriers. ✅ New therapies like amylin-based drugs may expand future treatment options. A major shift is underway in metabolic health care. Drugs originally developed to treat Type 2 Diabetes (T2D), known as GLP‑1 receptor agonists, are now being propelled into the spotlight as powerful tools for weight management and wider metabolic health. At the centre of the surge is a market now valued at more than US $58 billion , driven by two pharmaceutical giants: Novo Nordisk with brands like Wegovy & Ozempic, and Eli Lilly and Company with Mounjaro & Zepbound. According to a recent visualization by Inigo Insurance , Novo Nordisk’s Ozempic leads the market with 31.5% share, followed by Eli Lilly’s Mounjaro at 23.4%, with other products like Wegovy, Zepbound, Trulicity, Rybelsus, Saxenda, and Victoza filling out the remaining share. These drugs, originally developed for type 2 diabetes, mimic the hormone GLP‑1 to regulate blood sugar and appetite, helping patients feel fuller and reduce hunger. In the U.S., roughly 1 in 8 adults  have tried a GLP‑1 drug, with 6% currently using them, showing how mainstream these treatments have become. While the market concentration allows both companies to invest heavily in research and innovation, it also introduces potential risks, including regulatory scrutiny and patent challenges, highlighting the high‑stakes nature of the current metabolic drug revolution. This isn’t simply a business story - it matters for patients with T2D, those living with overweight or obesity, and for the providers working alongside them. From Diabetes Treatment to Weight-loss to Broad Metabolic Health Tool Historically, GLP‑1 medications were positioned primarily for glycemic control in T2D: lowering blood sugar, helping pancreatic function, maybe modest weight loss. But increasingly we are seeing a paradigm shift. These medications are now being used (and approved) for weight management, broader metabolic outcomes, and comorbidity reduction. In Canada, there are currently four prescription medications approved for long-term obesity management in adults. These are considered the main options for general obesity treatment, helping patients manage appetite, cravings, and weight over the long term. Semaglutide (Wegovy®) Tirzepatide (Zepbound™) Liraglutide (Saxenda®) Naltrexone/Bupropion (Contrave®) Two additional medications are sometimes listed, but they are specialized or mechanistically different: Orlistat (Xenical®) works by blocking fat absorption rather than affecting appetite. Setmelanotide (IMCIVREE®) is approved only for people with rare genetic disorders that affect weight regulation, such as Bardet‑Biedl Syndrome or POMC, PCSK1, or LEPR deficiency. The Health Canada safety monitoring of GLP‑1 receptor agonists includes longstanding approval for T2D and evolving use for obesity. Access, coverage and guideline alignment in the Canadian public/private setting remain important for patients and providers alike. For patients with T2D, this means that the tools available are broadening — weight‑reduction is becoming a direct target, not just a “nice side‑benefit” of diabetes treatment. Big News Beyond GLP‑1: A New Hormone Target in the Pipeline Recently, Eli Lilly’s investigational drug Eloralintide  has entered headlines. Unlike the well‑known GLP‑1 drugs (such as semaglutide or tirzepatide), eloralintide works by mimicking amylin - a hormone naturally released alongside insulin that regulates appetite, satiety and the speed of digestion. In a Phase II, 48‑week , multi-centre trial in adults with obesity (but without  T2D), participants on the highest dose lost nearly 20 % of their body weight (mean weight loss ~21.3 kg) compared with about a 0.4% loss in the placebo group. Why does this matter? It signals a potential “post‑GLP‑1” era of metabolic innovation, where other hormone‑pathways are targeted (amylin‑based, GIP, multi‑hormone combos). It may open the door for multi‑hormone therapies (amylin + GLP‑1 + GIP) that might improve tolerability, adherence and possibly allow even better outcomes. For patients with T2D and excess weight, it means more options may be coming - potentially for those who did not tolerate or respond fully to GLP‑1s. For providers and patients, this means staying updated on pipeline drugs, emerging mechanisms, and considering the future where metabolic care options are more varied and tailored. What the Growing Pipeline of Medications Means for Patients Tangible Outcomes for Patients: Greater weight loss : These drugs are showing substantial weight‑reductions, in non‑diabetic obese adults, trials indicate ~ 15‑25% body weight loss over 12–18 months when combined with lifestyle support. Dual benefit for T2D : For patients with T2D, the medications can help both glycemic control and  weight loss , which can lead to improvements in blood pressure, lipid profile, and potentially reduce cardiovascular or kidney‑related complications. Improved quality of life : As patients lose weight, they may feel more mobile, have better sleep, fewer joint issues, less fatigue, all of which contribute to improved day‑to‑day functioning. Reframing of obesity and T2D : Obesity is increasingly regarded as a chronic condition needing medical management, not simply lifestyle failure. This shift helps reduce stigma and opens more opportunities for comprehensive care. However, the benefits don't come without risk: High drop out rates: 30% of participants drop out  of the weight loss studies in the first 4 weeks, and increases with time. Weight‑regain after stopping treatment: A meta‑analysis found that participants who discontinued GLP‑1 therapy regained, on average, ~9.7 kg (for semaglutide/tirzepatide) after stopping. Gastrointestinal and serious side‑effects: Use of GLP‑1 RAs for weight loss was associated with increased risks of pancreatitis, gastroparesis and bowel obstruction compared with another weight‑loss agent. Lower effectiveness in “real‑world” practice vs clinical trials : Data from a large cohort found mean weight loss of only ~7.7% with semaglutide and ~12.4% with tirzepatide at one year in real‑world use - less than in controlled trials . Cost and access barriers: Early discontinuation has been linked to high out‑of‐pocket cost, lower income status, and lower adherence among younger patients. What It Means for Providers Broader treatment planning : Providers must expand their care pathways. It’s no longer “medication for blood sugar” but “medication for metabolic health, weight, heart risk, T2D.” So, assessment must include adiposity, weight history, comorbidities, patient goals. Lifestyle integration remains key : These medications are potent, but they are not  standalone fixes. They work best when combined with nutrition, physical activity (especially muscle‑preserving exercise), behavioural support and long‑term follow‑up. Monitoring & long‑term strategy : Providers must monitor not only HbA1c, but weight, body composition, nutritional status, side‑effects, and plan for the longer term - including what happens if medication is discontinued (weight regain risk). Patient‑centred communication : For patients facing T2D and overweight/obesity, conversations must clearly cover indications, expectations (what the medications can and cannot do), costs/coverage (especially in Canada where private insurance coverage varies) and long‑term commitment. What This All Means for the Future of T2D Care For patients with T2D, the future is promising. We’re moving from a model of managing high blood sugar and hoping for moderate weight change, to one where metabolic risk factors, adiposity and weight are front‑line targets. That shift implies: Earlier intervention : Rather than waiting until T2D is advanced, or until weight becomes extreme, we may see more proactive use of these drugs alongside lifestyle measures in earlier stages. Integrated care pathways : Diabetes care may increasingly overlap with obesity care, cardiology, nutrition, exercise physiology and behavioural health - making “metabolic health” rather than “just diabetes” the goal. Personalised medicine : With more drug options (GLP‑1s, amylin‑based therapies, GLP‑1/GIP dual agonists, newer agents in the pipeline) providers and patients will have more choices - enabling treatments tailored to weight goals, glycaemia, risk profile, preferences. Sustained outcomes : Importantly, weight regain and regression of benefits remain risks if medication and lifestyle interventions aren’t maintained. The Canadian guideline emphasises that pharmacotherapy for obesity is long‑term, not a short‑term fix. Access and equity issues : For all the promise, inequities in access remain real. In Canada many patients may not have coverage or may face high cost, stigma or system‑barriers. Addressing these will be key so that patients with T2D benefit equitably. Final Thoughts This evolving landscape of GLP‑1 (and related) medications plus emerging therapies like amylin‑based agents is not simply a pharma story, it’s changing how we talk about, treat and support people with T2D, overweight and metabolic risk. For healthcare providers it means updating practice, expanding conversations beyond sugar and focusing on weight, risk, lifestyle and long‑term outcomes. For patients it means more options, more hope, and more need for partnership, realistic expectations and sustained effort.

Key Insights: ✅ Over 4 million Canadians live with diabetes - most with Type 2. ✅ Diabetes causes strokes, heart attacks, and kidney failure. ✅ Up to 70% of non-traumatic amputations are linked to diabetes. ✅ The total economic burden exceeds $30 billion annually in Canada. ✅ Early screening and team-based care can prevent most serious complications. When we think about type 2 diabetes (T2D), the mind often goes first to blood‑sugar levels, medications, and lifestyle change. But the real clinical and public‑health challenge lies in the complications: heart disease, stroke, chronic kidney disease, retinopathy and vision loss, neuropathy and foot ulceration, lower‑limb amputation, and the many ways the condition can erode quality of life. A Global Lens on Diabetes Complications Globally, diabetes has surged over the past decades. While exact figures vary, recent studies suggest hundreds of millions of adults now live with diabetes, many of them undiagnosed or insufficiently treated. For example, a news summary cited more than 800 million  adults worldwide living with diabetes or had in fact much higher numbers than previously estimated. Of those, the vast majority ( around 90 %‑95 % ) are living with T2D. Why does this matter for complications? Because the longer someone lives with diabetes, and the less optimal the glucose and cardiovascular risk‑factor control, the higher the risk of complications such as: cardiovascular disease including myocardial infarction and stroke chronic kidney disease (CKD) progressing to dialysis diabetic retinopathy and vision loss diabetic neuropathy leading to foot ulcers non‑traumatic lower‑limb amputations increased risk of mortality and disability It is well documented that diabetes is among the leading causes of blindness , kidney failure, heart attack and lower‑limb amputation . The global burden is further compounded in low‑ and middle‑income countries, where the treatment gap is large and screening and prevention infrastructure may lag. In Canada, the prevalence of diabetes is 2.1 times higher in the lowest income group compared to the highest income group. CIHI data 2020-2023 The Diabetes Canada backgrounder (2024) estimates direct health‑care system costs in Canada at C$18.25 billion  in 2024. Out‑of‑pocket costs are also significant: up to C$10,014 per year for someone living with T2D in some provinces. Cost per hospital stay for diabetes‑associated major lower‑limb amputation is high in Canada, reflecting long stays (≈19 days) and high readmission risk. For the healthcare professional, this means two things: first, T2D is not just a metabolic disorder, it’s a multisystem disease of high‑risk complications. Second, the potential for prevention (or delay) of these complications makes early and consistent care pivotal. CIHI data 2020-2023 The Major Complications: Prevalence, Impact and Why They Matter Let’s look at the key complications of T2D, starting with those most common and then touching on the full range. Cardiovascular disease (CVD) Heart attack and stroke remain the top‑killers among people with T2D. While precise national Canadian incidence data is less frequently reported in summary form, international data show that people with T2D have 2‑4 times the risk of cardiovascular events compared to non‑diabetic peers. From a clinical perspective, this means that lipid, blood pressure, smoking and aspirin (where indicated) remain critical, and screening for CVD risk should be front‑and‑centre in your diabetes care plan. Chronic kidney disease (CKD) and end‑stage renal disease In Canada, ~50% of kidney‑failure requiring dialysis is attributable to diabetes. CKD in diabetes often starts silent (microalbuminuria or reduced GFR) and progresses unless addressed. For the patient, kidney disease adds layers of treatment complexity, risk of cardiovascular death and high cost. For you as a provider: regular screening (eGFR, albumin‑creatinine ratio) and early referral to nephrology/palliative care planners is essential. Diabetic retinopathy and vision loss Vision loss remains a feared complication. In Canada, the backgrounder flags diabetes as the leading cause of blindness among working‑age adults. Globally, rough estimates suggest that around one‑in-three people with diabetes develop some form of retinopathy, and ~10% experience vision‑threatening disease. From a care‑perspective: annual dilated eye exams, prompt treatment of retinopathy and tight glycemic/blood pressure control are non‑negotiable. Diabetic neuropathy, foot ulceration, and lower‑limb amputation One of the most dramatic complications in terms of life‑impact and cost is lower‑limb amputation. According to Canadian Institute for Health Information (CIHI) , the lifetime risk of developing a foot ulcer is about 15% to 25% , and it is widely cited that up to 85% of leg amputations are preventable. From your standpoint: foot care must be embedded in every diabetes review. Inspection, neuropathy screening, vascular assessment, and referring to podiatry or wound‑care services are crucial. CIHI data 2020 - 2023 Neuropathy pain and sensory loss Less often highlighted in system‑cost reports, but frequent and disabling, is diabetic neuropathy (both peripheral and autonomic). Patients living with chronic neuropathic pain, foot sensory loss and associated falls or ulcer risk face major quality‑of‑life reductions. Many of your patients may already live with it, and need active management. Mental health, disability, and quality of life Complications accumulate and feed into one another. For example, vision loss affects mental health, losing mobility increases depression risk, amputations reduce independence. CIHI highlights that amputations are associated with “loss of function, reduced quality of life, depression and high risk of premature death.” As a clinician you’ll recognize that complication‑prevention is also about preserving dignity, autonomy, and lived experience, too often overlooked in the clinical day. Why These Complications Occur - Clinical Insight for Practice Complication risk is not random. As a healthcare provider, understanding key drivers helps you intervene strategically. Duration of diabetes & glycemic control.  The longer someone has hyperglycemia, the greater the risk of microvascular (retinopathy, nephropathy, neuropathy) and macrovascular (CVD, stroke) complications. Tight A1c, early start of risk‑reducing therapy and lifestyle intervention matter. Cardiometabolic risk factors.  Hypertension, dyslipidemia, obesity, smoking all amplify complication risk. The “multiple risk‑factor” model requires you to treat beyond glucose. Socio‑economic and equity considerations.  The CIHI equity‑focused report on lower‑limb amputation notes that cost, access, and social determinants of health contribute significantly to risk. Thus, your care plan should consider these broader determinants, not only medication lists and lab values. Screening and early detection.  Many complications are preventable or modifiable if caught early. For example: foot ulcer prevention programs reduce amputation risk. In retinopathy, early detection prevents blindness. Your role includes establishing system‑wide screening, referral pathways and patient‑education modules. Patient engagement and self‑management.  Empowering individuals to monitor foot health , attend eye‑screening, control blood pressure, and maintain physical activity remains fundamental. The human impact of complications (loss of mobility, independence, employment) means you are dealing with more than physiology - you are dealing with lives. The Human Impact - Beyond the Numbers Numbers tell a story, but behind each one is a person. Consider a 55‑year‑old male with 15 years of T2D, moderate neuropathy, and retinopathy. A foot ulcer develops; within months he is hospitalized, undergoes above‑knee amputation, and loses his job driving trucks. His family incurs lost income and caregiving burden; his mental health deteriorates; his mobility is reduced; his risk of cardiovascular mortality increases. Now scale that story across thousands of Canadians: Mobility loss means fewer opportunities for physical activity and more comorbidities. Vision loss means reliance on others, early retirement, and increased mental‑health risk. Amputations carry high mortality, high readmission rates, and high healthcare cost. As a provider, your proactive screening and referrals don’t just reduce lab values—they preserve mobility, enable ongoing employment, maintain independence, and protect mental well‑being. That is the human impact of complication prevention. What This Means for Care Delivery - Practical Implications Given the magnitude of the burden, here are key practical actions for you r clinical practice: Embed screening for complications  in every T2D review. Annual dilated eye exam and prompt ophthalmology referral for retinopathy risk. Annual (or more frequent) foot exam including neuropathy screening, vascular pulses, skin integrity, and referral to podiatry/wound care where needed. Kidney screening: eGFR and albumin‑creatinine ratio at least annually, more frequently if CKD risk high. CVD risk factor review: blood pressure, lipids, smoking, aspirin (if indicated). Tailor your care plan around risk profiles.  Older age, longer diabetes duration, Indigenous/ethnic minority status, low income, remote residence—these increase complication risk. Use this info to intensify screening or consider multidisciplinary referral. Leverage multidisciplinary teams.  Podiatrists, diabetes educators, wound‑care specialists, ophthalmologists, nephrologists—and don’t forget mental‑health professionals. Collaborative care improves outcomes and reduces system cost. Prioritize equity and access.  Screen for cost or access barriers (e.g., inability to afford medications, devices, transport). The CIHI equity report shows that lower‑income diabetics often delay or forgo care. Use health‑system supports to bridge these gaps. Educate patients on complication significance and self‑care.  Foot care at home, annual eye exams, blood‑pressure control—they must understand why this matters. The human narrative (loss of mobility, job, independence) often motivates better than numbers alone. Monitor and audit outcomes.  Use your clinic population data to track complication incidence, screening rates, referral completion and outcomes. Feedback to your team promotes quality improvement. The Future: Where Care Must Go We know what works. But as the prevalence of T2D rises and the burden of complications grows, systems and clinicians must adapt. A few areas to watch: Enhanced digital and AI care models for remote or underserved populations. Better integration of screening (for foot, eye, kidney) into primary‑care workflows. New therapies with cardiovascular and renal benefit (SGLT2 inhibitors, GLP‑1 receptor agonists) that reduce complication risk beyond glucose‑lowering. Equity‑driven interventions to reduce the social‑determinant gap in complication rates. Cost‑savings pathways: preventing amputations, dialysis starts or blindness will save billions and preserve quality of life. Summary The burden of T2D in Canada is substantial, and the complication story is where the real cost (human and system) sits. From global prevalence to Canadian incidence, from cardiovascular disease to foot ulcer‑amputation, from kidney failure to vision loss, the scale and impact are clear. For you as a healthcare professional, the message is also clear: your screening, referral choices, multidisciplinary coordination and patient education matter. They matter not only for reducing lab values, but for preserving mobility, vision, employment, independence and quality of life. The next time you review a person with T2D, pause and ask: have we addressed the risk of complications? Do we have a plan for prevention, not just management? Because preventing complications  -  that is where we change lives.

Your input can inspire and help others, thanks for being part of the conversation!

Your input can inspire and help others, thanks for being part of the conversation!

Key Highlights ✅ CGMs track glucose in real time - no finger pricks needed. ✅ Shown to improve HbA1c, time in range, and quality of life. ✅ BC PharmaCare covers CGMs only for insulin users. ✅ Non-insulin users rely on private insurance or self-pay. ✅ Wider access could cut costs and boost self-management. ✅ Providers see CGMs as valuable for education and motivation. In the evolving landscape of diabetes management, Continuous Glucose Monitoring (CGM) stands out as a pivotal advancement, particularly for individuals living with Type 2 Diabetes (T2D). Unlike traditional blood glucose meters that offer intermittent snapshots of glucose levels, CGMs provide real-time, continuous data, enabling both patients and healthcare providers to gain deeper insights into glucose fluctuations throughout the day and night. What Is Continuous Glucose Monitoring? A CGM system comprises a small sensor inserted under the skin, typically on the abdomen or upper arm, which measures glucose levels in the interstitial fluid. This sensor transmits data wirelessly to a receiver or smartphone app, displaying glucose trends and patterns. Modern CGMs, such as the Dexcom G6 and FreeStyle Libre 2, offer features like real-time alerts for high or low glucose levels, helping users take proactive steps to manage their condition. CGM Canada hosts a wealth of resources The Clinical Utility of CGMs in T2D CGMs aren’t just for people on insulin anymore. A recent Canadian review article (Aronson et al, June 2025) looked at how CGMs can help people with T2D who aren’t using insulin and found some pretty promising results. Unlike the traditional finger-prick tests, CGMs track glucose continuously, giving a fuller picture of blood sugar ups and downs. The review included eight studies with over 500 participants, about half of whom used a CGM. The results? People using CGMs saw lower HbA1c levels, spent more time in their target glucose range, and had less time with high blood sugar. Beyond the numbers, CGMs also improved the overall experience for patients and even helped reduce healthcare visits and costs. In short, CGMs are showing real value for people with T2D, whether they’re on insulin or not, giving both patients and healthcare providers more tools to manage diabetes in everyday life. Beyond glycemic control, CGMs have been associated with a decrease in hypoglycemic events and an increase in time spent within target glucose ranges. This continuous feedback loop empowers patients to make informed decisions about their diet, exercise, and medication, fostering a more active role in their diabetes management. For individuals with T2D on intensive insulin therapy, CGMs have demonstrated significant benefits. Studies indicate that initiating real-time CGM in such patients can also lead to a reduction in HbA1c levels, a key marker of long-term blood glucose control. In another Canadian study assessing the cost effectiveness of CGMs in patients with T2D who were receiving insulin and are poorly controlled, CGM was found to be cost effective compared to self-monitoring blood glucose. So why the slow adoption? Challenges in Adopting and Funding CGMs Despite their advantages, the adoption of CGMs in T2D management is not without challenges. In 2021, British Columbia was the first province to cover Dexcom G6 Continuous Glucose Monitoring System for people with type 1 and type 2 diabetes on intensive insulin therapy. Of course, criteria and eligibility need to be met as well as a lengthy approval process, but what about those who weren't using insulin? Currently, under BC Pharma Care , CGMs and flash glucose monitors (FGMs) are not routinely covered for people with T2D who are not on intensive insulin therapy. Here’s how the policy works, and why many non-insulin-treated T2D patients are currently not eligible under the publicly funded criteria. PharmaCare lists CGMs/FGMs as a benefit if you meet these key eligibility requirements : You are enrolled in one of the covered plans: Fair PharmaCare, Plan C (Income Assistance), Plan F (At Home Program), or Plan W (First Nations Health Benefits). You have diabetes mellitus and meet the device-specific minimum age (e.g., 2+ yrs for CGM, 4+ for FGM) Crucially: You require intensive insulin therapy (i.e., multiple daily insulin injections or insulin pump therapy) - this is explicitly stated as a condition. You (or your caregiver) agree to comprehensive diabetes education and regular follow-up. The device is deemed medically necessary, and the prescriber obtains a Special Authority (SA) request for coverage. If you have T2D but are not on multiple daily injections of insulin or an insulin pump, then you typically do not meet the “intensive insulin therapy” criterion - and so you’re not eligible under the current PharmaCare CGM/FGM policy. You’ll likely need to rely on private insurance plans or paying out-of-pocket if you wish to use a CGM/FGM, because the provincial benefit doesn’t cover you under your current treatment regimen. It’s worth checking your extended health benefits or workplace insurance to see if your plan covers CGMs for non-insulin T2D. The cost of CGM systems can be a significant barrier, as many devices and sensors are not covered under standard insurance plans. Even in provinces like British Columbia, where some coverage is available for individuals on intensive insulin therapy, the application process can be complex, and not all eligible individuals may be aware of the funding options. Moreover, the influx of data from CGMs can lead to information overload for some users. Without proper education and support, patients may experience alert fatigue or become overwhelmed by the constant stream of glucose readings, potentially leading to underutilization of the device. So as part of the approval process, mandatory diabetes education is required. Recognizing the importance of equitable access to diabetes management tools, in March 2025, Diabetes Canada advocated for expanded coverage and streamlined access to CGMs across the country. Their efforts aim to ensure that all individuals with T2D, regardless of socioeconomic status, have the opportunity to benefit from this technology. Perspectives from Patients and Healthcare Providers Patient Perspective : Many individuals with T2D report that CGMs have transformed their approach to managing their condition. The ability to monitor glucose levels in real-time allows for immediate corrective actions, reducing the frequency of hypoglycemic episodes and enhancing overall well-being. Patients also appreciate the convenience of reduced fingerstick testing, leading to less discomfort and a more seamless daily routine. Healthcare Provider Perspective : Healthcare professionals recognize the value of CGMs in improving patient outcomes. CGMs provide clinicians with detailed data on glucose trends, enabling more precise adjustments to treatment plans. However, providers also emphasize the need for comprehensive patient education to ensure effective use of the technology and to mitigate potential challenges such as data overload. The Future of CGMs in T2D Management As technology continues to advance, the future of CGMs in T2D management looks promising. Emerging features like predictive alerts, integration with insulin pumps, and enhanced data analytics are poised to further personalize diabetes care. Additionally, ongoing research into expanding CGM access and affordability aims to make this technology accessible to a broader population, ensuring that more individuals with T2D can benefit from its advantages. While challenges remain in the widespread adoption of CGMs for T2D, their potential to revolutionize diabetes management is undeniable. With continued advocacy, education, and support, CGMs can play a pivotal role in improving the lives of individuals living with T2D in British Columbia and beyond.